<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        27-887-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEPTRIN 480MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SULFAMETHOXAZOLE, TRIMETHOPRIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400, 80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        18.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aspen SA Operations (PTY) Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aspen SA Operations (PTY) Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01EE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Septrin is and what is it used for</strong><br />Septrin 80 mg/400 mg Tablets (called &lsquo;Septrin&rsquo; in this leaflet) are made up of two different medicines called sulfamethoxazole and trimethoprim. These medicines are sometimes given the combined name co-trimoxazole. Both belong to a group of medicines called antibiotics. They are used to treat infections caused by bacteria. Like all antibiotics, Septrin only works against some types of bacteria. This means that it is only suitable for treating some types of infections.<br />Septrin can be used to treat or prevent:<br />&bull; lung infections (pneumonia or PCP) caused by a bacteria called Pneumocystis jiroveci (previously known as Pneumocystis carinii)<br />&bull; infections caused by a bacteria called Toxoplasma (toxoplasmosis).<br />Septrin can be used to treat:<br />&bull; bladder or urinary tract infections (water infections)<br />&bull; lung infections such as bronchitis<br />&bull; ear infections such as otitis media<br />&bull; an infection called nocardiosis, it can affect the lungs, skin and brain.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2 Before you take Septrin</strong></p><p><strong>Do not take Septrin if:</strong><br />&bull; you are allergic (hypersensitive) to sulfamethoxazole, trimethoprim or co-trimoxazole or any of the other ingredients of Septrin (see section 6: Further information)<br />&bull; you are allergic to sulphonamide medicines. Examples include sulphonylureas (such as gliclazide and glibenclamide) or thiazide diuretics (such as bendroflumethiazide &ndash; a water tablet)<br />&bull; you have liver or kidney problems<br />&bull; you have ever had a problem with your blood<br />&bull; it is for your child and they are less than 6 weeks old or were premature. Unless it is for the treatment or prevention of PCP.<br />In this case, babies should be at least 4 weeks old.<br />If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Septrin.<br /><strong>Take special care with Septrin</strong><br />Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of Septrin appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk.<br />Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first weeks of treatment.<br />If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of Septrin you must not be re-started on Septrin at any time. If you develop a rash or these skin symptoms, stop taking Septrin, seek urgent advice from a doctor and tell him that you are taking this medicine.<br />Before you take Septrin, tell your doctor or pharmacist if:<br />&bull; you have severe allergies or asthma<br />&bull; you have been told that you have a rare blood problem called porphyria, which can affect your skin or nervous system<br />&bull; you don&rsquo;t have enough folic acid (a vitamin) in your body which can make your skin pale and make you feel tired, weak and breathless. This is known as anaemia<br />&bull; you have ever had jaundice which can cause yellowing of your skin or the whites of your eyes<br />&bull; you have a problem with your metabolism called phenylketonuria and are not on a special diet to help your condition<br />&bull; you are elderly<br />&bull; you are underweight or malnourished<br />&bull; you have been told by your doctor that you have a lot of potassium in your blood.<br />&bull; you have been told by your doctor that you have an abnormally low level of sodium in your blood.<br />&bull; you have been told by your doctor that you have any serious disorders of the blood and blood forming tissues (haematological disorders) E.g. low blood cell counts.<br />If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Septrin.<br /><strong>Taking other medicines</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. This includes herbal medicines.<br />This is because Septrin can affect the way some medicines work. Also some other medicines can affect the way Septrin works. In particular tell your doctor or pharmacist if you are taking any of the following medicines:<br />&bull; Diuretics (water tablets), which help increase the amount of urine you produce<br />&bull; Pyrimethamine, used to treat and prevent malaria, and to treat diarrhoea<br />&bull; Ciclosporin, used after transplant operations or for your immune system<br />&bull; Medicines used to thin the blood such as warfarin<br />&bull; Phenytoin, used to treat epilepsy (fits)<br />&bull; Medicines for diabetes, such as glibenclamide, glipizide or tolbutamide (sulphonylureas)<br />&bull; Medicines to treat problems with the way your heart beats such as, digoxin or procainamide<br />&bull; Amantadine, used to treat Parkinson&rsquo;s disease, multiple sclerosis, &lsquo;flu or shingles<br />&bull; Medicines to treat HIV (Human Immunodeficiency Virus), called zidovudine or lamivudine<br />&bull; Medicines that can increase the amount of potassium in your blood, such as diuretics (water tablets, which help increase the amount of urine you produce), steroids (like prednisolone) and digoxin<br />&bull; Methotrexate, a medicine used to treat cancer or for your immune system.<br />If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Septrin.<br /><strong>Taking Septrin with food and drink</strong><br />You should take Septrin with some food or drink. This will stop you feeling sick (nausea) or having diarrhoea. Although it is better to take it with food, you can still take it on an empty stomach. Drink plenty of fluid such as water while you are taking Septrin.<br /><strong>Pregnancy and breast feeding</strong><br />Talk to your doctor before taking this medicine if you are pregnant, planning to get<br />pregnant, or breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3 How to take Septrin 80mg/400mg Tablets</strong><br />Always take Septrin exactly as your doctor has told you. The label on your pack will tell you how much to take and how often to take it. You should check with your doctor or pharmacist if you are not sure.<br /><strong>Usual Dose</strong><br />Adults and children over 12 years<br />&bull; The usual dose is two tablets in a morning and two tablets in an evening.<br />&bull; Septrin should be taken for at least five days.<br />&bull; Make sure that you finish the course of Septrin which your doctor has prescribed.<br />Septrin 80 mg/400 mg Tablets are not usually given to children under 12 years old. If they have been given to your child please speak to your doctor or pharmacist for more information.<br /><strong>Special Dose</strong><br />The dose of Septrin and how long you need to take it depends on the infection you have and how bad it is. Your doctor may prescribe you a different dose or length of course of Septrin to<br />&bull; treat urinary tract (water) infections<br />&bull; treat and prevent lung infections caused by the bacteria Pneumocystis jiroveci<br />&bull; treat infections caused by the bacteria Toxoplasma (toxoplasmosis) or Nocardia (nocardiosis).<br /><strong>If you have kidney problems your doctor may</strong><br />&bull; prescribe a lower dose of Septrin<br />&bull; take blood to test whether the medicine is working properly.<br />If you take Septrin for a long time your doctor may<br />&bull; take blood to test whether the medicine is working properly<br />&bull; prescribe folic acid (a vitamin) for you to take at the same time as Septrin.<br /><strong>If you take more Septrin than you should</strong><br />If you take more Septrin than you should, talk to your doctor or go to a hospital straight away. Take the medicine pack with you.<br /><strong>If you have taken too much Septrin you may</strong><br />&bull; feel or be sick<br />&bull; feel dizzy or confused.<br /><strong>If you forget to take Septrin</strong><br />&bull; If you forget to take a dose, take it as soon as you remember it.<br />&bull; Do not take a double dose to make up for the forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4 Possible side effects</strong><br />Like all medicines Septrin can cause side effects, although not everybody gets them. You may experience the following side effects with this medicine. Stop taking Septrin and tell your doctor immediately if you have an allergic reaction. Chances of an allergic reaction is very rare (fewer than 1 in 10,000 people are affected), signs of an allergic reaction include<br /><strong>Allergic reactions</strong><br />&bull; Difficulty in breathing<br />&bull; Fainting<br />&bull; Swelling of face<br />&bull; Swelling of mouth, tongue or throat which may be red and painful and/or cause difficulty in swallowing<br />&bull; Chest pain<br />&bull; Red patches on the skin<br /><strong>Very Common (more than 1 in 10 people)</strong><br />&bull; High levels of potassium in your blood, which can cause abnormal heart beats (palpitations).<br /><strong>Common (less than 1 in 10 people)</strong><br />&bull; An infection called thrush or candidiasis which can affect your mouth or vagina. It is caused by a fungus<br />&bull; Headache<br />&bull; Feeling sick (nausea)<br />&bull; Diarrhoea<br />&bull; Skin rashes.<br /><strong>Uncommon (less than 1 in 100)</strong><br />&bull; Being sick (vomiting).<br /><strong>Very Rare (less than 1 in 10,000 people)</strong><br />&bull; Fever (high temperature) or frequent infections<br />&bull; Sudden wheeziness or difficulty breathing<br />&bull; Mouth ulcers, cold sores and ulcers or soreness of your tongue<br />&bull; Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (see Take special care with Septrin).<br />&bull; Skin lumps or hives (raised, red or white, itchy patches of skin)<br />&bull; Blisters on your skin or inside your mouth, nose, vagina or bottom<br />&bull; Inflammation of the eye which causes pain and redness<br />&bull; The appearance of a rash or sunburn when you have been outside (even on a cloudy day)<br />&bull; Low levels of sodium in your blood<br />&bull; Changes in blood tests (low blood cell counts)<br />&bull; Feeling weak, tired or listless, pale skin (anaemia)<br />&bull; Heart problems<br />&bull; Jaundice (the skin and the whites of your eyes turn yellow).<br />This can occur at the same time as unexpected bleeding or bruising<br />&bull; Pains in your stomach, which can occur with blood in your faeces (poo)<br />&bull; Pains in your chest, muscles or joints and muscle weakness<br />&bull; Arthritis<br />&bull; Problems with your urine. Difficulty passing urine. Passing more or less urine than usual. Blood or cloudiness in your urine.<br />&bull; Kidney problems<br />&bull; Sudden headache or stiffness of your neck, accompanied by fever (high temperature)<br />&bull; Problems controlling your movements<br />&bull; Fits (convulsions or seizures)<br />&bull; Feeling unsteady or giddy<br />&bull; Ringing or other unusual sounds in your ears<br />&bull; Tingling or numbness in your hands and feet<br />&bull; Seeing strange or unusual sights (hallucinations)<br />&bull; Depression<br />&bull; Muscle pain and/or muscle weakness in HIV patients<br />&bull; Cough<br />&bull; Anorexia (loss of appetite/inability to eat)<br />&bull; Hypoglycaemia (an abnormally low level of glucose in the blood) Pseudomembranous colitis (Acute inflammation of the small and large intestinal mucosa with formation of pseudomembranous plaques over superficial ulceration.)<br />&bull; Pancreatitis (Acute inflammation of the pancreas)<br />&bull; Vertigo (An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space)<br />&bull; Hepatic necrosis (which may be fatal) (breakdown/death of liver tissue)<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5 How to store Septrin</strong><br />&bull; Keep out of the reach and sight of children.<br />&bull; Store in the original package in order to protect from light.<br />&bull; Do not store above 25&deg;C.<br />&bull; Do not take the tablets after the expiry date shown on the blister label and carton.<br />&bull; Store in the original package with this leaflet.<br />&bull; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Septrin contains</strong><br />Septrin is made up of two different medicines called sulfamethoxazole and trimethoprim. These medicines are sometimes given the combined name co-trimoxazole. Each Septrin 80 mg/400 mg Tablet contains 400 mg sulfamethoxazole and 80 mg trimethoprim. The other ingredients of Septrin 80 mg/400 mg Tablets are: povidone, sodium starch glycollate, magnesium stearate and docusate sodium. Sometimes your tablets will contain dioctyl sodium sulphosuccinate instead of docusate sodium, but this will not affect the way that the tablets work.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Septrin looks like and contents of the pack
Septrin 80 mg/400 mg Tablets are white, round, biconvex tablets debossed with S2 on one side and a score line on the other side.

Septrin 80 mg/400 mg Tablets are supplied to you in:
 amber glass bottles with a propylene snap fit closure,containing 50 or 100 tablets, or a carton containing PVC/aluminium foil blisters of 50 or 100 tablets in total.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorisation holder:</strong><br />Aspen Pharma Trading Limited,<br />3016 Lake Drive,<br />Citywest Business Campus,<br />Dublin 24, Ireland</p><p><strong>Manufacturer:</strong><br />ASPEN PORT ELIZABETH<br />7 Fairclough Road<br />Port Elizabeth 6001<br />South Africa</p><p><strong>Packaging at:</strong><br />Glaxo Saudi Arabia Ltd. Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                leaflet date: April 2014

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1- ما المقصود بالدواء بالدواء سبترين؟ وما دواعي استخدامه؟</strong><br />تتكون أقراص سبترين 80 مجم/ 400 مجم (تُسمى &quot;سبترين&quot; في هذه النشرة) من عقارين مختلفين هما: سولفاميثوكسازول وترايميثوبريم. أحيانًا يُطلق على هذين الدوائين الاسم المركب &quot;كو-تريموكسازول&quot;. تنتمي كلتا هاتين المادتين إلى فئة من الأدوية تُسمى &quot;المضادات الحيوية&quot;. تُستخدم هذه الفئة من الأدوية لعلاج العدوى الجرثومية. مثل كل المضادات الحيوية؛ يعمل سبترين ضد أنواع معينة من الجراثيم. يعني هذا أنه مناسب فقط لعلاج بعض أنواع العدوى.</p><p><strong>يمكن استخدام سبترين لعلاج الحالات التالية أو الوقاية منها:</strong><br />&bull; عدوى الرئتين (الالتهاب الرئوي) بسبب نوع من الجراثيم تُسمى المتكيسة الرئوية (عُرفت سابقًا باسم المتكيسة الرئوية الجؤجؤية)<br />&bull; العدوى الناجمة عن نوع من الجراثيم تُسمى المقوسة (داء المقوسات)</p><p>يمكن استخدام سبترين لعلاج الحالات التالية:<br />&bull; عدوى المثانة أو المسالك البولية<br />&bull; عدوى الرئتين مثل التهاب الشعب الهوائية<br />&bull; عدوى الأذن مثل التهاب الأذن الوسطى<br />&bull; عدوى تُسمى داء النوكارديات؛ يمكن أن تؤثر في الرئتين والجلد والدماغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2- قبل استخدام سبترين</strong><br />لا تأخذ سبترين في الحالات التالية:<br />&bull; فرط الحساسية تجاه مادة سولفاميثوكسازول أو ترايميثوبريم أو كو-تريموكسازول أو أيٍ من المكونات الأخرى في سبترين (انظر القسم 6: معلومات إضافية)<br />&bull; فرط الحساسية تجاه أدوية السولفوناميد. تشمل الأمثلة سولفونيل يوريا (مثل جليكلازيد وليبنكلاميد) أو مدرات البول الثيازيدية (مثل بندروفلوميثيازيد - أقراص الماء)<br />&bull; وجود مشاكل في الكبد أو الكلى<br />&bull; وجود مشكلة في الدم في أي وقت سابق أو حالي<br />&bull; إذا كنت ستأخذه لطفلك الذي يقل عمره عن 6 أسابيع أو كان مبتسرًا. إلا إذا كان الاستخدام لعلاج الالتهاب الرئوي أو الوقاية منه. في هذه الحالة؛ ينبغي ألا يقل عمر الطفل عن 4 أسابيع. إذا كنت لا تعلم هل أي من الحالات المذكورة أعلاه تنطبق عليك أم لا؛ فينبغي استشارة الطبيب أو الصيدلي قبل استخدام أقراص سبترين.</p><p><strong>اتخاذ الرعاية الخاصة مع سبترين</strong><br />تم الإبلاغ عن حدوث طفوح جلدية مهددة للحياة بدرجة كبيرة (متلازمة ستيفنز-جونسون، تقشر الأنسجة المتموتة الجلدية السامة) مع استخدام سبترين، حيث تظهر مبدئيًا في شكل بقع حمراء مستديرة مع وجود تنفطات مركزية على الجذع غالبًا. كما تشمل العلامات الإضافية التي يجب التأكد منها القروح في الفم والحلق والأنف والأعضاء التناسلية والتهاب الملتحمة (احمرار وتورم العينين).</p><p>غالبًا تكون هذه الطفوح الجلدية المهددة للحياة بدرجة كبيرة مصحوبة بأعراض شبيهة بالأنفلونزا. قد يتفاقم الطفح الجلدي إلى تنفط واسع الانتشار وتقشر في الجلد. وتكون أعلى درجات احتمال الإصابة بتفاعلات جلدية خطيرة خلال الأسابيع الأولى من العلاج.</p><p>في حالة الإصابة بمتلازمة ستيفنز-جونسون أو تقشر الأنسجة المتموتة الجلدية السامة مع استخدام سبترين؛ يجب عليك عدم استخدام سبترين مرة أخرى أبدًا. في حالة الإصابة بطفح جلدي أو هذه الأعراض الجلدية؛ توقف عن أخذ سبترين واطلب النصيحة الطبية العاجلة من طبيب وأخبره أنه تأخذ هذا الدواء.</p><p><strong>قبل استخدام سبترين؛ ينبغي إخبار الطبيب أو الصيدلي في الحالات التالية:</strong><br />&bull; إذا كنت تعاني من أي حساسية خطيرة أو ربو<br />&bull; إذا كنت تعلم بواسطة الأطباء أنك تعاني من مشكلة نادرة في الدم تُسمى البرفيرية التي يمكن أن تؤثر في الجلد أو الجهاز العصبي<br />&bull; إذا كنت تعاني من نقص حمض الفوليك (فيتامين) في جسمك مما يجعل لون جلدك شاحبًا ويجعلك تشعر بالتعب والضعف وقصر النفس. تُعرف هذه الحالة بفقر الدم.<br />&bull; الإصابة باليرقان الذي يمكن أن يسبب اصفرار الجلد أو اصفرار بياض العينين<br />&bull; إذا كنت تعاني من مشكلة في الأيض تُسمى بيلة الفينيل كيتون ولست تسير على نظام غذائي خاص للمساعدة في حالتك<br />&bull; الشيخوخة؛<br />&bull; نقص الوزن أو سوء التغذية<br />&bull; إذا كنت علمت بواسطة طبيب أنك تعاني من زيادة البوتاسيوم في الدم.<br />&bull; إذا كنت علمت بواسطة طبيب أنك تعاني من نقص الصوديوم في الدم.<br />&bull; إذا كنت علمت بواسطة طبيب أنك تعاني من أي اضطرابات خطيرة في الدم والأنسجة المكونة للدم (اضطرابات الدم) مثل نقص عدد خلايا الدم.<br />إذا كنت لا تعلم هل أي من الحالات المذكورة أعلاه تنطبق عليك أم لا؛ فينبغي استشارة الطبيب أو الصيدلي قبل استخدام أقراص سبترين.</p><p><strong>استخدام أدوية أخرى</strong><br />يُرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول حاليًا - أو تناولت مؤخرًا - أي أدوية أخرى، بما في ذلك الأدوية التي تحصل عليها دون وصفة طبية. يشمل هذا الأعشاب الطبية.<br />هذا لأن سبترين يمكن أن يؤثر على كيفية عمل بعض الأدوية الأخرى. كما يمكن أن تؤثر بعض الأدوية الأخرى على كيفية عمل سبترين. على وجه الخصوص؛ أخبر الطبيب أو الصيدلي إذا كنت تستخدم أيًا من الأدوية التالية:<br />مدرات البول (أقراص الماء) التي تساعد على زيادة كمية البول المخرجة<br />&bull; بيرايميثامين - عقار يُستخدم لعلاج المالاريا والوقاية منها، ولعلاج الإسهال<br />&bull; سيكلوسبورين؛ يُستخدم بعد عمليات زرع الأعضاء أو للجهاز المناعي<br />&bull; الأدوية المستخدمة لترقيق الدم مثل وارفارين<br />&bull; فينيتوين؛ يُستخدم لعلاج الصرع (التشنجات)<br />&bull; الأدوية المستخدمة لعلاج داء السكري مثل جليبنكلاميد أو جليبيزيد أو تولبوتاميد (سولفونيل يوريا)<br />&bull; الأدوية المستخدمة لعلاج مشكلات نبض القلب مثل ديجوكسين أو بروكايناميد<br />&bull; أمانتادين؛ يُستخدم لعلاج داء باركنسون أو التصلب المتعدد أو الأنفلونزا أو الهربس النطاقي<br />&bull; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشرية تُسمى زيدوفودين أو لاميفودين<br />&bull; الأدوية التي يمكن أن تزيد من نسبة البوتاسيوم في الدم مثل مدرات البول (أقراص الماء التي تساعد على زيادة كمية البول المخرجة)، الستيرويدات (مثل بريدنيزولون) وديجوكسين<br />&bull; ميثوتريكسات؛ عقار يُستخدم لعلاج السرطان أو الجهاز المناعي.</p><p>إذا كنت لا تعلم هل أي من الحالات المذكورة أعلاه تنطبق عليك أم لا؛ فينبغي استشارة الطبيب أو الصيدلي قبل استخدام أقراص سبترين.</p><p><strong>تناول سبترين مع الطعام والشراب</strong><br />ينبغي أخذ سبترين مع بعض الطعام أو الشراب. سيمنع هذا شعورك بالغثيان أو حدوث إسهال. على الرغم من أنه من الأفضل أخذ هذا الدواء مع الطعام؛ فيمكنك أخذه على معدة خاوية. احرص على شرب كمية وافرة من السوائل مثل الماء أثناء أخذ سبترين.</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />ينبغي استشارة الطبيب قبل أخذ هذا الدواء إذا كانت المريضة حاملاً أو تنوي الحمل أو إذا كانت تُرضع رضاعة طبيعية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3- كيفية استخدام أقراص سبترين 80 مجم/ 400 مجم</strong><br />يجب أخذ سبترين حسب إرشادات الطبيب دائمًا. يُفيدك الملصق الموجود على عبوة الدواء عن الجرعة التي تأخذها من هذا الدواء (عدد الأقراص وعدد المرات). ينبغي استشارة الطبيب أو الصيدلي في حالة عدم التأكد من كيفية الاستخدام.</p><p><strong>الجرعة العادية</strong><br />البالغون والأطفال فوق 12 سنوات<br />&bull; الجرعة العادية هي قرصان في الصباح وقرصان في المساء.<br />&bull; ينبغي أخذ أقراص سبترين لمدة خمسة أيام على الأقل.<br />&bull; احرص على إنهاء الدورة العلاجية بأقراص سبترين حسب ما وصفه لك الطبيب.</p><p>عادةً لا تُعطى أقراص سبترين 80 مجم/ 400 مجم للأطفال تحت 12 سنة. في حالة إعطاء هذه الأقراص لطفلك؛ يُرجى استشارة الطبيب أو الصيدلي للحصول على مزيد من المعلومات.</p><p><strong>الجرعة الخاصة</strong><br />تعتمد جرعة سبترين ومدة العلاج بأقراص سبترين التي تحتاج إليها على نوع العدوى التي تعاني منها ودرجة خطورتها.</p><p>يمكن أن يصف لك الطبيب جرعة مختلفة أو مدة مختلفة للدورة العلاجية بأقراص سبترين من أجل:<br />&bull; علاج عدوى المسالك البولية<br />&bull; العلاج والوقاية من عدوى الرئة الناجمة عن جراثيم المتكيسة الرئوية<br />&bull; علاج العدوى الناجمة عن نوع من الجراثيم تُسمى المقوسة (داء المقوسات).</p><p><strong>إذا كنت تعاني من مشكلات في الكلى، فيمكن أن يقوم الطبيب بإجراء مما يلي:</strong><br />&bull; وصف جرعة أقل من سبترين<br />&bull; أخذ عينة دم لفحص درجة فعالية الدواء.</p><p><strong>في حالة أخذ سبترين لمدة طويلة؛ فيمكن أن يقوم الطبيب بإجراء مما يلي:</strong><br />&bull; أخذ عينة دم لفحص درجة فعالية الدواء.<br />&bull; وصف حمض الفوليك (فيتامين) لك لتأخذه في الوقت نفسه مع سبترين.</p><p><strong>في حالة تناول جرعة زائدة من سبترين عن الجرعة الموصوفة</strong><br />في حالة تناول جرعة زائدة من سبترين عن الجرعة الموصوفة، ينبغي استشارة الطبيب أو الذهاب إلى المستشفى على الفور.<br />خذ عبوة الدواء معك.</p><p><strong>في حالة أخذ جرعة مفرطة من سبترين فقد:</strong><br />&bull; تشعر بغثيان أو تُصاب بالقيء.<br />&bull; تشعر بدوار أو ارتباك.</p><p><strong>في حالة نسيان جرعة سبترين</strong><br />&bull; في حالة نسيان جرعة من هذا الدواء، ينبغي تناولها حال تذكرها على الفور.<br />&bull; لا تتناول جرعة مزدوجة لتعويض الجرعة الفائتة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>الآثار الجانبية الممكنة</strong><br />مثل كل الأدوية، يمكن أن يسبب سبترين آثارًا جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه. قد تُصاب بالآثار الجانبية التالية مع استخدام هذا الدواء. توقف عن تناول سبترين وأخبر طبيبك فورًا إذا أُصبت برد فعل تحسسي. إنفرص حدوث رد فعل تحسسي نادرة جدًا (تُصيب أقل من شخص واحد من كل 10000 شخص)، وتشمل علامات رد الفعل</p><p>التحسسي ما يلي:<br />تفاعلت تحسسية<br />&bull; صعوبة في التنفس<br />&bull; إغماء<br />&bull; تورم الوجه<br />&bull; تورم الفم أو اللسان أو الحلق الذي قد يكون محمر اللون ومؤلمًا و/أو يسبب صعوبة في البلع<br />&bull; ألم في الصدر<br />&bull; بقع حمراء على الجلد</p><p><strong>الآثار الجانبية الشائعة جدًا (أكثر من مريض واحد من كل 10 مرضى):</strong><br />&bull; ارتفاع مستويات البوتاسيوم في الدم؛ مما قد يسبب اضطراب نبض القلب (خفقان).</p><p><strong>الآثار الشائعة (أقل من مريض واحد من كل 10 مرضى):</strong><br />&bull; عدوى تُسمى السلاق أو داء المبيضات الذي يمكن أن يُصيب الفم أو المهبل. تحدث هذه العدوى بسبب نوع من الفطريات.<br />&bull; صداع<br />&bull; شعور بالغثيان<br />&bull; إسهال<br />&bull; طفوح جلدية.</p><p><strong>الآثار غير الشائعة (أقل من مريض واحد من كل 100 مريض):</strong><br />&bull; شعور بالغثيان (قيء).</p><p><strong>آثار جانبية نادرة جدًا (أقل من مريض واحد من كل 10000 مريض)</strong><br />&bull; حمى (ارتفاع درجة حرارة الجسم) أو تكرار العدوى<br />&bull; أزيز مفاجئ أو صعوبة في التنفس<br />&bull; قروح فموية، قروح الزكام أو قرحة اللسان<br />&bull; تم الإبلاغ عن حدوث قروح جلدية مهددة للحياة بدرجة قوية (متلازمة ستيفنز-جونسون، تقشر الأنسجة المتموتة الجلدية السامة).<br />&bull; (انظر القسم &ldquo;اتخاذ الرعاية الخاصة مع سبترين&rdquo;).<br />&bull; كتل جلدية أو شرى (بقع جلدية حمراء أو بيضاء منتفخة مصحوبة بحكة)<br />&bull; تنفطات على الجلد أو داخل الفم أو الأنف أو المهبل أو المقعدة<br />&bull; التهاب العينين الذي يسبب ألمًا واحمرارًا<br />&bull; ظهور طفح جلدي أو حروق شمسية عند الخروج من المنزل (حتى في الأيام الغائمة)<br />&bull; نقص مستويات الصوديوم في الدم<br />&bull; تغيرات في نتائج اختبارات الدم (نقص عدد خلايا الدم)<br />&bull; شعور بالضعف أو التعب أو عدم الارتياح، شحوب الجلد (فقر دم)<br />&bull; اضطرابات القلب<br />&bull; اليرقان (اصفرار الجلد وبياض العينين).<br />&bull; يمكن حدوث ذلك في الوقت نفسه مع حدوث نزيف أو كدمات غير متوقعة.<br />&bull; شعور بألم في المعدة وقد يكون مصحوبًا بدم في البراز<br />&bull; شعور بألم في الصدر أو العضلات أو المفاصل وضعف العضلات<br />&bull; التهاب المفاصل<br />&bull; مشكلات في البول. صعوبة في التبول. تبول كمية من البول أكثر أو قل من المعتاد. وجود دم أو تعكر في البول.<br />&bull; مشكلات في الكلى<br />&bull; صداع مفاجئ أو تصلب الرقبة مصحوب بحمى(ارتفاع درجة حرارة الجسم)<br />&bull; صعوبة في التحكم في الحركات<br />&bull; نوبات (اختلاجات أو تشنجات)<br />&bull; شعور بعدم الثبات أو الدوار<br />&bull; طنين أو أصوات أخرى غير عادية في الأذنين<br />&bull; وخز أو نمل في اليدين والقدمين<br />&bull; رؤية أشياء غريبة أو غير عادية (هلوسات)<br />&bull; اكتئاب<br />&bull; ألم في العضلات و/أو ضعف في العضلات في مرضى فيروس نقص المناعة البشرية<br />&bull; سعال<br />&bull; فقدان الشهية/ عدم القدرة على الأكل<br />&bull; نقص السكر في الدم (انخفاض غير سوي في مستوى السكر في الدم) التهاب القولون الغشائي الكاذب (التهاب حاد&nbsp;في الغشاء المخاطي للأمعاء الدقيقة والغليظة مع تكون لويحات غشائية كاذبة فوق التقرح الظاهري).<br />&bull; التهاب البنكرياس (التهاب حاد في البنكرياس)<br />&bull; دوار (توهم الحركة إما بدوران العالم الخارجي المحيط بالشخص أو بدوران الشخص نفسه في المكان)<br />&bull; نخر كبدي (قد يكون مميتًا) (تحلل/موت أنسجة الكبد)<br />&bull; إذا زادت خطورة أي من الآثار الجانبية، أو إذا لاحظت حدوث أي آثار جانبية غير المذكورة هنا؛ يجب استشارة الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5- كيفية تخزين سبترين</strong><br />&bull; يجب حفظه بعيدًا عن متناول الأطفال ونظرهم.<br />&bull; يُخزَّن في العبوة الأصلية لحمايته من الضوء.<br />&bull; لا يُحفظ في درجة حرارة أعلى من 25 درجة مئوية.<br />&bull; يجب عدم أخذ هذه الأقراص بعد تاريخ انتهاء الصلاحية المكتوب على الملصق والعلبة الكرتونية.<br />&bull; يُخزن في العبوة الأصلية مع هذه النشرة.<br />&bull; ينبغي عدم التخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من<br />الأدوية التي لا تحتاج إليها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات سبترين</strong><br />يتكون سبترين من عقارين مختلفين يُسميان سولفاميثوكسازول وترايميثوبريم. أحيانًا يُطلق على هذين الدوائين الاسم المركب &quot;كو-تريموكسازول&quot;. يحتوي كل قرص سبترين تركيزه 80 مجم/ 400 مجم على 400 مجم سولفاميثوكسازول و 80 مجم ترايميثوبريم. المكونات الأخرى في أقراص سبترين 80 مجم/ 400 مجم هي: بوفيدون، جليكولات نشا صوديوم، ستيرات ماغنيسيوم، صوديوم دوكوسات. أحيانًا ستكون الأقراص محتوية على ديوكتيل صوديوم سولفوساكسينات بدلاً من صوديوم دوكوسات؛ ولكن لن يؤثر هذا على مفعول الأقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>شكل أقراص سبترين 80 مج/ 400 مجم ومحتويات العبوة</strong><br />&nbsp;الأقراص بيضاء اللون ومحدبة من الجانبين. الأقراص مقسومة بخط من المنتصف ومنقوش على أحد جانبيها الرمز S2.<br />تأتي أٌقراص سبترين 80 مجم/ 400 مجم في:<br />&bull; زجاجات لونها عنبرية بسدادة محكمة من البروبيلين؛ وتحتوي كل زجاجة على 50 أو 100 قرص، أو تأتي الأقراص في علبة كرتونية تحتوي على شرائط منفطة من رقائق الألومنيوم/مادة بي في سي، وتحتوي العلبة على 50 أو 100 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة صاحبة تفويض التسويق:</strong><br />أسبن فارما تريدينج المحدودة،<br />3016 ليك درايف<br />سيتي ويست بزنس كامبوس<br />دوبلن 24 ، أيرلندا</p><p><strong>الشركة المصنعة:</strong><br />اسبن بورت اليزابيث<br />7 طريق فاركلو<br />بورت اليزابيث 6001 ، جنوب افريقيا.</p><p><strong>يعبأ في:</strong><br />جلاكسو السعودية المحدودة. جدة، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ث.تاريخ إصدار النشرة: أبريل 2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Co-Trimoxazole 80 mg/400 mg Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 80 mg Trimethoprim and 400 mg Sulfamethoxazole. Excipients:
For a full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.
White, round, biconvex tablets embossed with “S2” on one side with scoreline on the other side. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Co-Trimoxazole tablets are indicated in children (&gt;12 to &lt;18 years old) and adults (&gt;18 years old) for the treatment of the following infections when owing to sensitive organisms (see section 5.1):<br />&bull; Treatment and prevention of Pneumocystis jirovecii pneumonitis or &ldquo;PJP&rdquo;.<br />&bull; Treatment and prophylaxis of toxoplasmosis.<br />&bull; Treatment of nocardiosis.<br />The following infections may be treated with Co -Trimoxazole where there is bacterial evidence of sensitivity to Co -Trimoxazole and good reason to prefer the combination of antibiotics in Co - Trimoxazole to a single antibiotic:<br />&bull; Acute uncomplicated urinary tract infection.<br />&bull; Acute otitis media.<br />&bull; Acute exacerbation of chronic bronchitis.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><u><strong>General Dosage Recommendations</strong></u></p><p>Where dosage is expressed as &quot;tablets&quot; this refers to the adult tablet, i.e. 80 mg Trimethoprim BP and 400 mg Sulfamethoxazole BP. If other formulations are to be used appropriate adjustment should be made.</p><p><u><strong>Standard dosage recommendations for acute infections </strong></u></p><p><strong>Adults (&gt;18 years old) :</strong></p><p><img alt="" width="600" height="95" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAkACQAAD/4RD6RXhpZgAATU0AKgAAAAgABAE7AAIAAAAQAAAISodpAAQAAAABAAAIWpydAAEAAAAgAAAQ0uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEFobWFkIEFsWmFocmFuaQAABZADAAIAAAAUAAAQqJAEAAIAAAAUAAAQvJKRAAIAAAADNTYAAJKSAAIAAAADNTYAAOocAAcAAAgMAAAInAAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADIwMjA6MDQ6MjEgMTQ6Mjc6NDQAMjAyMDowNDoyMSAxNDoyNzo0NAAAAEEAaABtAGEAZAAgAEEAbABaAGEAaAByAGEAbgBpAAAA/+ELImh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjAtMDQtMjFUMTQ6Mjc6NDQuNTYxPC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPkFobWFkIEFsWmFocmFuaTwvcmRmOmxpPjwvcmRmOlNlcT4NCgkJCTwvZGM6Y3JlYXRvcj48L3JkZjpEZXNjcmlwdGlvbj48L3JkZjpSREY+PC94OnhtcG1ldGE+DQogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgIDw/eHBhY2tldCBlbmQ9J3cnPz7/2wBDAAcFBQYFBAcGBQYIBwcIChELCgkJChUPEAwRGBUaGRgVGBcbHichGx0lHRcYIi4iJSgpKywrGiAvMy8qMicqKyr/2wBDAQcICAoJChQLCxQqHBgcKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKir/wAARCADvBewDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6IvNSsdO2f2he29r5mdnnyqm7HXGTz1H51V/4SXQv+g1p3/gUn+NE/wDyNlh/15XP/ocFadAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf41p0UAZn/CS6F/0GtO/wDApP8AGj/hJdC/6DWnf+BSf41p0UAZn/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NadFAGZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWnRQBnxeINGmmSKHV7GSR2CoiXKEsT0AGeTWhWZr/APyDYv8Ar9tP/SiOtOgDMn/5Gyw/68rn/wBDgri/iZ421zSdf8P+EvB62qazr0jhbu7G6O2jXq23uevr93ociu0n/wCRssP+vK5/9DgrnPiP8N4PHttYzwajPpGs6XIZbDUIPvRMcZBGRkZUHggjH1BAKvhvTvidoviW0h8Ra3p3iTRbgOLm4FqttPakISpCrgMpYBe5+bPasHxxpvxQ0DR9d8Q2fxFhWzs0muobIaNASsYyyx7yD0GBk5pmifEDxl4O8aaZ4S+KVrb3UeqyCDTtbshhZpMhQrrgDJJA4AIyOCDmu0+Kv/JI/FH/AGC5/wD0A0Acb4I034o6/o2h+ILv4iwtZ3kcN1LZHRoAWQ4Zo94AxkZGRXU/FrxddeDfh9c3uksBq11JHaaeu0MWmc4GFPBIUMcYPSrPwq/5JH4X/wCwXB/6AK4D4geINJ1T4/eGdC1rVbKw0vw/GdUumvLhIka4I/dJliAWHyNj0Y0AdL8GvGGseJNF1bTPF06zeINC1B7S8ZUVNwydrYUAdQ44AztzWd8cfFni3w7/AMI3ZeBrpbe+1S5ljx5CSGUqq7UG8EDJP545FYFn4k0TRf2n0udC1mw1DTPFlmIZ/sV1HMsd0vC7tpOCdoA9TIa3vi7/AMlG+GP/AGGm/wDadAHX/DfxpB498DWWsx7UuSPKvIR/yynXhlx2B4YezCsb4TeKdY8T/wDCV/23d/af7P16e0tv3SJ5cS42r8oGcepyfeubTPwo+Ouwfu/DPjV8qP4La+z+gYt/4/6JV34D/wDM8/8AYz3X9KAOd8A3/wAVPiPpep6tY+P4NMitdSls0tn0iCQfKqsPm25x84Hc8V0vh7x/4p8PeP7XwX8ToLN5dRBOmavZArHckfwsp6N24xgkDBBBqn+zR/yIevf9jDcf+ioaT4+hW1T4frb/APIQPiCL7Ofbcuff72zpQB6l4i1q38OeGdR1m8P7mxtnnYZ+9tGQo9ycAfWvJ/gv8RPFeteJrvQ/H1wklzeafDqumFYEj/cvyQNoGeGXGcnhuTVr9oPWoG0jQ/B8t9DYr4g1CNbueaQRpFbIwLszHgfMUPP901z3xQ8UeF9E8Z+CfGPhbXdJuzpM4sLu3sb2OZ/sjA9FVicKpkH1YUAd/wDG/wAU6v4O+GVxqvh26FpfLcRRrMYlk2hm54YEdOORXL64Pi74N8MSeKD4y0/xBbWcQuLiwuNLjg3R4y2GQAkge4/pV/8AaTdZPgtcOjBla7tyGByCN3WuO8fav8SIfDWn6d4+bS9K8Kai8dte6jocDzSRxnGFcSP8oOOSB+f3SAen6944uLj4E3XjLQSbO5k0v7VBvUP5LkDIwRg4OeowcdK5Tw1p3xf17wjpviCz+IdlI17apcpZXWkQqnzLkKzoufxArpPiNpVlof7PmsaXpIxZWmlCKD5t2UGADnuT1z3rX+FX/JI/C/8A2C4P/QBQBkfDb4i6h4i1bVPC/i/T49N8T6PgzxRNmOeM4xInJOOV9eGUg84HoleN3QB/bAs/sPGPD5+2e/L46f8AbPr/AIV7JQB4N4Nv/ij8Q5dfu9N8ew6VBYapNaR27aTBLwOR8xXOMEDnJ4rf0fx94r8KePbHwj8T4rKdNWJXTdZsl2JK/TY6noSSBwBgkdQciv8As7/8gzxf/wBjDP8AyWm/tFgHS/CAtuNQPiCH7OfT5Wz7/e2dKAOm+JvxCvPCb6XovhmwTU/EutSGOytnJ2IB1kfGOASOMjuc8GsWbw98aoLRr6HxvpFzdqu/+zDpqLCxx9wS7d34nH1FVNVIP7X2iC86LoDm0B7NmXOPfG//ADivY6AOF+HHxITxn4Tvb7VLT+ztT0iR4NTtBk+U6DJIzzg4PB5BBHOMnjvDGsfFH4n6XJ4n0DxDpvhzTXndLLT2slnMqqcfvHYEjkYyvucDipvhOkcnxo+KRtlVrRryFZAB8pkzLuHvzvzUM/w98b/C+a8v/hVqMeo6PJI08nh6+Utt7kRNnk446qTxnccUAeqeFpddm8NWreLbe2ttYG9blLVt0RIchWU56MoVsds4rx74o/FbxRoPxAmTwvKp0Lw4ls+toIUfzGlkHybiCR8pA4I5Jr0Lwb8TtM8WfDm48WSRPYx2Cyi/gc5MDxqGcA9xggj6+vFeXfD698La78L/ABVL4r8TaLZav4wuLiaeO41CJJIByIgVZsja2WHHQigD6DtriK8tYrm2kEkMyCSN16MpGQfyNeUXnjzxd468XajoHwuFlZ2GlP5N9rt8hdfNyQUiXocYPUHOOwwTJ8B/E0uvfB9bJpfMv9F8ywbYwbIUZiII6jaQoPfaarfsz+V/wp8tBsM51Cfzjnkv8uN3vt2/hQBoQ6d8YPDt9bTvrul+LbJplW5t5bRbSZUJAJQphTgZPJ/A0fGvxR4i8PQ+GbTwpqa6Zcatqi2klwbdJsK3A+VwR1OfXjrWL4i8d/FnwWdKuvE+n+E2sb7UobE/YhcNIC+TxufA4VueeccUftFC7J8EDTTELw64n2cz58sScbd2OcZxnHagDoLDwj8U4NStpb74mQXVrHKrTQDRIE81AQWXcBkZGRkdM16VXAeHoPi0mv2reKbvwnJpIJ+0LYifziNpxt3KB97HXtmu/oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDM1/wD5BsX/AF+2n/pRHWnWZr//ACDYv+v20/8ASiOtOgDMn/5Gyw/68rn/ANDgrnPGU3xD07W7e/8ABVrp2saZ5Gy40u5kEMvmAsd6SHA5BAwTgbenJNdHP/yNlh/15XP/AKHBWnQB5DH4Y8dfEHxtoOr+OtOs/Duk6Bcfa4NPguhcTTzggqWZTtwCo/UYOcjvfH+l3mt/DvXtL0yLzry7sJYYI9wXe5UgDJIA59TXQ0UAc94A0u80T4d6DpepxeTeWlhFDPHuDbHCgEZBIPPoa4jwD8Mze6p4l8R/Evw9Y3Gp6xqBeC2vo4br7Pbr9wA/MAcHHB6ItesUUAeTfFL4SWl/4Whuvh5oGm6f4g068iurU2VvFbNLtPKlsKOM7uT1WtDxv4b1/wATeIvh5qtvpoT+zL4XOpRGdM2wIQkdfmwQR8ua9JooA5T4k+C4vHnge80gsI7sfv7KY8eVOv3DnsOoPsTXNfAvwn4l8K+HdZHjK2FvqGoao90R5qSF9yrlsoSBkg8V6hRQB4H8P7D4qfDnTNT0my8AwanFdalLdrcvq8EYwwVR8u4nGEB7HnpXUeH/AAF4n8Q+PrTxp8TJrOObTUK6ZpFiS8duT/GzHq30zkgHIwBXqlFAHlz+AbzxT8b9S1/xlo9vcaBY2KWmlQ3XlzpMx5aQx5OMEv1APK+lani74SeFNb8H6pp2leGtGsL6e3YW1zb2MUTxyjlDuVQQMgZ9s13tFAHifiTwd418Sfs22Hhy60k/8JFatDG9s13ES6RtgNv3bclME5OetekeK/Csfiv4d3vh27Chrmz8tSeQkoAKN+DAH8K6SigDyq28O+L9S/ZvufDOtad5fiBLB7OOFriNvOCn92d4YqCVAHJ6jnFZvhjUfi9oPhPTfD9r8PLJGsbVLdLy61eFkO0Y3MiNn8Aa9nooA89+HHw8v/Durar4o8W38Wo+J9YwLiWBcRQRjGI0zyRwvPH3VHbJ9CoooA8G8GWHxQ+Hs2vWmneAodVt9Q1SW7juG1eCL5W4Hy7s4wAecHnpXRaP4E8VeK/Hmn+Lvia9jbrpOW0zRrEl0ic8+Y7nqwIB4zkgdMYPq9FAHnnxO+Huo+JrzSfEfhK9isPEuiOWtpJh+7mQ9Y26479sckHrkZcniD41X1qbGDwXo+m3TLtOpy6kkkKn+8IwS3uAc/j0r1eigDhfBHw9ufBHgXUNPsdTEviDUfNuJ9Ukj3ZuXUhX2nOVU4OD15PesIa78a4Lb+z5PB+i3V3goNWj1BVgB7MYiQ5/DH07V6vRQB4hqHwu8UaL8D5fCOhMNS1jXNRE+rXSzLGkQfBkYbiCVxGi4AyQWOOcV6JZfC/wRZafb2v/AAieiT+REsfmzadC7vtGNzMVyScZJPU11dFAHl3hPwNqfgr4061c6LpkcXhHWbRJD5DxoltcL0UR5Bx9/ouPnHpVG48B+MvAHi3Uda+Fxsr/AEvVZDNd6HeyeWFkJyWibgDqepGM4wcDHr9FAHiniHRfib8TZtIstc8NaZ4a07T9Siv5JJNQFxI5QEYXy8jo54OOccitv41+F/EXiGHwzd+FNMXU7jSdUW7ktzcJDlV5HzOQOox689K9QooA80tPF/xVlvoI7v4YwQQPIqyyjXIG8tSeWwDk4HOK9LoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDM1//kGxf9ftp/6UR1p1ma//AMg2L/r9tP8A0ojrToAzJ/8AkbLD/ryuf/Q4K06zJ/8AkbLD/ryuf/Q4K06ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMzX/APkGxf8AX7af+lEdadZmv/8AINi/6/bT/wBKI606AMyf/kbLD/ryuf8A0OCtOsyf/kbLD/ryuf8A0OCtOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDM1/8A5BsX/X7af+lEdadZmv8A/INi/wCv20/9KI606AMyf/kbLD/ryuf/AEOCtOsyf/kbLD/ryuf/AEOCtOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDM1//AJBsX/X7af8ApRHWnWZr/wDyDYv+v20/9KI606AMyf8A5Gyw/wCvK5/9DgrTrMn/AORssP8Aryuf/Q4K06ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMzX/+QbF/1+2n/pRHWnWZr/8AyDYv+v20/wDSiOtOgDMn/wCRssP+vK5/9DgrTrMn/wCRssP+vK5/9DgrToAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzNf8A+QbF/wBftp/6UR1p1ma//wAg2L/r9tP/AEojrToAzJ/+RssP+vK5/wDQ4K06wNdjvJdbsE0x2juvs853iZYxs3RZB3RSZJJXsOhqD7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSj7D4p/5/f/JyL/5EoA6aiuZ+w+Kf+f3/AMnIv/kSoLdfEtzPdRJeMGtZRE+buLBJRX4/0Tphx+OaAOtormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKAOmormfsPin/AJ/f/JyL/wCRKPsPin/n9/8AJyL/AORKANPX/wDkGxf9ftp/6UR1p1yj2ur/AG/T4NYupHt57pcCO5jb54wZlyBbIcZi7MK6ugDMn/5Gyw/68rn/ANDgrTrMn/5Gyw/68rn/ANDgrToAKK8w0/4/+D9S8dp4Vt49RF1JeGzjumijEDyAlRg792CRgfL3Fen0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVmaV/wAhLWv+v1f/AEnhrTrDS/i0tPEuoXCu0VpOZ3WMZYqtrExAHrgUAblFeJf8NV+CP+gV4g/8B4P/AI9Wz4R/aD8KeM/FVl4f0vT9Ziu7wsI3uIIgg2oXOSshPRT2oA9UooqO4l8i2lmI3eWhbHrgZoAkorgfhP8AFAfFDSL++GkHS/sc4h2fafO35XOc7Vx9K76gAorz34cfFVfiD4g8QaYNHOn/ANjShBKbnzfOBd1zjaNv3M4yetehUAFFFc94d8e+GvFeqahp3h/U1vLvTm23UYhkTYdxXqygMMg8jNAHQ0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBmar/wAhLRf+v1v/AEnmrTrM1X/kJaL/ANfrf+k81adAGZP/AMjZYf8AXlc/+hwVj/E7xP8A8If8Nda1iOTZcRW5jtj381/kQ/gzA/hWxP8A8jZYf9eVz/6HBXiP7SeqT61rPhfwBpkn7/ULlZ5lHOCzeXFn2yZD+AoA821j4fzaB8A/DPjW0RodU/tBrmaUfeWOQgQtn0BiQj3kNfTY8e2w+EQ8cCPzIxpn2wwqer7eY89vn+XPavL9S/Z48UzeHJtOb4o6pe2aQBY9Olgk8l9gyibTOQACq44OMDjiud+FXiy4f9nvxroH2P7ddaXBI0Vq6k5hmBDcdTtYOx+ooAlm8afGvVPh3P8AEKy1vTbHRcsy2kVvEZAiyFCwDxtwGBHL546V2Xhv4k+IvDvwHuPG/jfUINauLuTOmxxRrETuwixuFRQMMrk4zwOCeleLeFtP8Gah4YsrDX/irqWl2sx8y80MWM5iWQMeQwJj6AHJU/0r2f4seH7DWP2dILf4fmO+0zTHimhFq/m7ok3K2D3I3EnvwaAOIf4pfEz+wh4p/wCE58HiLZ5/9gLcQGfb127Mb84/h8zd268V778O/GC+O/AeneIBB9nkuVZZoQchJFYq2D6ZGR7EV86eErv4AS+DbF/FWnTQ61FAqXce+8JmkAwXUo2wBiM4yMZ6Cvof4ar4d/4V9psvgywlsNGnDy28ExJcZc5JJZjycnqeMUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWZpX/IS1r/r9X/0nhrTrM0r/kJa1/1+r/6Tw0AeOftXf8k/0f8A7Cg/9FPXrngz/kQ9A/7Btt/6KWvI/wBq7/kn+j/9hQf+inr1bww80fw10d7VA866RAY0P8TeSMD86APNdQsv2gNVuLq7sdT0PRIY5H8myAR2kUH5eTG4yQO7Dr27XPgx8T9R+I3g3W49dSH+0dMUK80KbRKjq20legOUbOOOnFeD6PdeFfFMmr3/AMZvFPiCLVopiIbO3jJZvUDcjKhByNp2gY6+ne/ssqU03x0rAqwitQQR04uKAOc+B7/EW80PV9K+HJsLBDMs9zqV6uQrbcLGoKsMnBP3T9R39W+CvxS1/wAR+ItX8H+OVjOtaYHYTIgQvscJIrBcLkEjBAGRn0rzX9n/AOJ+heAtL1W08U/aLS2vJvNgvVheSN3RQGj+UE7sMp9OeccZ3/gOlx4s+NnivxvBbSQ6XL56xl1xlpZVZV9MhFJODwSPWgCx+zrKkHjr4hSzMEjjmDMx6ACWYk1Rf4weNPHerahN4V8V+GfB+lWsmy3XV7iGOa5HY4kVznvwABnGTg1P8ArVr7xV8SrRGCtcExBj0BZ5hn9a4L4d2vw30W71bRfjLpU9tqVtcYjldrkBABhkKwt6jIODkHr0oA9h+G/xK8V/ELw74l0BLnT7fxTpibbXUocNby5YrvOAynBXqAQQwIFeTfCTS/iFe+OPEMXgvXdP07UYn/4mM11GGSb94c7R5TfxZPRa9v8Ag43wzudS1uT4YaZcW5t0hjurqUylZQxcqE8xyeNhzwO3Xt5V8LfGGjfDb4s+M4/GM8lgZppIoz5DvuYTE4woJ5ByDjGO9AHbfED4k+Mrv4vnwB4H1DTdDkhjQte6gFxK7RiTALKwxhgAApJOa9G+Ha+OodMvLb4jNZT3cM4Ftd2m0LPHtGSQAMYOR91fp3rzT4uXnwh13xZf6V43nvdI13To40F9bwOTIGRZFA2hgwAcD5gD1APen/sw6rrt/o2uWt9c3N5olnNGmnTXIPB+bcq5zxgIducDPvQB7vRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZmq/8hLRf+v1v/SeatOszVf+Qlov/X63/pPNWnQBmT/8jZYf9eVz/wChwU+fQNHudYh1e50mxm1KBdsV7JbI00Y54VyNwHJ6Huaq6k92nibTzYQwzSfY7nKzTGMAb4OchW56cYqfz9d/6B2nf+DB/wD4zQBp1538SfAAvfh7r1v4D0nT7DWtQQCSS1hjgkuk8wM6GQAZ3AHqcHPPWux8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/GaAPmCzt9atfA58KP8AArz9V8hoP7ZksmLbiD+83+X1Gc5EgGRxjpXtXwL8Dar4D+HZsdeIS9u7p7t7dXDCAFVULkcE/Jk445rtfP13/oHad/4MH/8AjNHn67/0DtO/8GD/APxmgCvL4J8Kz3xvZ/DOjy3ZO4zvYRGQn13Fc1tIixxqkahEUAKqjAA9BWb5+u/9A7Tv/Bg//wAZo8/Xf+gdp3/gwf8A+M0AadFZnn67/wBA7Tv/AAYP/wDGaPP13/oHad/4MH/+M0AadFZnn67/ANA7Tv8AwYP/APGaPP13/oHad/4MH/8AjNAGnRWZ5+u/9A7Tv/Bg/wD8Zo8/Xf8AoHad/wCDB/8A4zQBp0Vmefrv/QO07/wYP/8AGaPP13/oHad/4MH/APjNAGnRWZ5+u/8AQO07/wAGD/8Axmjz9d/6B2nf+DB//jNAGnRWZ5+u/wDQO07/AMGD/wDxmjz9d/6B2nf+DB//AIzQBp0Vmefrv/QO07/wYP8A/GaPP13/AKB2nf8Agwf/AOM0AadFZnn67/0DtO/8GD//ABmjz9d/6B2nf+DB/wD4zQBp0Vmefrv/AEDtO/8ABg//AMZo8/Xf+gdp3/gwf/4zQBp0Vmefrv8A0DtO/wDBg/8A8Zo8/Xf+gdp3/gwf/wCM0AadFZnn67/0DtO/8GD/APxmjz9d/wCgdp3/AIMH/wDjNAGnRWZ5+u/9A7Tv/Bg//wAZo8/Xf+gdp3/gwf8A+M0AadFZnn67/wBA7Tv/AAYP/wDGaPP13/oHad/4MH/+M0AadFZnn67/ANA7Tv8AwYP/APGaPP13/oHad/4MH/8AjNAGnRWZ5+u/9A7Tv/Bg/wD8Zo8/Xf8AoHad/wCDB/8A4zQBp0Vmefrv/QO07/wYP/8AGaPP13/oHad/4MH/APjNAGnRWZ5+u/8AQO07/wAGD/8Axmjz9d/6B2nf+DB//jNAGnRWZ5+u/wDQO07/AMGD/wDxmjz9d/6B2nf+DB//AIzQBp0Vmefrv/QO07/wYP8A/GaPP13/AKB2nf8Agwf/AOM0AadFZnn67/0DtO/8GD//ABmjz9d/6B2nf+DB/wD4zQBp0Vmefrv/AEDtO/8ABg//AMZo8/Xf+gdp3/gwf/4zQBp0Vmefrv8A0DtO/wDBg/8A8Zo8/Xf+gdp3/gwf/wCM0AadFZnn67/0DtO/8GD/APxmjz9d/wCgdp3/AIMH/wDjNAGnRWZ5+u/9A7Tv/Bg//wAZo8/Xf+gdp3/gwf8A+M0AadFZnn67/wBA7Tv/AAYP/wDGaPP13/oHad/4MH/+M0AadFZnn67/ANA7Tv8AwYP/APGaPP13/oHad/4MH/8AjNAGnRWZ5+u/9A7Tv/Bg/wD8Zo8/Xf8AoHad/wCDB/8A4zQBp0Vmefrv/QO07/wYP/8AGaPP13/oHad/4MH/APjNAGnRWZ5+u/8AQO07/wAGD/8Axmjz9d/6B2nf+DB//jNAGnRWZ5+u/wDQO07/AMGD/wDxmjz9d/6B2nf+DB//AIzQBp1maV/yEta/6/V/9J4aPP13/oHad/4MH/8AjNZ+mzayNQ1fZYWJY3i7wb5wFPkRcD91yMYOeOSR2yQDV1XQ9J162W31zTLPUoEbesV5bpMqtjGQGBAOCeauRxpDEscSKkaKFVFGAoHQAdhWd5+u/wDQO07/AMGD/wDxmjz9d/6B2nf+DB//AIzQAy48K+HrrVBqd1oOmTX6nIu5LONpQfXeRn9ansdC0nTJbuXTdLsrOS9ffdPb26RmdueXIHzH5jyc9T61H5+u/wDQO07/AMGD/wDxmjz9d/6B2nf+DB//AIzQBCPB/hldJOlr4d0kaeZPNNoLGPyi/Tds24zwOcdq0rKwtNNs0tNOtYLS2jGEhgjCIo9lHAqn5+u/9A7Tv/Bg/wD8Zo8/Xf8AoHad/wCDB/8A4zQA/TtA0fSLi4n0nSbGxmum3XEltbJG0xyTlioBY5J6+pqPVfDGga7IsmuaHpupOgwrXlpHMV+hYGl8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/GaALVhptjpdsLbTLO3s4ByIreJY1H4AAVUvfC+galqKahqOh6bd3seClzPaRvIuOmGIyKXz9d/6B2nf+DB//jNHn67/ANA7Tv8AwYP/APGaAG6r4W8P65KJdb0LTdRkUYD3dnHKR+LA1oW1tBZ2yW9nBHbwRjakUSBVUegA4FUfP13/AKB2nf8Agwf/AOM0efrv/QO07/wYP/8AGaANOiszz9d/6B2nf+DB/wD4zR5+u/8AQO07/wAGD/8AxmgDTorM8/Xf+gdp3/gwf/4zR5+u/wDQO07/AMGD/wDxmgDTorM8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/GaANOiszz9d/wCgdp3/AIMH/wDjNHn67/0DtO/8GD//ABmgDTorM8/Xf+gdp3/gwf8A+M0efrv/AEDtO/8ABg//AMZoA06KzPP13/oHad/4MH/+M0efrv8A0DtO/wDBg/8A8ZoA06KzPP13/oHad/4MH/8AjNHn67/0DtO/8GD/APxmgDTorM8/Xf8AoHad/wCDB/8A4zR5+u/9A7Tv/Bg//wAZoA06KzPP13/oHad/4MH/APjNHn67/wBA7Tv/AAYP/wDGaANOiszz9d/6B2nf+DB//jNHn67/ANA7Tv8AwYP/APGaANOiszz9d/6B2nf+DB//AIzR5+u/9A7Tv/Bg/wD8ZoA06KzPP13/AKB2nf8Agwf/AOM0efrv/QO07/wYP/8AGaANOiszz9d/6B2nf+DB/wD4zR5+u/8AQO07/wAGD/8AxmgDTorM8/Xf+gdp3/gwf/4zR5+u/wDQO07/AMGD/wDxmgDTorM8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/GaANOiszz9d/wCgdp3/AIMH/wDjNHn67/0DtO/8GD//ABmgDTorM8/Xf+gdp3/gwf8A+M0efrv/AEDtO/8ABg//AMZoA06KzPP13/oHad/4MH/+M0efrv8A0DtO/wDBg/8A8ZoA06KzPP13/oHad/4MH/8AjNHn67/0DtO/8GD/APxmgDTorM8/Xf8AoHad/wCDB/8A4zR5+u/9A7Tv/Bg//wAZoA06KzPP13/oHad/4MH/APjNHn67/wBA7Tv/AAYP/wDGaANOiszz9d/6B2nf+DB//jNHn67/ANA7Tv8AwYP/APGaANOiszz9d/6B2nf+DB//AIzR5+u/9A7Tv/Bg/wD8ZoA06KzPP13/AKB2nf8Agwf/AOM0efrv/QO07/wYP/8AGaANOiszz9d/6B2nf+DB/wD4zR5+u/8AQO07/wAGD/8AxmgDTorM8/Xf+gdp3/gwf/4zR5+u/wDQO07/AMGD/wDxmgDTorM8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/GaANOiszz9d/wCgdp3/AIMH/wDjNHn67/0DtO/8GD//ABmgDTorM8/Xf+gdp3/gwf8A+M0efrv/AEDtO/8ABg//AMZoA06KzPP13/oHad/4MH/+M0efrv8A0DtO/wDBg/8A8ZoA06KzPP13/oHad/4MH/8AjNHn67/0DtO/8GD/APxmgDTorM8/Xf8AoHad/wCDB/8A4zR5+u/9A7Tv/Bg//wAZoA06KzPP13/oHad/4MH/APjNHn67/wBA7Tv/AAYP/wDGaANOiszz9d/6B2nf+DB//jNHn67/ANA7Tv8AwYP/APGaANOiszz9d/6B2nf+DB//AIzR5+u/9A7Tv/Bg/wD8ZoA06KzPP13/AKB2nf8Agwf/AOM0efrv/QO07/wYP/8AGaANOiszz9d/6B2nf+DB/wD4zR5+u/8AQO07/wAGD/8AxmgDTorM8/Xf+gdp3/gwf/4zR5+u/wDQO07/AMGD/wDxmgDTorM8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/GaANOiszz9d/wCgdp3/AIMH/wDjNHn67/0DtO/8GD//ABmgDTorM8/Xf+gdp3/gwf8A+M0efrv/AEDtO/8ABg//AMZoA06KzPP13/oHad/4MH/+M0efrv8A0DtO/wDBg/8A8ZoA06KzPP13/oHad/4MH/8AjNHn67/0DtO/8GD/APxmgDTorM8/Xf8AoHad/wCDB/8A4zR5+u/9A7Tv/Bg//wAZoA06KzPP13/oHad/4MH/APjNHn67/wBA7Tv/AAYP/wDGaANOiszz9d/6B2nf+DB//jNHn67/ANA7Tv8AwYP/APGaANOiszz9d/6B2nf+DB//AIzR5+u/9A7Tv/Bg/wD8ZoA06KzPP13/AKB2nf8Agwf/AOM0efrv/QO07/wYP/8AGaANOiszz9d/6B2nf+DB/wD4zR5+u/8AQO07/wAGD/8AxmgDTorM8/Xf+gdp3/gwf/4zR5+u/wDQO07/AMGD/wDxmgDTorM8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/GaANOiszz9d/wCgdp3/AIMH/wDjNHn67/0DtO/8GD//ABmgDTorM8/Xf+gdp3/gwf8A+M0efrv/AEDtO/8ABg//AMZoANV/5CWi/wDX63/pPNWnWBdS6k+saML+0tYY/tjYaG6aQk/Z5uMGNeOvOa36AMyf/kbLD/ryuf8A0OCtOsyf/kbLD/ryuf8A0OCtOgAooqlrGs6doGlzalrV7DZWcIzJNM21R7e5PYDk0AXaK5HwH8S9C+Iw1JvDq3fladKsbyXEQQSbs4ZRknHynqAfarfjDx3ofge0t5dcnk827k8u1tbeMyzXDeiIOvUc9OQO4oA6OiuA0X4w6HqniK20PUdL1zw9qF4dtrFrVgbfzz6KckZ+uPTuK7+gAooooAKKKKACiiigAooooAKKKKACiiuX+I3jT/hAPBF34h+wf2h9neNfs/neVu3uF+9tbGM56UAdRRUdvL59tFMBt8xA2PTIzWJ458Uf8IX4J1LxCbT7b9hjD/Z/M8vflguN2Djr6GgDfoqlo2o/2voNhqQi8r7ZbR3Hl7t2zeobGe+M9au0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWZpX/ACEta/6/V/8ASeGtOszSv+QlrX/X6v8A6Tw0AadFeea/8avDmiateaba2Ws65c2DlLwaTZGZbZhnIdiVHGDnBOPwro/BvjfQ/Hmif2p4cujNCr+XIjrtkib0Ze3H4GgDoKKKq2Oqafqnn/2bfW159nlMM32eZZPKkHVGweGHcHmgC1RRRQAUVyfhfxyPEvjLxVoA0/7N/wAI9NDF5/nb/tHmBznbtG3Gz1Oc11lABRXJ+H/HI134geJvDH9n+R/YPkf6T527z/MXd93aNuPqc+1dZQAUUVVtNUsL+4uYLG+trma0fy7mOGZXaF/7rgH5T7GgC1RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWV4i8TaP4T0iTU/EN/DY2sf8AHIeWP91VHLH2AJrN8BePtJ+Iuh3GraFFdxW0F01qwukVGZlVWyAGPGHHv7UAdPRXIeL/AIm6D4N1CHTbxL7UNUnj82PT9NtjPMyZI3Y4AGQepFR+Cfin4d8dX1zp+m/bLLU7UbptP1CHyplXOCcZIODjODxkZ60AdnRRXJ6P45GrfE3xD4Q/s/yjosMEv2vzt3neYitjZtG3G7HU59qAOsooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMzVf+Qlov/X63/pPNWnWZqv/ACEtF/6/W/8ASeatOgDMn/5Gyw/68rn/ANDgrK8X+Hdd1aS0vvC3iWfRb+zDBYmQS2tyCQcSxn6YDDkZNas//I2WH/Xlc/8AocFZXi/xFrukyWlj4W8NT61f3gYrKziK1tgCBmWQ/XIUcnBoA56D4n6h4ZnSy+KehvorMwRNYs909hMen3h80ZJ7MPxrr9X8N6B4uTT7jWLK31SC2b7RaiX54iWHDbejcdM5HNcbb/Cu+8S3Sah8VNbfXHVt8ekWhaGwgPptHMmPVvxzXbarr+g+ErG3/tnUbLSbU4ig8+RY14H3Vz6DtQB5j8DkWPxz8UERQqr4gkAUDAA82birPxjtL7QPEnhv4j2kUN5beHTIl5aSyrGWjkG3chbgsMnjrnbgGub+D3jXwzpvjf4hy6hrthbR6jrry2bSzqouEMkuGTPUfMPzFaHxKvbGD4+eGV8esqeFI7JpLX7QCbY3eW5fsSBs68DjsTQBUfxTZfHbx/4ctPD6iz03w/cR6pdTXjolxI4wRFHGCSRxhm6fkN3vVeAfGDV/DWtar4bm+HV9Y33jUalELWbSpFkby8HIlZDjZ04J6Z7Zr3+gDg/DPjnUr34qeJfBviCC1hksFS6014EZTPbt3bcxyw3ICRgZ3cDFP/4TbUrz42DwdpVvbPp1jp/2vVLiRWMiO3+rRSGAH3kPIOQT0xmua+L4PhDxl4U+I8CsIrG4/s/VNgyTbSZwx/3cv+JWrnwNsZr7R9Z8b6jGVvPFN/JcoGHKW6sVjT8Pmx6jFACx+OfG/jPUL8/DTS9ETSbC5e1/tHW5ZcXbr97y0j5Cg9z19ug3PAPjq88S32saH4h01NM1/RJES7ghkLxSK4ykiE9iOxzjj1rw/wCG/g/4YW8Wp6B8U7a1sfEWm3rxs99fy2qzRfwsp8xVPfp1GDzmvXfAGmfDrR01y5+FcNvc3UMKrc/Z7madXOGZEDOxByQfun69qAIZ9U+NM0Ml7aaB4UtIkBZbC5uZpbhgP4Q6ER5/IVq+F/iL/wAJX8Ip/GFpZrb3ENrcO1tISyrLErcZ4JU4B7cGvJvDviHTvFfhV/Efj34uaxo+otJKZNJ0q/WzNuAxCosQUs+QAQQO+Dk5NdB8IEaP9mHV0kUo6w6gGVhgg7G4NAGl4L+InxE8eWOl6po3h3SodKDJHqFxdu6NO27Eht1DHCqM8tnJH4VfuPHXjTxJ421zQ/h7p2hpBoMiQ3dxrUsuZnIPCLHyBwRk5BxnvitL4G/8kT8N/wDXB/8A0a9cz4vh+GWr65qWsWfjaPwt4mspHt7m7tL37PK0kZ2lXibHmgFcfKOcDk0AeqeH7jVbrQrabxFYxWGpEMJ7eGXzEUhiAVb0IAb1GcHpWN8RPHdr8P8Awx/ac9s97dTyrb2dnEcNcTNnC55wOCScH8SQKofBzxDrPij4Y6dqniM77yRpEE/l7PPRWIV8e4H44zXO/H23ubWw8L+J4raW6tPD2sxXl5FGMkRBgS2PqoH/AAKgCLUfGvxd8OaTJ4h17wpoMukQJ51zZ2dxJ9qhj7ksSVOBycA/pTPjXrtn4m/Zvn1rS2ZrW++yyx7hhgDKuQR6g5B9xV/xp8ZPBE3w91IaVrcGo3eoWclva2dvuM0kkilVBXGV5PcD88CuP8YeH7zwv+xzbaTqaNFdxCGSWN+sbSXPmbT7jfj8KAPS/HPj1fAPgrT7mCybUdSvmitLCzU486Vl4yfQfzIHevN/ijr/AMS4Phfq9v428NaYbC+hVRc6RMxNm29SBKrE5BxjcvAP1FbXxo8zSrTwD4rkt2n0/QtThlvNibiiNs+bH/AMD3IqD4x/FHwprPwu1PSPD2pLrF7fwBljslL+TGrKzSSH+AADvzkjjrgA9U8Gf8iHoH/YNtv/AEUtbVYvgz/kQ9A/7Btt/wCilraoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACszSv+QlrX/X6v/pPDWnWZpX/IS1r/AK/V/wDSeGgC2I7PTLaeZUgtIcvPO4UIuTyzsfXuSa8f/Z+tzear468T2kHkaRrOrE2C7SoZUeUlgD2/eKOO4I7VlePviFp3jzxhN4GXX7XQfDdlLt1nUJ7gRSXZU4MEQPUZBBPTj0wG9W8H+IPBtzaw6F4L1XTbiOxtxstbOdXMcYIGSAc9SMk9SeetAGxrn9r/ANi3P/CN/Yv7U2/6P9v3+RuyPv7PmxjPSvCvgt/wsH+0vEX9mf8ACNfYv+Ejl/tb7R9o8zflfN8jHGMfd3c5619CV4d8IPFeh+Hdc8Z6NrmpwWGo3Hiebybac7Xl3sEXaO+T6fXpQB3niS9+JL69JaeDtK0COwjRSt9q9xIRKxGSAkXzDB45ql4C8ea5q3i3WPCPjPTbSy1vSoknMlg7NBPG2PmXdkj7y9T37YrjvEfiOfW/jDrfhzxR45uvBejabBE1mtpcLaPeblBZ/Pb0zjH5cg5qfB/+zj8ePEp0XXNS1+y/spBFqOpTGaSfDoGw5A3KGBUEDHFAEWga34l0/wCNPxG0/wAGaHHqWoXt3bsbi7k2W1oiK+WkI5JJcAKOThj2rtvCHxF8RH4gP4J+Imk2dhq8lubmyuNPZjBdIM5ADEkHAbv/AAtwOM8n4T8baL4P+OPxBi8RztYwalewJDeSIfIV0RyUZ+ikh8jPHymrsGs2fxB/aY0XUPC0i3um+G9Pm+130akxs8iugQN0P3wR64bHSgDS+H3/ACcD8S/+3L/0WauHxz4z8X6zqVv8M9M0b+ztLuWtJtT1qSXZPMv3ljSPnAyOTwc1T+H3/JwPxL/7cv8A0Wa838DeEfhrb6t4g0H4r21tZ67Z6jI0U19fS2qT25xtKkOqnkE+4YdaAPX/AAv468Q6+3iLw5e6ZY6Z4x0aMFEkkd7OfeuY5Mj5gmcZHXBHfIHnXwy/4WP/AMJ742/sr/hFvP8A7WT+1vtP2jbvy+fI284xu+97V6H8NNF+GGn6vqj/AA0FtJdQxxx3kttdTTqFcsVAZ2ZTkofuntz2rlPAPivQ/CvxT+I9p4j1ODTZ7nVkkgjuG2mVTvxt9fvLwPUUAdR4k8deJ7n4iyeCvANhpTX9rZreXV3rEkghVSRhVWP5ieRz059q67wrc+I7nSX/AOEw0+zstQjmKf6DMZIZkwCJFzyuSSMHn5feuG8e23w01/xNNFrniWLw/wCJtKRU+2w332O4iVlDqAzYDjDA8Zxk9Oan+CXiTWPEOgauuraidYtdP1KS1sNVaLYbyJejH1+vv3xQB2Xi/wAU2Hgvwpfa9qu429mgOxPvSMSAqj3JIFcHceKPi7a6LJ4jm8NeHBp0cRuH0oXMxvRGBuI342bse34dqu/H7RL7Xfg/qUOmQPcT28kdyYkXLMiN82B7Ak/hXD6R4e/Z31Pw9Bqcv9mWheIPJbXGsTpNG2OV8sy7iQeOAfbNAHX+J/i1Pp3hDwn4x0a2t5PD+qXUcWpG4RjLbI/GVKsACpVwcggnFdD8UPG0vgTwJNq+nwxXV/LLHb2MEgLLLK54GAQT8oY4B5xVO68GeHfEfwQl8OeEY0j0e8smfTeXIDMxlRsv8338HnmvLPAut3HxU8UeBtGv0l2eEbR7vVBKv37iNvKiBz1b5UY/7zelAHqXifx1rOiSaF4d0zS7fVPF+rQb2gEhjtrfav7yRjknZuyAM5ODznrmf8J3428Ia9pFr8SdM0RtP1i6Wzhv9Fkl2wTN91XWTk59RjAye1cp8ZdE0MfGjw1rPjyyafwtdWB0+abdIiwTK8jKWZCCBlx36Bj2rRsPCPwCt9c01dLfTLjUJrmMWkdtqs9wxl3DblVkbHOPvDHrQBu+PvibrfhX4i6Z4a0XRY9WfU7BpLeFcrI0+8quX3YWMBSWOO3UVU8SeOPiL4K8CjX/ABLpWhs9vqUUd2ll5rqbRwAWXL5Dhjt5yOQcUeIf+TqPCf8A2Bbj/wBq16N4j0O28S+GdR0W9/1F9bvAxxkruGAw9wcEe4oAxvH3jeHwh8Nr7xPaGK5KwK1mGyUleQgR9CCR8wJwRwDW34en1O68Nadca9FDDqU1skl1FApCRyFQSoBJPBOOp6V85+E72/8AHF/4N+GurRNu8K3082rgj5WS2O2Ffp82z8Qa+naAMbVvCWha7q9lqes6ZBfXVgrC2M671i3EEkKeM/KOSMjHFea/s0f8iHr3/Yw3H/oqGvTNc8W+H/DLQr4h1my01pwTELqZULgYzjPXGRXjf7Oni3w/p/hnUtLvtZsre/vdfla2tpZlV5g6RKu0HrkggepoA92FrbrePdrBELl0EbzBBvZASQpbqQCxIHufWvGbER+I/wBrW51HRUVrXQ9L+z6hcRj5XmIZQpPdhuA/7Zn0rR+L/wAUjoF5B4O0C8trLW9SQeZqF3KIodPibP7wsf48A4A6deTgHR+G+ofDrwtpNr4d8N+JtMvb25kzLILpWmvJ26secknsOwoA9JrwFtb17Sv2lPHFt4T0T+1tTvbezRDLJsgt1EEWZJW645HA5Ne/V5L4P/5Oc+IX/XnY/wDomOgC74R+IPif/hYb+CviHpNhZ6nLam7s7nTXYwzoDyMMSc8Nzn+E8dKd4m+I2vz+OpvBvw50e11LVLOIS393fyFba13AFVO3BY4I6H8Dzij4h/5Oo8J/9gW4/wDatY+i6/p/w2+PXjKDxhP/AGfbeIjBdWF9OD5Thd2V3duXI54+Tr0yAdBovxG8T6T450/wp8TdGsbK41YN/Z+oaZIxt5WH8BDEkHoOvUrxg5rZ/wCE11D/AIXl/wAIZ5Ft/Z39jfb/ADdred5nmbcZ3Y247Yz71w3ivXdO+J3xe8E6b4OuP7Ti0G9Oo6he2+TDCqsjBd2MHOzHHqB64seKNasvBv7Tmn6x4ilFlpmoaEbSK8kB8sSCQkgnt0H03CgDsvGfjXUPDvj/AMF6HZQW0ltr89xHcvKrF0EYQjYQwAPznOQaxPHHxO1/w58UrTwloWiQ6tJqGlCe1j5V/tBldcu+7CxBEJPGfcVzHizxrovjD44fD2Pw5cNfQabe3CTXkaHyGd0QhFfoxAXJx6it/U/+TttI/wCxYb/0dLQBoax498U+Bvhpda1450rTpdYF4ttaW+mysIJQ4XazM+SuDvz/ALo6ZrT8N3nxMGtWyeLtM8OvptwrF5tKnlElqdpK7lk4fJAX5fXPStHx7c+EovDX2Tx9LbR6TqEy23+k5CNIQWX5h90/ISGyMY615ZoOpQ+Ffix4e8PfD3xlL4l0PUvNF3pr3K3iWCKuQySj7o9Fz25zmgD3miiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDM1X/kJaL/1+t/6TzVp1mar/wAhLRf+v1v/AEnmrToAzJ/+RssP+vK5/wDQ4K06ytRF1DrdneW9jNeRpbzxOIWjBUs0RH32Xj5G6U7+1bz/AKAGo/8Afy3/APjtAGnVDVtB0fX4Y4dd0qx1OKNtyJeWyTKh6ZAYHBqP+1bz/oAaj/38t/8A47R/at5/0ANR/wC/lv8A/HaAM9Ph34KjkV4/B+go6kFWXTIQQfUfLW3fafZapatbanZwXluxy0VxEsiH8CCKqf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QAmleGNB0J2fRNE07TWb7zWdpHCT9doFalZn9q3n/QA1H/v5b/8Ax2j+1bz/AKAGo/8Afy3/APjtAHE/HW21fVvh8nh/w/plxf3OsXsNs7RQGRbeMNvMjkAhRlVGTjGc54rvdH0u30TQ7HSrIbbeyt0t4h/sqoUfyqD+1bz/AKAGo/8Afy3/APjtH9q3n/QA1H/v5b//AB2gA1bw1oWvMh1zRdO1Ix/cN5aJNt+m4HFWrDTbHS7YW2mWdvZwDkRW8SxqPwAAqr/at5/0ANR/7+W//wAdo/tW8/6AGo/9/Lf/AOO0AN/4RXw9/a39q/2Dpn9o53fbPscfnZ9d+M/rVqDSdOtbGWytrC1htZi5lgjhVUkL/fJUDBzk5z1zVf8AtW8/6AGo/wDfy3/+O0f2ref9ADUf+/lv/wDHaALljYWmmWUVnptrBZ2sIxHBbxiNEHXAUcCs698I+G9Tvhe6l4f0q7ugcieeyjkcH13Fc1L/AGref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBpIixoqIoVVGAoGAB6UMqupVwGVhggjIIrN/tW8/6AGo/wDfy3/+O0f2ref9ADUf+/lv/wDHaAIrPwh4a06/+3af4e0q1u85+0QWUaSZ/wB4Lmr2o6ZYaxYvZavY219ayEF4LqFZY2wcjKsCDgjNVv7VvP8AoAaj/wB/Lf8A+O0f2ref9ADUf+/lv/8AHaAL8kEM1u1vLEjwsuxo2UFSvTBHTHtWZbeEfDdnZ3NpZ+H9Lt7a7GLmGKyjVJh6OoGG/GpP7VvP+gBqP/fy3/8AjtH9q3n/AEANR/7+W/8A8doA0IYY7eCOG3jSKKNQiRooVVUDAAA6ACn1mf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp1maV/yEta/6/V/9J4aP7VvP+gBqP/fy3/8AjtU7K61C2u9QlfQr4rdXAlTElvkARRpz+965Q/higBs/gDwbdXElxc+EtCmmlcvJJJpsLM7E5JJK5JJ5zVvSvCfh3QbprnQ9A0vTZ3Ty2ls7OOFmXIO0lQCRkA49hT/7VvP+gBqP/fy3/wDjtH9q3n/QA1H/AL+W/wD8doA06zJvDeh3GsJq0+i6fLqUZBS8e1QzKR0w5G4Y+tH9q3n/AEANR/7+W/8A8do/tW8/6AGo/wDfy3/+O0ALqvhzQ9eaM65o2n6kYv8AVm8tUm2fTcDiprfSNNtLsXVrp9rDcCEW4mjhVX8oHITcBnaDzjpUH9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QAs3hzRLhLxLjRtPlW/YPdh7VGFwwGAZMj5iB65qbTdI03RbX7No+n2un2+c+VawLEmfXCgCoP7VvP+gBqP/fy3/8AjtH9q3n/AEANR/7+W/8A8doAsW+lafaahc39rYW0F5ebftNxHCqyT7Rhd7AZbA6Z6VBq3hzRNe2f25o2n6l5f3Ptlqk236bgcUn9q3n/AEANR/7+W/8A8do/tW8/6AGo/wDfy3/+O0AWdP0vT9JtRbaVY21jAOkVtCsaj8FAFVrzw3oeo6lFqOoaLp91fQ48q6ntUeVMdMORkfhR/at5/wBADUf+/lv/APHaP7VvP+gBqP8A38t//jtADdU8L6Brkyy61oem6jIv3Xu7SOUj6Fga0be3htLdILWGOCGMYSONQqqPQAcCqH9q3n/QA1H/AL+W/wD8do/tW8/6AGo/9/Lf/wCO0AadYkngvwtNf/bpvDWjyXZO43DWERkz67tuasf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AaSqqKFQBVUYAAwAKpWGh6Tpd1c3WmaXZWdxeNvuZre3SN52yTlyACxyScn1NRf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBeurS3vrZ7e9giuIJBh4pUDqw9weDWbpnhPw5ok/naNoGl6fL/z0tLKOJvzUCpP7VvP+gBqP/fy3/8AjtH9q3n/AEANR/7+W/8A8doAsyaXp8uqRanLY2z38KGOK7aFTLGp6qr4yAcngGrVZn9q3n/QA1H/AL+W/wD8do/tW8/6AGo/9/Lf/wCO0AeefCHQ9Qm8T+MPGmuaXcaZc6xfmK1t7qAxSLbp0baQD82VyT1KZr1asz+1bz/oAaj/AN/Lf/47R/at5/0ANR/7+W//AMdoANX8NaF4gaJte0XTtTMIIiN7aJN5ecZxuBxnA6elU7bwF4PsruK6s/Cmh29xC4kimi06FXjYHIZSFyCDzkVc/tW8/wCgBqP/AH8t/wD47R/at5/0ANR/7+W//wAdoAi1Pwf4a1u8+16z4d0nULnaF867sY5XwOg3MpOKhtPAnhHT7yK7sPCui2tzCweKaHTokdGHQhguQfpVv+1bz/oAaj/38t//AI7R/at5/wBADUf+/lv/APHaANOqsOlafb6ncajBYW0V9dKqz3SQqJZgowoZwMsABgZPFVv7VvP+gBqP/fy3/wDjtH9q3n/QA1H/AL+W/wD8doAsyaXp8uqRanLY2z38KGOK7aFTLGp6qr4yAcngGm6no+ma1bC31nTrTUIAciK7gWVQfXDAioP7VvP+gBqP/fy3/wDjtH9q3n/QA1H/AL+W/wD8doAn0zR9M0W2Nvo2nWmnwE5MVpAsSk+uFAFGp6RputWv2XWdOtNQt87vKu4FlTPrhgRUH9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QA6Pw9osK2SxaRYItgxazC2yAWxIwTHx8hPtip20rT31ZNUewtm1BIvJS7MKmVY852B8ZC5JOM45qt/at5/wBADUf+/lv/APHaP7VvP+gBqP8A38t//jtAFy9sbTUrVrbULWG7gb70U8YdT9QeKqaT4d0TQQ40PR9P00Sff+x2qQ7vrtAzSf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QBp0Vmf2ref9ADUf+/lv/wDHaP7VvP8AoAaj/wB/Lf8A+O0AadFZn9q3n/QA1H/v5b//AB2j+1bz/oAaj/38t/8A47QBp0Vmf2ref9ADUf8Av5b/APx2j+1bz/oAaj/38t//AI7QBp0Vmf2ref8AQA1H/v5b/wDx2j+1bz/oAaj/AN/Lf/47QAar/wAhLRf+v1v/AEnmrTrFllvb/U9MJ0m6to7e4aWSSZ4cAeTIn8MjHOXHatqgD//Z" /></p><p><strong>Children over 12 years old (&gt;12 to &lt;18 years old):</strong><br />The standard dosage for children is equivalent to approximately 6 mg trimethoprim and 30 mg sulfamethoxazole per kg body weight per day, given in two equally divided doses. The schedules for children are according to the child&#39;s age and provided in the table below:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Age</td><td>Tablets</td></tr><tr><td>&gt;12 to &lt;18 years old</td><td>2 tablets every 12 hours</td></tr></tbody></table><p>Treatment should be continued until the patient has been symptom free for two days; the majority will require treatment for at least 5 days. If clinical improvement is not evident after 7 days therapy, the patient should be reassessed.</p><p>As an alternative to Standard Dosage for acute uncomplicated lower urinary tract infections, short- term therapy of 1 to 3 days duration has been shown to be effective.</p><p><strong>Elderly patients:</strong><br />See Special Warnings and Precautions for Use (Section 4.4). Unless otherwise specified standard dosage applies.<br />Impaired hepatic function:<br />No data are available relating to dosage in patients with impaired hepatic function. Impaired renal function:</p><p><u><strong>Dosage recommendation :</strong></u></p><p><strong>Children (&gt;12 to &lt;18 years old) and adults (&gt;18 years old):</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Creatinine Clearance (ml/min)</td><td>Recommended Dosage</td></tr><tr><td>&gt;30</td><td>2 tablets every 12 hours</td></tr><tr><td>15 to 30</td><td>1 tablets every 12 hours</td></tr><tr><td>&lt;15</td><td>Not recommended</td></tr></tbody></table><p>No information available for children aged 12 years and under with renal failure. See section 5.2 for the pharmacokinetics in the paediatric population with normal renal function of both components of Co-Trimoxazole, TMP and SMZ.</p><p>Measurements of plasma concentration of sulfamethoxazole at intervals of 2 to 3 days are recommended in samples obtained 12 hours after administration of Co -Trimoxazo le. If the concentration of total sulfamethoxazole exceeds 150 microgram/ml then treatment should be interrupted until the value falls below 120 microgram/ml.</p><p><u><strong>Pneumocystis jirovecii pneumonitis</strong></u></p><p>Treatment - Children (&gt;12 to &lt;18 years old) and adults (&gt;18 years old):</p><p>A higher dosage is recommended, using 20 mg trimethoprim and 100 mg sulfamethoxazole per kg of body weight per day in two or more divided doses for two weeks. The aim is to obtain pea k plasma or serum levels of trimethoprim of <u>greater than or equal to</u> 5 microgram/ml (verified in patients receiving 1 -hour infusions of intravenous Co -Trimoxazole). (See 4.8 Undesirable Effects).</p><p>Prevention - Adults (&gt;18 years old):</p><p>The following dose sch edules may be used:</p><p>160 mg trimethoprim/800 mg sulfamethoxazole daily 7 days per week.<br />160 mg trimethoprim/800 mg sulfamethoxazole three times per week on alternate days.<br />320 mg trimethoprim/1600 mg sulfamethoxazole per day in two divided doses three times per week on alternate days.</p><p>Prevention - Children (&gt;12 to &lt;18 years old):</p><p>The standard dosage for children is equivalent to approximately 6 mg trimethoprim and 30 mg sulfamethoxazole per kg body weight per day, given in two equally divided doses. The following dose schedules may be used for the duration of the period at risk:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:119px">Age</td><td style="width:378px">Tablets</td></tr><tr><td style="width:119px">&gt;12 to &lt;18 years old</td><td style="width:378px">2 tablets every 12 hours, seven days per week</td></tr><tr><td style="width:119px">&gt;12 to &lt;18 years old</td><td style="width:378px">2 tablets every 12 hours, three times per week on alternative days</td></tr><tr><td style="width:119px">&gt;12 to &lt;18 years old</td><td style="width:378px">2 tablets every 12 hours, three times per week on consecutive days</td></tr><tr><td style="width:119px">&gt;12 to &lt;18 years old</td><td style="width:378px">4 tablets once a day, three times per week on consecutive days</td></tr></tbody></table><p>The daily dose given on a treatment day approximates to 150 mg trimethoprim/m <sup>2</sup>/day and 750 mg sulfamethoxazole/m <sup>2</sup>/day. The total daily dose should not exceed 320 mg trimethoprim and 1600 mg sulfamethoxazole.</p><p><strong>Nocardiosis - Adults (&gt;18 years old):</strong></p><p>There is no consensus on the most appropriate dosage. Adult doses of 6 to 8 tablets daily for up to 3 months have been used.</p><p><strong>Toxoplasmosis:</strong></p><p>There is no consensus on the most appropriate dosage for the treatment or prophylaxis of this condition. The decision should be based on clinical experience. For prophylaxis, however, the dosages suggested for p revention of Pneumocystis jirovecii pneumonitis may be appropriate.</p><p><u><strong>Method of administration :&nbsp;</strong></u><br />Oral.</p><p>It may be preferable to take Co -Trimoxazole with some food or drink to minimise the possibility of gastrointestinal disturbances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance(s) sulphonamides, trimethoprim, co-trimoxazole or to any of the excipients listed in section 6.1.
• Co-Trimoxazole should not be given to patients with severe hepatic parenchymal damage. Contra - indicated in severe renal insufficiency where repeated measurements of the plasma concentration cannot be performed.
• Co-trimoxazole should not be given to infants during the first 6 weeks of life.
• Co-Trimoxazole should not be given to patients with a history of drug -induced immune thrombocytopenia with use of trimethoprim and/or sulphonamides.
• Co-Trimoxazole should not be given to patients with acute porphyria.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fatalities, although very rare, have occurred due to severe react ions including Stevens -Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, other blood dyscrasias and hypersensitivity of the respiratory tract.</p><p>&bull; Life-threatening cutaneous reactions Stevens -Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of Co -Trimoxazole.<br />&bull; Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment.<br />&bull; If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, Co -Trimoxazole treatment should be discontinued (see section 4.8).<br />&bull; The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis.<br />&bull; If the patient has developed SJS or TEN with the use of Co-Trimoxazole, Co -Trimoxazole must not be re -started in this patient at any time.<br />Particular care is always advisable when treating elderly patients because, as a group, they are more susceptible to adverse reactions and more likely to suffer serious effects as a result particularly<br />when complicating conditions exi st, e.g. impaired kidney and/or liver function and/or concomitant use of other drugs.<br />For patients with known renal impairment special measures should be adopted (see section 4.2).<br />An adequate urinary output should be maintained at all times. Evidence of c rystalluria in vivo is rare, although sulphonamide crystals have been noted in cooled urine from treated patients. In patients suffering from malnutrition the risk may be increased.<br />Regular monthly blood counts are advisable when Co -Trimoxazole is given fo r long periods, or to folate deficient patients or to the elderly; since there exists a possibility of asymptomatic changes in haematological laboratory indices due to lack of available folate. Supplementation with folinic acid may be considered during tre atment but this should be initiated with caution due to possible interference with antimicrobial efficacy (see section 4.5).<br />In glucose -6-phosphate dehydrogenase (G -6-PD) deficient patients haemolysis may occur.<br />Co-Trimoxazole should be given with caution to patients with severe atopy or bronchial asthma.<br />Co-Trimoxazole should not be used in the treatment of streptococcal pharyngitis due to Group A beta -haemolytic streptococci ; eradication of these organisms from the oropharynx is less effective than with penicillin.<br />Trimethoprim has been noted to impair phenylalanine metabolism but this is of no significance in phenylketonuric patients on appropriate dietary restriction.<br />The administration of Co -Trimoxazole to patients known or suspected to be at risk of po rphyria should be avoided. Both trimethoprim and sulphonamides (although not specifically sulfamethoxazole) have been associated with clinical exacerbation of porphyria.<br />Close monitoring of serum potassium is warranted in patients at risk of hyperkalaemia and hyponatraemia.<br />Co-Trimoxazole has been associated with metabolic acidosis when other possible underlying causes have been excluded. Close monitoring is always advisable when metabolic acidosis is suspected.<br />Except under careful supervision Co -Trimoxazole should not be given to patients with serious haematological disorders (see 4.8 Undesirable Effects). Co -Trimoxazole has been given to patients receiving cytotoxic therapy with little or no additional effect on the bone marrow or peripheral bloo d.<br />The combination of antibiotics in Co -Trimoxazole should only be used where, in the judgement of the physician, the benefits of treatment outweigh any possible risks; consideration should be given to the use of a single effective antibacterial agent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Interaction with laboratory tests: </strong></u>trimethoprim may interfere with the estimation of serum/plasma creatinine when the alkaline picrate reaction is used. This may result in overestim ation of serum/plasma creatinine of the order of 10%. The creatinine clearance is reduced: the renal tubular secretion of creatinine is decreased from 23% to 9% whilst the glomerular filtration remains unchanged.</p><p><u><strong>Zidovudine</strong></u> : in some situations, concomitant treatment with zidovudine may increase the risk of haematological adverse reactions to co -trimoxazole. If concomitant treatment is necessary, consideration should be given to monitoring of haematological parameters.</p><p><strong><u>Cyclosporin</u></strong>: reversible deterioration in renal function has been observed in patients treated with co - trimoxazole and cyclosporin following renal transplantation.</p><p><u><strong>Rifampicin</strong></u>: concurrent use of rifampicin and Co -Trimoxazole results in a shortening of the plasma half-life of trimethoprim after a period of about one week. This is not thought to be of clinical significance.</p><p>When trimethoprim is administered simultaneously with drugs that form cations at physiological pH, and are also partly excreted by active renal s ecretion (<u>e.g. procainamide, amantadine</u> ), there is the possibility of competitive inhibition of this process which may lead to an increase in plasma concentration of one or both of the drugs.</p><p><u><strong>Diuretics (thiazides):</strong></u> in elderly patients concurrently receivin g diuretics, mainly thiazides, there appears to be an increased risk of thrombocytopenia with or without purpura.</p><p><u><strong>Pyrimethamine:</strong></u> occasional reports suggest that patients receiving pyrimethamine at doses in excess of 25 mg weekly may develop megaloblastic a naemia should co - trimoxazole be prescribed concurrently.</p><p><u><strong>Warfarin:</strong></u> co-trimoxazole has been shown to potentiate the anticoagulant activity of warfarin via stereo -selective inhibition of its metabolism. Sulfamethoxazole may displace warfarin from plasma - albumin protein-binding sites in vitro. Careful control of the anticoagulant therapy during treatment with Co-Trimoxazole is advisable.</p><p><u><strong>Phenytoin:</strong></u> co-trimoxazole prolongs the half -life of phenytoin and if co -administered could result in excessive phenytoin effect. Close monitoring of the patient&#39;s condition and serum phenytoin levels are advisable.</p><p><u><strong>Digoxin:</strong></u> concomitant use of trimethoprim with digoxin has been sho wn to increase plasma digoxin levels in a proportion of elderly patients.</p><p><u><strong>Methotrexate:</strong></u> co-trimoxazole may increase the free plasma levels of methotrexate. If Co - Trimoxazole is considered appropriate therapy in patients receiving other anti - folate drugs s uch as methotrexate, a folate supplement should be considered (see section 4.4).</p><p>Trimethoprim interferes with assays for serum methotrexate when dihydrofolate reductase from Lactobacillus casei is used in the assay. No interference occurs if methotrexate i s measured by radioimmuno assay.</p><p><u><strong>Lamivudine: </strong></u>administration of trimethoprim /sulfamethoxazole 160 mg/800 mg (co - trimoxazole) causes a 40% increase in lamivudine exposure because of the trimethoprim component. Lamivudine has no effect on the pharmacokineti cs of trimethoprim or sulfamethoxazole.</p><p>Interaction with <u>sulphonylurea hypoglycaemic</u> agents is uncommon but potentiation has been reported.</p><p><u><strong>Hyperkalaemia:</strong></u> caution should be exercised in patients taking any other drugs that can cause hyperkalaemia.</p><p><u><strong>Repaglinide:</strong></u> trimethoprim may increase the exposure of repaglinide which may result in hypoglycaemia.</p><p><u><strong>Folinic acid:</strong></u> folinic acid supplementation has been shown to interfere with the antimicrobial efficacy of trimethoprim -sulfamethoxazole. This has been observed in Pneumocystis jirovecii pneumonia prophylaxis and treatment.</p><p><u><strong>Contraceptives:</strong></u> oral contraceptive failures have been reported with antibiotics. The mechanism of this effect has not been elucidated. Women on treatment with antibiotics should temporarily use a barrier method in addition to the oral contraceptive, or choose another method of contraception.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Pregnancy</strong></u><br />Trimethoprim and sulfamethoxazole cross the placenta and their safety in pregnant women has not been established. Case -control studies have shown that there may be an association between exposure to folate antagonists and birth defects in humans.</p><p>Trimethoprim is a folate antagonist and, in animal studies, both agents have been shown to cause foetal abnorm alities (see section 5.3).</p><p>Co-Trimoxazole should not be used in pregnancy, particularly in the first trimester, unless clearly necessary. Folate supplementation should be considered if Co -Trimoxazole is used in pregnancy.</p><p>Sulfamethoxazole competes with bil irubin for binding to plasma albumin. As significantly maternally derived drug levels persist for several days in the newborn, there may be a risk of precipitating or exacerbating neonatal hyperbilirubinaemia, with an associated theoretical risk of kernict erus, when Co-Trimoxazole is administered to the mother near the time of delivery. This theoretical risk is particularly relevant in infants at increased risk of hyperbilirubinaemia, such as those who are preterm and those with glucose -6- phosphate dehydro genase deficiency.</p><p><u><strong>Breast -feeding</strong></u><br />The components of Co -Trimoxazole (trimethoprim and sulfamethoxazole) are excreted in breast milk. Administration of Co -Trimoxazole should be avoided in late pregnancy and in lactating mothers where the mother or infant ha s, or is at particular risk of developing, hyperbilirubinaemia.<br />Additionally, administration of Co -Trimoxazole should be avoided in infants younger than eight weeks in view of the predisposition of young infants to hyperbilirubinaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effect of Co -Trimoxazole on driving performance or the ability to operate machinery. Further a detrimental effect on such activities cannot be predicted from the pharmacology of the drug. Nevertheless the clinical status of the patient and the adverse events profile of Co -Trimoxazole should be borne in mind when considering the patients ability to operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The frequency categories associated with the adverse events below are estimates. For most events, suitable data for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on the indication.</p><p>Data from large published clinical trials were used to det ermine the frequency of very common to rare adverse events. Very rare adverse events were primarily determined from post -marketing experience data and therefore refer to reporting rate rather than a &quot;true&quot; frequency.</p><p>The following convention has been used for the classification of adverse events in terms of frequency:</p><p>Very common &ge;1/10, common &ge;1/100 and &lt;1/10, uncommon &ge;1/1000 and &lt;1/100, rare &ge;1/10,000 and &lt;1/1000, <strong>very rare &lt;1/10,000.</strong></p><p><img alt="" width="442" height="588" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAkACQAAD/4RD6RXhpZgAATU0AKgAAAAgABAE7AAIAAAAQAAAISodpAAQAAAABAAAIWpydAAEAAAAgAAAQ0uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEFobWFkIEFsWmFocmFuaQAABZADAAIAAAAUAAAQqJAEAAIAAAAUAAAQvJKRAAIAAAADNzkAAJKSAAIAAAADNzkAAOocAAcAAAgMAAAInAAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADIwMjA6MDQ6MjEgMTQ6NDg6MjUAMjAyMDowNDoyMSAxNDo0ODoyNQAAAEEAaABtAGEAZAAgAEEAbABaAGEAaAByAGEAbgBpAAAA/+ELImh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjAtMDQtMjFUMTQ6NDg6MjUuNzg5PC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPkFobWFkIEFsWmFocmFuaTwvcmRmOmxpPjwvcmRmOlNlcT4NCgkJCTwvZGM6Y3JlYXRvcj48L3JkZjpEZXNjcmlwdGlvbj48L3JkZjpSREY+PC94OnhtcG1ldGE+DQogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgIDw/eHBhY2tldCBlbmQ9J3cnPz7/2wBDAAcFBQYFBAcGBQYIBwcIChELCgkJChUPEAwRGBUaGRgVGBcbHichGx0lHRcYIi4iJSgpKywrGiAvMy8qMicqKyr/2wBDAQcICAoJChQLCxQqHBgcKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKir/wAARCAJMAboDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1611kmDWL7XfE50m0tNUltUeRreKNVBG0FpEPPOOtbyabcyxrJH4hv3RgCrKlsQR6g+VXAX2jXmr6dqT6bbX8tzaeI7mWOXTriGOeElNuQs2I5AQxBViOCSMnilmj1+ybwt4eF5DbX+oWa22oWlhMIhaRRsHM0aIQE+UPGSoA3MmOgpx108weh6AdLu1UlvEGoADkkpb8f+QqRNNupI1ePxDfujDKsqWxBHqP3VcRJ4d8S3Wp+KLOVdQn0/UbS4SGe8vWTa7D5EiVLhlC8kZ8qIgAZLZNQ6JoPjS28SaSWkvrPSoLaBBDLILjylVMSRyH7WAWZs4by5SARhlxiktfw/X/ACB6fj+n+f4Hff2Vef8AQf1H/v3b/wDxqq99D/ZlnJd6l4qurO2jGXmuDaxog92MWBXnn/CL+PI9JZ0uNVa//suRwG1hiDerPmIY8zGPLJyPukcNmu88S2F9cSaNqFratfNplybiWyR0VpsxMnylyF3KWBGSB7in0uK+tixZQHUrOO707xRdXdtKN0c0H2V0ceoYRYNT/wBlXn/Qf1H/AL92/wD8arjo/DOvXWsRXjJeabY6hrDXd3Z2995Tww/ZDGA7RvyWkVWIQkZIOeprB0fWNXuvGE1nZz3t/qNudSN3bSamUikOQLceXu3QLjCglUycsN2d1DX5D/r8z0/+yrz/AKD+o/8Afu3/APjVI2mXaqWbxBqAAGSSlvx/5CrgtH8P+M5IIrbUn1K3s21hJtn9pN50dobdgyNJ58jnEmOjk55GBgDcTQte1L4UTaLqbkao6SRj7RNv8xBIdiu4LE7kCgnJPJzzQ1oHVGhb3+n3djJeWvjjz7WKQRSTxz2bIjkgBSwjwDkgY65NaX9lXn/Qf1H/AL92/wD8arlPEWnat4l8M38dt4V/s26eSzVfOng86ZY51ZgdjFQijJXL5OT8o70bjSvGdz4s1S4SLUdP02e1uYMW9+JSz5XyZYhJPtQlc8BIsHOSeGC/r8P1Gkdz/ZV5/wBB/Uf+/dv/APGqP7KvP+g/qP8A37t//jVefy6N4xl8AwWzQ6tFfwXrMkUF6xknj28GZmvg6jJPCXDdAcYyo9J0z7V/ZNp/aEaRXXkp50aSGRVfAyAx5Iz3PWnbckrf2Vef9B/Uf+/dv/8AGqP7KvP+g/qP/fu3/wDjVadFIZmf2Vef9B/Uf+/dv/8AGqP7KvP+g/qP/fu3/wDjVadFAHIPq9rptgLjxF40/ssSXNxDEbqW0hD+XKyDG+Pk4UE49a2LazlvLWK5tPEt7PBMgeOWIWzK6kZBBEWCD61zNxoGpaxq+jXOnXt1p0Npd6p513aeSXTdMwUbZUcEHB6KenUVLq2heJprrxJcaZf3aXDWUUWkvJdkReZsIkYxKQoYnHJUYPIxzS6B1R0v9lXn/Qf1H/v3b/8Axqj+yrz/AKD+o/8Afu3/APjVcHa6N4vh0Gw/tKTVriGO6leW0huRb3ES7AI90pu5S6BgzEGUk5A2kDbWbpUfjbUfB9hPp76le/2jpOmsl0t+q+VIku6ctvcNl0YcgHdjB7Vdr3+X4h0uenf2Vef9B/Uf+/dv/wDGqP7KvP8AoP6j/wB+7f8A+NVwUWh+Pvt3id7i+uiZ7e6Wy8t8RyFs+R5bG5PlMgwMiGPnOWb71WZND8V2yX8ER1K5sGezlMY1M/aJhtYXCRSNIDGc7CBuReuCM1PT7v6+Q3p+P4f59DtP7KvP+g/qP/fu3/8AjVH9lXn/AEH9R/792/8A8arhNRfXI9S0DRYL66gutViMN5ayaiJbi1gSTeJty4+bYGjLj+JkG5sZPp3SnbS5Jmf2Vef9B/Uf+/dv/wDGqP7KvP8AoP6j/wB+7f8A+NVp0UhmZ/ZV5/0H9R/792//AMarH1I6nZ+JtF06LXLww3/n+azRQbl2IGGP3eOp5zmurrmNfGfHXhcAZyLzgnGf3QoewD472wlivZYvG5ePTyReOs1oRbEdfMPl/Jj3xVuS3aFoFm8UXcbXLbIA32Yea2C2F/dfMcAnA7A15zp/hPxdp2keILbSbO7sw2kyW9gLi5t2nim3EolvcRkOYRkkebtIOOBzV+68O+KrnxPY3DwXkkttqDzi9lvVa2SI20iRhYTISGVmAYhBnOct2elh2V38/wAv6R3v9lXn/Qf1H/v3b/8AxqmT2M1tbyT3PiS+hhjUs8ki2yqgHUkmLAFc98N9M8U6daXf/CW3NxJI2wCOcbsyAHfIj/aJiVYkfLiMDHCLnFcpqHhDxzq2ieK7HVZ7q5N3BKtvEsuyO4cyZiKObo7AqjBXyolOTnd1I1rYSd9z0G0ntdQuEgsPGUlzNJALlI4ZLR2aI8CQAR5Kn+90q9/ZV5/0H9R/792//wAarzzUPBPiOxuPElz4ba8ikuzYrEz6hJK88MagTKuZ1IfjAYuh64cZzV3+yPGEdrpQum1S/ZLchfs94tm1vMZMqZ8zSCRAmF6zZxnBJzRo/wCv69PUm7tf+v6/Q7RNOuZCwj8RX7FG2ttS2O0+h/ddead/ZV5/0H9R/wC/dv8A/Gq87vPCniCz0jVodKg1pJ5Nblu0Fvf7kuY3BIyftcLqozyA6nIHDCvTdM+1f2Taf2hGkV15KedGkhkVXwMgMeSM9z1pLWN/T8iutvX8yt/ZV5/0H9R/792//wAao/sq8/6D+o/9+7f/AONVp0UAZn9lXn/Qf1H/AL92/wD8ao/sq8/6D+o/9+7f/wCNVp0UAZn9lXn/AEH9R/792/8A8ao/sq8/6D+o/wDfu3/+NVp0UAZn9lXn/Qf1H/v3b/8Axqj+yrz/AKD+o/8Afu3/APjVadFAGZ/ZV5/0H9R/792//wAao/sq8/6D+o/9+7f/AONVp0UAZn9lXn/Qf1H/AL92/wD8ao/sq8/6D+o/9+7f/wCNVp0UAZn9lXn/AEH9R/792/8A8ao/sq8/6D+o/wDfu3/+NVp0UAZn9lXn/Qf1H/v3b/8Axqj+yrz/AKD+o/8Afu3/APjVadFAGLLFe2Gp6YDq11cx3Fw0UkcyQ4I8mR/4Y1OcoO9bVZmq/wDIS0X/AK/W/wDSeatOgDz7RLXVJ9Q1kaf4jTS1k1i5RLdrWOUysMEkFjnp2HpmtO+s9c0yAT6l48gtImdYxJcWEMalmOFXJPUngDvWHb6bqV8+pyaSjGWDV9Sw6SBGRmgKoQSRzuI5HSpJPBWqtqWnoZ9TmtbW8gulluNVldkk+zyrIcmTcV3mP5fu8nAwTQH/AAfwR0H9h+Kf+hw/8pkX+NQzad4gtv8Aj48cRRcqvz6fCvLHao5Pc8D1PFcvo2h+PIdI1FNUub+WVjF5kSy7GucPmUwSm7kMZZcgcQgZBAU9Jbfw34hh1gX1raazC88VrGr3WrrM0Mcd4XeOT958x8ph038BgXJPzUlqPudT/Yfin/ocP/KZF/jR/Yfin/ocP/KZF/jXKW/h/wAYTRLBIdZtWbyV1GaTVwwuZPtEZeS3xITEnliXKgR5DAbSRU+r6D4qgtLCPSzq101pfT+XE+oMUeEvmMzSi5jkOBxk+bwTlGOKVtv6/ry/QGdJ/Yfin/ocP/KZF/jR/Yfin/ocP/KZF/jWf8RLPxLqFlb2/hm3ufO2OwuLe8MQilGNm9RNEWU/N3cA4yjCq7aB4mfU59Sju7+K6a7VYke/JgSA2iqxMIfYf32T0znkcGl0b/r+v0CxqLpfiNrl7dfG0ZnjVXeIadDuVTkAkZyAdpwfY+lEGleI7mIS23jVJoySA8enQsCQcHkHsQRVTwPo+p2Otajd6jZajbLNaW0W7UL9bp5JUaUyFWDsQp3ggcDngDoKC+HPE81zJd3F1qazQCA2qJqbLGzfapTJuQPtb9yUHzAjGAORxTVmT/X5GtaWmuX7zpY+PLe5a2kMM4hsIXMTjkq2D8rcjg81O+jeJo0LyeMgqqMlm02IAfrXFXfg7xfp1pZwaDcahBAbm6lkWO5eeSKR52KSnddxArswdhLjJJKEkmrep+GvE2oXHie1kj1K6tL60kEMk96YcycFUiVLpkC5BHMcRx1Zsmp6DOqOi+J1Us3jEBQMknTIuP1pkWmeIp3dIfG0cjR4DqmnQkrkZGeeMgg1zOoaL4s1TxDiKy1Kz0x4JbadJdTLCSJrdgmNtwQrB9oYiPdnkSMM08aL4kj022jlsNck0+NYlawtdXWK64gRRiXzhwHDEjzBnOfm6Uf1+Ydjp/7D8U/9Dh/5TIv8aP7D8U/9Dh/5TIv8aw4vDviky217eXmoPe2y6eoWLUSIWAf/AEktGGCOdh5LLzjK81f8C6fr2n32qJrK3z2zyboJ9QuC8shyc4UXEqBcY+6IvTYMU7B0uXf7D8U/9Dh/5TIv8aP7D8U/9Dh/5TIv8a6aikBwESanpWiy3uo+ObXSrNbudGkurSFE3+e4J3MwA3Nk47ZxWrBpXiO6t457bxqk0Mihkkj06FlYHoQQcEVSNrfQX1lrdnpkmrpaXGowtaQyRrKpkuTiRPMZUJAQg5YHDceho6xpPiOW2g+w6TeWitDKbe10nUlt1s7lpCyyT/OokXBBYDeM7vlbOaEPqb/9h+Kf+hw/8pkX+NH9h+Kf+hw/8pkX+NYE/hXxFc3Tyz3urbpmvPNEOrSRoMYNvtVXG0bs9MccNxxU9z4b1+/1KK4ubrVEVp7eOVINTeJBB5GJiFRwAd/cfMOq4ySV/wAD8f61F/wfw/z6Gx/Yfin/AKHD/wApkX+NH9h+Kf8AocP/ACmRf41zV9o3i829rGo1WadLMRWksGqCNbW4EjfvLgFx5ylfL6iT7rfLk5rZ8P6HrVhrsd9e3N/IJ5b37Uk9+0sSoZs2+2MsVX5P7oBxwfSq6XAuf2H4p/6HD/ymRf40f2H4p/6HD/ymRf4101FIDmf7D8U/9Dh/5TIv8aP7D8U/9Dh/5TIv8a6aigDmf7D8U/8AQ4f+UyL/ABrB1jTNdg8V6El14mDzOLkxXJsY1FuBGCx25w2Rxz0r0SuR8VxPN4s8PxRDc8kN8qjOMkw4FKTaTaGtXZkUaarLa2l1F8QrR7e9YJazLZwFJ2OcBDuwxODwM9Ku/wBh+Kf+hw/8pkX+NcV4e8B67p9joun3FiqWmi3Fvc2g85G2M+wzd/4CJQPUScZq1b+H/GE0SwSHWbVm8ldRmk1cMLmT7RGXkt8SExJ5YlyoEeQwG0kVpyq9k+v9f1/wSItta+X6nR3FlrtpIsd147ggd13KslhCpYZC5AJ6ZZR9WHrUkGleI7mIS23jVJoySA8enQsCQcHkHsQRWNc+HfEZjis0N3cWcLzhRcXvmll+1wPEWLsSxEayYLZIGR1PNTUdN8cSXOmi0gvg9tOJWuBqGUdDcMXR0E6Any9u0skoxkYU81K1t5lPQ6SDS/EdzGZLbxtHMgZkLR6dCwDKSGGQeoIII7EVJ/Yfin/ocP8AymRf41Rk0fWoPA9zaWsVwty2pTzvDa3KxTS27XTuVSTcArMh4O5SM9VPIoDRvFo0u3Fm1/CtxNLavBdajvms7WQqRKZNzb5U2tghmPz/AHjijd2/r+v+CD0f9f1/SN3+w/FP/Q4f+UyL/Gj+w/FP/Q4f+UyL/GuTTQvHqah4g3Xt6fNtrpbV0fEchOfICM103lsoxyIUyc5Y9TDc3j6b8RLbQ4r3VZbsXlsYFOrOyi3IDSB4nk3SfNvPmbWUD5dy420LW3mD0Tfa52X9h+Kf+hw/8pkX+NH9h+Kf+hw/8pkX+NctdeHPE8Gn22z+3by6lticwa2U+zXmeJJN0gDRAbfkXeOD8hJzUOr6B8RH8SSLp95cnTvMESyrf7cxXA/fSbSc7oWXKezYHSha/wBf1/wwPQ6kad4gNyLceOIjOwZhF/Z8O4hSAxxnPBZc+mR61N/Yfin/AKHD/wApkX+Ncm/gbVDrmpSW8WrW6Kt/LbXKasw82WQwtFtIl3AZRsqQFyOQRjPpFjLcPD5d1BJHJGqAyOVIlO0EkbSTwcjkDkccYNC+FMHo/vMP+w/FP/Q4f+UyL/Gj+w/FP/Q4f+UyL/GumopAcz/Yfin/AKHD/wApkX+NH9h+Kf8AocP/ACmRf4101FAHM/2H4p/6HD/ymRf40f2H4p/6HD/ymRf4101FAHM/2H4p/wChw/8AKZF/jR/Yfin/AKHD/wApkX+NdNRQBzP9h+Kf+hw/8pkX+NH9h+Kf+hw/8pkX+NdNRQBzP9h+Kf8AocP/ACmRf40f2H4p/wChw/8AKZF/jXTUUAcoNN1qz13R5NV17+0YTdOqxfY0i2t5EvzZU56AjHvXV1mar/yEtF/6/W/9J5q06APMbe+OmTazcXPjSx8N20ms3KKl4kOJHBBJDSMOxHA9K6G3sdeuyotfHUMxeMSr5dhC25D0YYPQ469K5SXT9YuNVmvdFi1Vha63qAmfSWtBModYwOLo7CDjnHNWovC/iKx0y0RLe6kSK0ihuI7O7SC4mjE0rFA6soWTayElWUE7sMKSB/1951H9h+Kf+hw/8pkX+NRvpXiOKWOKTxqiSTEiNG06EFyBk4GeeOa5eTRPGZt0Hl6wzGJhpuzV1BsH81ypuj5g88BDGP8Alr91hzncdWw0XW/+E9t73ULfUJFgurh3vJL5WtWiZGESxw7yUKghT8i5PJLdRVgloa/9h+Kf+hw/8pkX+NH9h+Kf+hw/8pkX+NZGpWXiuf4jW93ZW91DpsMuyVxeZhmhMZ5EfnAKwc85iJwAQ/aqNv4b8T2GjQI0us3nmWdq2oQjVyZ5ZQW85IpGkHlkgr91lU44IJzSWquNqxu/Ytd+zNcf8J3B5CuYzL9gh2hw20rnOM7vlx68VY/sPxT/ANDh/wCUyL/Gs7T9A1OP4cnTZLSVLttQecQzTq7hDeGQFn3EE7OTyT+NYqW3iHXdX1e0sNUupdO0u/it4ZrW+ZWlV7iOScM+RkxIDGOScFh14p2vLlQdLnV/2H4p/wChw/8AKZF/jUb6V4jiljik8aokkxIjRtOhBcgZOBnnjmuXvdJ8SaF4b1a9e91RfL0/U1Ly6m8pRVfNoy5c4by8/MPm/vHOKtW3hbV9UnszeJrFnYJcPII59WLXUeYGUnzkkLBWcghVbj0AO0DVlcJK1vX8jov7D8U/9Dh/5TIv8aiTTfEMs3lReN4nk2b9i6fCTtyRnGemQRn2rnY9P8cS6zoL3Fvexi1S2W+nF+DHMpQCYFBOq7wxYkmJ8gZVweKSx8O+JNP0VbK3ttVS0gQJLbrqf764AnkZ/KkMuULKUIJZTjjKnono7ef9MR1H9h+Kf+hw/wDKZF/jR/Yfin/ocP8AymRf41S1PTdZm+G6WlsNYivwwKxpeJLchd5IR5RLDn5cA4lDcY3t1OPF/wAJD/wkWgaK928Ml1apPqkCXkkklqkDkqwJdyPNJCNlzna3LYJp9bB0udI2jeJkxv8AGQXccDOmxDJ9OtL/AGH4p/6HD/ymRf41yNr4a8SvIf7QttXuobbVYbqF59RKTyAMwY7RdvHsAIOB5eenl8CnaToPjwRanFql9feZKI1LxvsWVvOUtJE5upCgCBhtEcQOemaS1/r0B6P+vM6z+w/FP/Q4f+UyL/Gj+w/FP/Q4f+UyL/GqOgeH9Y0zXY5pbjUZLZZ7mIi51J51+z8GH5Wc5bOfm+/2JxXaUdLh1OG0jT9deN7eDxhHBKZ7lvI+wxMzbZ3VnwTnBbn0G7FX7fTPEV3F5tr42jnj3Mu+PToWGVJBGQeoIIPuKp3tjqh02HVPDlslxqdrfX0SozKu6OSaQHkkcBhG5GeQhxzisvVPDXiuy17R4NCvLkaVaW8MSvAN3lurHzHlU3UQfcMdUl74APVrX+v68geh0n9h+Kf+hw/8pkX+NH9h+Kf+hw/8pkX+NctrNpr2i6bp/wBi1O7GuatezWbw3N/JL+6lZgJY03FQYlCP8oHAOTkmuv1TSLu51TSFhmvDZ2kchm8u9eLzHATy95VgWGQc5yDznIOCulw62If7D8U/9Dh/5TIv8aP7D8U/9Dh/5TIv8a5TTtG8bXDagt2mpWVveSWjCM6kWkiInBuNsnnvhTHnGzy+ONgPXQ0DRfFtj4/lkv7y7fSlaTYzM0sUkOCIkJe6JDjglhACSDljnNNL+v6/AHotDb/sPxT/ANDh/wCUyL/Gj+w/FP8A0OH/AJTIv8a6aikBzP8AYfin/ocP/KZF/jR/Yfin/ocP/KZF/jXTUUAcz/Yfin/ocP8AymRf41g6xpmuweK9CS68TB5nFyYrk2Mai3AjBY7c4bI456V6JXI+K4nm8WeH4ohueSG+VRnGSYcClJtJtDWrsyWHSfElzbxz2/jVJYZFDpJHpsTK6kZBBB5B9af/AGH4p/6HD/ymRf41zU1v4vu/h5p2kafo+o6RdWEdvHc+ZNAWukWMqyxNDdIwO4KcmSPjv2qV7Txra6PFAsOoX9xc6eITMs8UBtZRKzZcGdudjBdytITt5POatpczS7kJvlTe9joP7D8U/wDQ4f8AlMi/xo/sPxT/ANDh/wCUyL/GueudI8WNJqXkpq/2l3YyTrqqrBcxecrKkEZYmJ/KDLuxFgnJLcMMq4tPEa6tZ2Bg8QiGeK8ls7FdaAuLdQbcI00vm4cK5c43udrYw3K0lr/X9f1vYux239h+Kf8AocP/ACmRf41HNpXiO3CmfxqkQdwil9OhG5icADJ5J9K5+TRvHX/CatPLfXD2nlgLJbj9zt8oBkKm6UKxkydwgYjI+bHAtab4f8S6WsMcNxqM6FdPlmN1qTSkyhn+0jLOSFxsyo+U9h1ot+n4kt6adja/sPxT/wBDh/5TIv8AGj+w/FP/AEOH/lMi/wAaxPCS+KNK1a/u9d0/UvsV2IFjtmuftLRTNIVkYEzyfuwGDZUIAoPyAjnR8ZaHrGq3ck2lXGoRfZ9NmNqtrftbq13uUx7gGAboeGyvJzRbVD6/1/XqWv7D8U/9Dh/5TIv8aRtG8TIVD+MgpY4UHTYhk+g5rnI9F8ct4q1SSe+uVt5o7gQSJxCyspEKAm6OxlJU7lgBypyx60s2l+I9Y1LT9R1DSNUt0s7y2dLY6jGHGIZUkkwk20jc6EjJJXPByVpdA6/f+C/U6P8AsPxT/wBDh/5TIv8AGj+w/FP/AEOH/lMi/wAa5e48OeKLfRNOjX+3Ly7awXe0OtFDb3xAzJKWkAeMYHyrvXg/Ic5o0618U32panLp09/Fcxz3kP226vfMtG+VljRIN/yssm052DgEZOcAe7Xr+A7fn/X9f8OdR/Yfin/ocP8AymRf41Gul+I2uXt18bRmeNVd4hp0O5VOQCRnIB2nB9j6VzOh+GfF1zFbW2u3mrRWn24NcIt20D+WIZQWEq3k0hVpDH8oZcY4UDNWLnTvGMekmFoNQvC9laQOItQCSK6mbzHBE0ZJ5i3YkQsP4iRim1YFr/XmdF/Yfin/AKHD/wApkX+NH9h+Kf8AocP/ACmRf41J4OfV7fRLTTfEUFydQgg3TXLkNG/7xgAG3MS20A8knBGSTmuioe5K2OZ/sPxT/wBDh/5TIv8AGj+w/FP/AEOH/lMi/wAa6aikM5n+w/FP/Q4f+UyL/Gj+w/FP/Q4f+UyL/GumooA5n+w/FP8A0OH/AJTIv8aP7D8U/wDQ4f8AlMi/xrpqKAOZ/sPxT/0OH/lMi/xo/sPxT/0OH/lMi/xrpqKAOUGm61Z67o8mq69/aMJunVYvsaRbW8iX5sqc9ARj3rq6zNV/5CWi/wDX63/pPNWnQB57pviQaEuuQwWN1f3k2q3sqQ2yqdqIE3O25lG0Fl4BLHPANSr8TrWysbeXVoXeS4mjhHleTbxxs0EUpBkmmVT/AKzjkMegU7STJofh7TdeXWhqcUrGHW7rY0NxJCwBChlLRspKnup4OORW3L4K0OW0a18m6igdlaSOC/niWTEaxgOEcb12Io2tkHHI5NOOl7g7afP/AIBVuvHljaXUyy6dqJtImki+3KkZheVELtGPn35wp5KhcjG6qmoePpIrZPseh6gsxMDStOkRS3SWUIhfbLnLDJAXJHG4L0rUk8EeH5b2S6exYtIrAxi4lEILLsZhFu2K5UkbwA2D1qW+8I6LqV3Dc3dtKZIURF8u5ljVlRtyB1VgH2nkbgcc+tJef9dwfkYNv8WvDV3c6lBbSSTPYRSTbYZIZGmVGCvtRZCykEjiQIT2yK0dN8c2mo+KW8Pyafd2N+kQleO6mtlZeAcBFlLt1+8qlc5G7INXV8JaQgvEEVyYbwES25vpzCATk7Iy+xOeflAqdvD2nya6mryrcS3cfMYkvJXijOCu5Yi3lq2CRuCg4J55NNW0uLXU06KKKQwooooAKKKKACiiigAooooAKKKKAMzQP+QbL/1+3f8A6USVp1maB/yDZf8Ar9u//SiStOgAooooAKKKKACiiigAooooAK5PxRO1r4v8OzxxNM8Ud66xIQC5EIOBkgZPuQK6yuY19Q/jrwurDKsLwEeo8oUpXtoNWvqZvh/4h3GpTQDUtEu7aK5NsqzII2SB5olZVc+Zk5J4KqcAjdirI+Itu1v58eg6zJEIjcOypCdluODMR5uduQw2jLnaSFIwTr2PhLRdOtEtrS1kESSxzKJLiWQhowAnLMTgAAAZxgVFd+CdAvre2gns5BFbR+Six3Use6POTG+1h5iE/wAL5B9Kp7/1t/X4eZMfPy/4P9dzPufiFaw6hJa2+i6teEStDFJCsISaRYxIyqXkU8Id2SAOCM54pqePU/tZg1hcyaVJDaSpexIu2AT52mUFw2Cdo+VTjJzgc1u/8I5pQuEnFoBIkzzqQ7DDvH5bHGccpxjp+NUIvCPhqW+jlgh3y6eIoDEl5KUXylBjWSMPtYqGDDeCRkH0NGn5f8H/AIAvevr5/wDAKafEbT2iR30zU4hcxiTTw8cYOoKzqimL5+Ml04k2HDA9MkTXXj2xsLUSajp2o2c7wtJHaTxossrrIIzEvz7WfcyYIO0hgQxFLB4N8KIl7HDCGVR5Uo+3St9kAxIFjy/7jHysAm3Hyn0preDNNvLnQJ7WSNtO0qZ72FDumknmdSBIZmYkj5yxzksdp3cYJp/X9f8AD+RT62/r+vw8yjZfElH0qO6vtC1KJ1gNzeiIQutnDvZRI58zkHYxwm5uDxVu5+Iml2Ml02oWl9aWVs80f2+ZE8mR4lLOq4ctnapIJUA4654qefwL4Z+Qz20qqGI2m+mCyAsX8txvw6biSEbKjJwBTNL8G6G7XWoORqa6i8sysZneDZLn7ibigJU43qASKX/B/wCB+oPy/rv/AF/w5RsPilpGq2MU2kWV5qFxJdfZBaWc1tM4cxtIMusxjwVQ/wAfHQ4qw3xAso9NudS8ieS2iggmEREULoJAxO55JVTgKc5K4x1bNbFn4Z02yW2CC7mNrOZ4Wu76e4ZHKFCQ0jscbWYY6c9Kqy+B9AlSJfscsZhKGN4buaJ02BguGVwejsCM8g85ofkHb+v66Gno+q22uaLaapYEtbXcSyxFuu0jI6VgN8RdJj1nUNMmhuUubKEzhQ0LmdQ4T5VWQspLMoAcJnPGcGtvTNDtNH8tNPM0VtFbrbx2vnM0SKpJBCknn5sZ9AB2rGufh7ops7tLBJbae4hliSWSeWdYRIwZgsbuVVdyg7Vxjtg80PfTbX/gAv8AL/gjrbxxHdXyWK6HqqXpuGgkt3EG6IqkbszESldoWVTwSTg4B4zUX4maZJPe20On3015aTQxG1he3kkkMrFUI2ykLkjo5UgckYqfwt4RstEaaK9vk1LVN7TyvvkyiyKsf3XkkfBEIGXZiSGwe1XLDwN4f0xo2tLObdH5flmW8ml2CNtyKN7nCqScL0GcYxT0uu2n/BE78rtuQp4705tMmvZLS9i8i0nupYXRN6CF9kiHDEFgwI4JBx1qu3jk295e20ml3d/LBcS4SwRMxwIsZMj73UHl8YXJPZTV6/8AAvh7UoRFd2UhT99uWO7mj3iZi8ittcblLHO05APQDFJqHhLw5fXapeQslzM8koEV5LC8oIUODscFkIVMocr0yKP+D+eg3vp3/CxXPj2ydJ7i00zVLywhjZzfW8KtEzKm9k+9uBC9yoUngEniqdx8SbOPXDbwWF1cabFDcPNqMewpmJY2wg37m/1oU/L97j1I2H8JaZFdyX2nQLb33lssJdpHt43Kbd/kBwmccEjDEcZrO03wR4a03RdK0O4Ec5s4pYI180xecZF3SgxqwDA/e2kEDAPYGjQFtqM1D4k2Ok6bJc6rpWo2U0UyQyWty1vG0e8EqzSNMIgpAPJk68deKZffEnT9LlYXkUsqyXi20RRoIUTMMcnzSyTBG/1nGCCegU43HVTwVo0WnSWcX9oRpK4eWVNVuhNIQMANMJPMIA42lse1D+CNBeyNmltcW9szhnhtb2eBHxGsYDBHAZdiKNpyOOnJoVtf67f8EF5m8rBlDDoRkUtVbKwSxa48qWZkmkDiOSQssQCKu1B/Cvy5x6knvVqkAUU2WWOCF5ZnWOONSzu5wFA6knsKVWV0DIwZWGQQcgigDN1X/kJaL/1+t/6TzVp1mar/AMhLRf8Ar9b/ANJ5q06AOZ8F/wDMwf8AYbuf/Za6auZ8F/8AMwf9hu5/9lrpqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzNA/wCQbL/1+3f/AKUSVp1maB/yDZf+v27/APSiStOgAooooAKKKKACiiigAooooAK5PxSsr+LvDq2+RK0V6EwcHd5Ixz25rrK5PxTM1v4u8OzoAWjivXAPTIhBqZW5XcqN7qxi6d4X8R2V1bzNeatI0JsH/f6q8is5OLvcpfDDaBwRgHlADWPc2vjPRYtc1DW9RvEtFGZXRiscyGZeYnN0/kkR7l3CKJRuJY8bq6zT/iFFL4fkvdQ0q9t7m3tYLmSFzDGJUlUkOjNLtVco/wB9lIxyKr3Xxg8K2kOnSzXO1b+AXA3TwIYoyxXcQ0gL/MpGIt54z0wa1lfmt1/z/wCGM4WST/rT/hzllPiXxD4TdvCceqSQvdTtZXT6uZGh2qgjDutwvmpnfyHkXPVXHNbF9oXiT+0Lq4ey1Oe0ubgyvBpmpJazNJ9mt0SQuJEyiskoK7vQ7WFbE/xMsYZJx/Y2ryJCLh/NVIdrpbybJnXMoOFODyASCNoJyBcvPG9tb3U8EVhetFG/kfbzGn2cTlNyxn59+eRyF25OM5qW7L5f5f16+ZaTT18/6+Ry1j4c8VQ6lO11Betd3Do896l+otJVFpHHIDCHGXZ1IDFOMZyBwZbPSfGEPiTRSlrd2tlZxRQXJW9DxSxeRg4TzgoYSdcxEkAEP2rQu/iZDZ+Gjcf2fcXOrLb+YbOIIuSLbzzJ8z8RYOM5znjGauR+O1Es0DaZf3V8H4sLaKPzo0EMUjkky7X2+aoypBJOArYyaad3/WxK95KS7P8AT/gHM2XhrxM9hs1O01a5FpqsFzA0upMlzKBuDEj7XIm0AqcBkB5/djAzqaFpXiiDUtLbWk1SaWOK3BuI9TUQRKIVEqTRlz5rmTcdwQ9R864rp/EHie28O6GNUureaWEgEoHihZRjJLGZ0VcDsSD7ZrPtfiBYX17ax2un6hJaXJgAvwkYhRpkDxg5ffkggcKQD1x1pJvbzX5W/H/gDb0v5Gb4ps/FV14ysJtFtrtLW2mgZp47zEMkRcechj85Bu25+9HJkdCpxUFtofibStMkkhGqX9xc6fi5hl1Ys3n+av8Aqy0mEPllsbSoOBkg81eu/ipoFhLqcV+JbZ9OVWZZJrf94GcIuMS/u8sR/rdnBz0yab/wtXRX0mHULS1vb2FoZ5pjaGGUW6QlBKWYSbWxvB+QtkZxngGY6rTz/r+tmPVu3XT8Nf67o5abQfiKdIs4lnvlSK5mIjjmLzKrbDEzE3yFgvzgq80gz/CwwRvz+GPEN3rqzXV9qhgl1BUn8jUngT7L9jAYqiSfITOo+78w5wcEk7C+NoZpIVNpd2bi8a2mguIUZzi3acEFZNqgqAQfm9CAeRc8L+LLHxZb3cljHJC9nOYJ4pJIpCj4Bxuid16HpuyOhANVqtPIW2vf9b/0jkLzTPGraXDBJBf3LS2FnDM0OobHjmXzvMf5Zoi3Ji3YkUsO7YxXXeFJdUi0Ww0/X4Lg6jDZRtc3LYaN5MlSAwY5b5c/QjnOa3qKTd2/Mb1Z5LqkPjKzbxDqU0eoWNnJYTqF/tDficSJ5bxnzmCgruxtjjxzuB4NaUOkeJYVa8ttP1FkjS5+y2l7qayXMYdIhtMpkbksrlfnOOOV6D0iil0sL7VzyY6F41/4RWS3ddYM6akZbWFL0lvIMa4WV/tyyYD7ukzc87SuALz+HvFUOt6rcaXHc2k98fONwb8yW+/7GIwoVnJyso67O6nnGB6XRTvv/Xb/ACD+vxucvoFvqln4c1Hy7HU4ZiWa0tdV1NbiXOwceaC+0Fs4y74z2HyjltH8OeLLy4S31dtXs9Mkv1mZP7UdZki8iUMrSLcSP/rPLPyuByCFXkD1GijqB5lqGm+OH/sKO1hvvOs44DNc/b8q+JP3qSKJ0DNsAwzJKDz9081Fa6D488/Xhd319vnglWF4n2xyuXGxoma6fyyq5GBFEDk5zgGvUqKE/wBfxE9VY87PhnxHZz3b2F1qrjz7mK3E2qvIPs7WxMZw8h+bzzwx+ceoWnW9l4uHj+yvXtb2LT4SY7ote+ZFPH5J2sqeftBEmM/ug2ejkZr0Kii9tfKwf8H8f60MWe5N63h26ME1sZrnzPJuF2yR5tpjtYZOCOhFbVZmq/8AIS0X/r9b/wBJ5q06QzmfBf8AzMH/AGG7n/2WumrmfBf/ADMH/Ybuf/Za6agAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMzQP8AkGy/9ft3/wClEladZmgf8g2X/r9u/wD0okrToAKKKKACiiigAooooAKKKKACuX8QxJN448MxSjcki3isM4yDEAa6iuT8UtKni7w61vnzVivSmBk7vJGOO/NKVknca30L934L0K9WIS2sqNCkMcUkF3NFJGsQYR7XRgwwJHGQckMQc0J4M0WJbUW0N1a/Zc+Wba+nhJG8vtYo4LruYna2QMniuW06XxpFdW73mo6jcohsHkjksIlWTzjtnQ7YwQIwMjBBXPzEjisi4vfHepxa7b6g95aRxqXCWltI8ke2VSogJtAjgoGyBJKxyMY5FW731ZEWmtPL/hvwPRH8JaJIrK9lkNFcxH96/KXDb5h1/iYZ9u2KZJ4N0ObVDfyWjmZsFl+0yiIsF2hzFu2F9vG/bu965a1PiDRZLm/tm1S6tbi5vmNgLFMgAM8cgygfczDGCdpzgLmsptf8ejw3cNFHfvs1BVW8ltXW4NsYshggsic7/lI+zsQO/wDHU7rXt+Zd23bzZ2cPgbTxr13qF0sM0UumrpUMCxFTHbD7ys+4lySevGAAOuSZ38D6DJb+S1tcfeDmVb6cSsdixkGQPvIKooIJw2Oc1y9tN44vmtpLnUbu08yeC3kS0sV2LG8OXlBmhDghsfeAAJIKngBl9q/jCK3tfn1SO5FmDbpb6WsiXtyJGBW4Ow+Uu0Icgxj5mIPGKerdvl+v9eYumna/6fp9yO21Lw1peqxWcd3BIFsjm3+z3EkBQY2lcxspKkcFTkHuKZaeFNFsbSO2tbPZDG8LovmucGJQsfU9goHvjnNed67rus6o+raWl5fXElymoW506OyVoAscbiMRShMu5O3cA7EMcEL0M2u3Xiq9s9ZsNmqzvLDexS2P9m4to4BG/kvFMEzJIx8vK72PzN8q4otf56jt087HZQeAPDltE8cNnOFaPyxuvp2MS7g4EZL5jAZQV2Y2npirUnhLR5rL7Lcw3FzH9lltC1zeTSuYpcb1Ls5Y52ryTkY4Irj5LzxHJapJaLqN8lvdSm3ub7SljnU/ZJuieWuFEm1VfaC2duWBy093f+KNI0m9hnu9YvpH+zmG9i09DJCzoxcbY4GGwMoGfKkZd/OeoNV/XcSbun1f6HU3vhDQ9RSZL2xEqzSeZIDK43N5Pk54P/PP5f1680WPhXTtLZTpz3kLees8rG9lkadlQoBIzsxYYI4J/hX0FcDFr/xEe70RZ7aS3DxIJd9vKVlk81lcS7LR9o2hSDuhB3Z5HAuSzeOVWaddR1Mn7Lc3SQjT4tokjn2xw/6rOHQ5IzuOMqV5p2bdv60Jclb5fmemUV5n4n1XxRp0V+mhWeoR3T3s0tu1rYjy59sce1HYQSfey2GIXO3HmLXcW+qvfaVdGxXzL+1TY8MkbRgTGNXCnIHHzLyPX1Bqfs8xS1djUoryfTNc8dS6bI2ryX9vB9pjW5ntdPkmu7YFXL+VG9nGrpuEajasxALHc3BF3+2PGCXvh95W1GSKVmWe2isTG8qeaQskrfZ5EQmPaSheEg7uegDtrYOlz0uivNrB/F0c3nxy3ltbW93Ai2EenRLHMkly6ys37vdwhDZUjHU5zVS88ReLLS3vJmudVWRUP2pJtJVYrNzMiotu2wedlS38UnQcqeKQLVXPVKK81EHiPVZbOaLUNWhFuLz7NqMunxx3EkeyIqJIniCoS+4YKKSF4AJzVTUI9fvbdruXSZDc/aDJtGnght1hGCWUr83zlly2em3tgNK9yZSsrnqtFef2HiTXU8c3r6hFqUegRQ3DTfabMhYGjI27NsI3BlBYESSZ6YU8Hvo5FliWSM5V1DKcYyDS6XK6jqKKKAMzVf8AkJaL/wBfrf8ApPNWnWZqv/IS0X/r9b/0nmrToA5nwX/zMH/Ybuf/AGWumrmfBf8AzMH/AGG7n/2WumoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDM0D/kGy/9ft3/AOlEladZmgf8g2X/AK/bv/0okrToAKKKKACiiigAooooAKKKKACuX8QypD448MyynaiLeMxxnAEQJrqK5PxTC1x4u8OwIQGkivUBPTJhApSuk7DVr6l/TPGmg6uYxY3kjGV0SMS2ssRferMjKHUZUhWww+U4IzUd3468PWKB7i8l2eW8rNHZzOERWZWZiqHaNyMMnHOPUZzdP+Hog0e1iu9c1JtSt44FjvUeItb+UCAkYMW0r8z8urMQeTwMSXngOJfDV7p+m3lwbi4sjaLLcyDoZGk3Eqv3suecenFVKyen9af5kXdr+X4mvYeKtI1Lyxa3EgeSV4RHNbSROHVN5DI6hl+X5hkDIIIzkVXj8b6FMrNbz3VwqwJcEwWFxJ8jqrJ91D8xDAhfvHnjg4gbwPC0SOda1X7etwZ31DdD50hMfllSPL2BdnHCg9855pg8AWEegNpVtqGoQRsIB5qtGz4iRUUEMhRgQvIZSDnpS/4H/BKXmb+manaaxp8d9p8hkgkyAWRkYEEggqwDKQQQQQCCMGsiz8aabPr13pFx5lvdQXDwITFIY5dsYc/vNuwNtJOzduwM9Kl8PeF4/C9ra2Gk3ci6bbrN/ojRR4LySBwQVUbQuWAUDGG9hTbzwfY3vmb7i8jL3cl3uilCsrvCYTggZACsSO+e/am7XdtrB/X5/wDAKVtrfg+G5vNctrNYL9nWG4lGkypeTEjKjZ5YlkBC5GAQQDjpVifx/wCG7aSJJb+TdIiONlpM4UOzIoYhCFJZGXDYO4YxkgVkf8Kj8Pvpt1a3Mk1y11NHcPNNbWrHzUDKJPL8ny2Yq5B3Ic8HrzWjB8PNItrJbWF5o4wtqMQxwwqTbzNMp2RxqoJZjuwAD2weaFbZ+X/BBef9a/5FmXx14fhsre6e6nKXG/aiWU7SIEO1y8YTdGFPDFwAD1xTYfG+kk6h9smW3Sz82QONziWGNUZpAQOf9YvyjJ6etR3Pga0l+a11TUrCRnuDJJbPHmRJpPMeM7kYBd3QgBh2aqGp/Dy3urjSre0VV0+21AX05kmbfhUVVhVQuGRtqk7j/D0OeBWvr/Wv+X37dhSvfT+v+H/rqa6+MtLuIbp7F5ZBayrFJJNazxQljIEIWUxlWIJxhc4PXHUXNJ8Q6frklwumtcSC3co8r2kscbEEg7HZQr8g8qTWN/wrzSzrV/qklzcNcXxXzNkUEWArq4BMcSl+UAzIXIGcEZNXNE8HWOh69qGrwTyy3V/xIWhgiAGc/wDLKNN5/wBp9zY78nKXmN+REfHmiW8ixX1wyStJIn7i3nmRFWZotzuIwEG5cEthQe5GCdHWvEmleHxEdVuHi80FgI4JJSqrjc7bFO1BkZdsKMjJqgPBGmiC+i8+623qSJId65AeZ5jj5f70hHfjH1q3rPhyPV7uC6j1C9065ijaEzWTorPExBaMllbAJUHK4YY4Io7A/ifYYfGGhi6uLc3jbrdHZ5Ps8nlHYCzhZNux2ABJVSSMdKp2fj/SL67v4ootSEdlDHMZG0y5HmhywHlqY9z/AHeNoOc8ZwaqR/C/w/DrV9qcMfly3qSrIBa2xZWlBDuJjEZtxyerkc9McVc1TwRbanJKw1TULTzYIYHWAwlWERJUkPGwb7zAg5Ug9MgGjoD3/ry/4Is3jzRIIYLl7km0njLIVt52mL+YI9nlCMtncdpBwwPG30uvruiXvhh9YnkWTS1BdzNbtlSjcgxsu4MGXG3GQR0zWXpvw60fSobCK0luljsHZ4UBjVRmbzsYCAAbuABjjitePw/bw6DdaVDPMkVzJNI0hWN2UyuztgMpUjLHAZTx1zTduXTf+rCV+bXbT/gka+LNI+xPdSy3FvGltJdsLmzmhdYkOGYo6Bu/TGT2zQvivR2vL22E8wNghe5ma1lEEeACQZivl5AI+UNn2rBX4WaVDpA0+01PUrSJoZoJvswgjE0cpBZSixbEGVBHlqnf1Obl38PNI1DXrvVL6SaaS6t2tmjEUEYCMuCN6RrI3qA7sAeQOBRp+f8AwA1/r+vUtDx3oDWonW4uifMMZg+wXHnqQASWh2eYqgMp3FQMEHODT08baDLqRsYbySWcEDMdtK0ZYxiRVEgXYWKMCBnJ7ZxWVqvwz03XbSFNb1C91K6gdmjvL2G1nZQwUFRG8JiAwq9EB75ySTJpXgVbLWru5mvZRY/ao57XT4fLWAeXBHGrMoQEMChwqnb04yODe/8AX9f16lFe3+J1hcWum3a2dz9nvmjBQQTNPEGilcHyhHlv9Vgbc5znpjOmfHGlrdzB2ZrVba3nhmhjeV5zK0gCLEqlyR5ROACevAxVOD4c2drDbi11nVYZrVkMFwrQF4giSIqgGIqQFlYcgk4GSecpqHww0DU7L7PdCWQCOJUaVIptrRmQiTbIjIzEzPncpHPQU5W1sGn9ev8Aka099balLoF3ZSebDJeuVbBB4t5gQQeQQQQQeQRg1t1zsOj22gW/hzTLFVWC3u2VdsMcQP8Ao8xJ2xqqAkkn5VAroqTtfQlXtqcz4L/5mD/sN3P/ALLXTVwOg6brV5d67JpWvf2dCNXuFaL7Gku5sj5ssc9CBj2rY/sPxT/0OH/lMi/xpDOmormf7D8U/wDQ4f8AlMi/xo/sPxT/ANDh/wCUyL/GgDpqK5n+w/FP/Q4f+UyL/Gj+w/FP/Q4f+UyL/GgDpqK5n+w/FP8A0OH/AJTIv8aP7D8U/wDQ4f8AlMi/xoA6aiuZ/sPxT/0OH/lMi/xo/sPxT/0OH/lMi/xoA6aiuZ/sPxT/ANDh/wCUyL/Gj+w/FP8A0OH/AJTIv8aAOmormf7D8U/9Dh/5TIv8aP7D8U/9Dh/5TIv8aAOmormf7D8U/wDQ4f8AlMi/xo/sPxT/ANDh/wCUyL/GgDpqK5n+w/FP/Q4f+UyL/Gj+w/FP/Q4f+UyL/GgDT0D/AJBsv/X7d/8ApRJWnXF6Ro3iSSxkaDxV5Ki6uFK/2dG2WEzhmyT3IJx2zir39h+Kf+hw/wDKZF/jQB01Fcz/AGH4p/6HD/ymRf40f2H4p/6HD/ymRf40AdNRXM/2H4p/6HD/AMpkX+NH9h+Kf+hw/wDKZF/jQB01Fcz/AGH4p/6HD/ymRf40f2H4p/6HD/ymRf40AdNRXM/2H4p/6HD/AMpkX+NH9h+Kf+hw/wDKZF/jQB01cr4kEjeNfDQgYLKUvQhPY+SMVJ/Yfin/AKHD/wApkX+NYeq6Vr8fi7QIp/Enm3Ev2nyJ/sEa+RiMFvlBw2Rxz0pNXVhrRmfo9jcWniDSH0bQFj1KNNmsTXemzwySP5bZdr3cElUttG3bLjOeMDC+MNJ1nVdWtbvV7KRbiO3Q2Ftp0ZvYRdLI5+aZoQ0IK7MuPLPBG/jnq/7D8U/9Dh/5TIv8aP7D8U/9Dh/5TIv8aq+qfYlq6a7mR4u0TWfE82k2moaVowjj1F2X7TC+p2/liCQB5YyItpyQANxAJHJrNv8Awvoui6ho9r4l0X+3LGGyugog0KS5hhleWNgqRosnkrjcFBPAGM11P9h+Kf8AocP/ACmRf40f2H4p/wChw/8AKZF/jSWj/rtYe6KQGuaX8NbdYvtkN2jgOY4vtNxb25l/hTDb5FjIGMNyOjdDylxfeM9M0i1/sVb7yZ727lkup7KRJpGMmYvMiS1mYKykk4ROn3k6HuP7D8U/9Dh/5TIv8aP7D8U/9Dh/5TIv8aOtw6WORTSfEOna5qut2lo93qt1cybWls4yqhbMFAknlq+zexUZbnGOpbNl7/xObM3OjjUNVmiiufs1xqukray52xYBxGCOd+PkXdjGHxk9L/Yfin/ocP8AymRf40f2H4p/6HD/AMpkX+ND1VvKwo6O/mcvpV1431XTYEn1K+sx/pLi4jsczMFRCiyCe0iAJctjbEMjjJIzW94YfVP7a1W41WW/D3NlazrDNb7YIm8rDhG2D5t2cqWJHpVr+w/FP/Q4f+UyL/Gg6F4oIIPjDIPUf2XF/jQ9U7B2OT0LxN4kufCL6hLPrV951jA7zDSlSSCdyAxhURfvUCncSFk9t33RUjn8W3ltBc6smqPcGxvLcWxsBLFKyzIY2kBgXlkyQSqA7cBQcg9nB4b8R2tvHBbeK0hhiUJHHHpUKqijgAAHAHtUn9h+Kf8AocP/ACmRf41V1zXQSXMmjkjrPxAfVNdiKyQeWk/2dFtZJBHhsRNEfsoRiVwSDNJ16LggWtRTxPb3tssuq6vKtjqksUV2NOWTzo3tMo0qRRfMglYrlQo9TkZHR/2H4p/6HD/ymRf40f2H4p/6HD/ymRf41PQfVsreA9X1W50cJ4iXUZLlrgxx3FzbMvmDZuzj7NAY14I+dBzwGbIrr65n+w/FP/Q4f+UyL/Gj+w/FP/Q4f+UyL/Gm9RI6aiuZ/sPxT/0OH/lMi/xo/sPxT/0OH/lMi/xpDOmormf7D8U/9Dh/5TIv8aP7D8U/9Dh/5TIv8aAOmormf7D8U/8AQ4f+UyL/ABo/sPxT/wBDh/5TIv8AGgDpqK5n+w/FP/Q4f+UyL/Gj+w/FP/Q4f+UyL/GgDT1X/kJaL/1+t/6TzVp1yg03WrPXdHk1XXv7RhN06rF9jSLa3kS/NlTnoCMe9dXQB5lGl+Li/udLhmknt9Y1N1aKIvsf7OQnGCOWwAD1PFXrNvF9vqgNzqeo3cMVzAhSSxiVZUki3OSVjBwjcAgjHRt1bPgv/mYP+w3c/wDstdNSsB5lp1x46VbaW8v9SmIttOuZIn06JVd5ZSk8RxGCAigNgEMpOSccVPe6/wCKniurKyg1KO9g+3bpv7MJj/1o+zbWKbX+Q/wk5wd3NejUVbafQbd9jy/XtR8d6SklrZT3t5bwXrp/aD2v76RPKiZBthtJQy7mkUlYh93G4Hk7vi6+8RW3guwuLC4kt9SJjN0LG1llLnb8yp/o8xQbu7RHgYO3OR2dFT0t6Bpe553qWu+Kf7a0/SrMy2j6nYi+82eJJXshEv72NkVfnLM0Q4H8T4IwBWfYXviu8tNGu7qTWnuLXUJULSWuEud1u2zeptYnSPfhclABuJ3Hhh6aljaR38l6lrCt3KixyXAjAkdVyQpbqQMnA9zU9N/1/XoL+vwPL9C1Lx5qGmzR389xbSveW0ZkFm5lgDORNt8y0iQoFxggSY5Jdhit3wjN4mOpQjXbq8uYZre43rcWiRLE8UwSMgqinLoSxBJB6qAOK7Oinf8Ar5W/4JNn3/q55hqb69e+IZvtC6lPJbG+CWraZm1jTyXWEpJ5eJC4xlSzcnGF6FYdX8Yw6hq8EQv7pUtw1vssDHFbcrwqPbp5jhS2Ns0gJH3V4FenUVH+RX+d/wAjz3T7rxTfm3httQ1b7GbyQJfXmmx29xLEsO4B0aIBB5vy7vLUkdOzVjpe+Llg1LUrEandal9gt45GvdONv5D+c3nLDiFvMCKSVISUn/b6V61RT63BHnmjXXjHUba2a91C4tFjs7iXzFsWbzXDARiUSW8b5wSSqIhbAxWx8Pr/AFi+0KU6/wDbXnjmKrPeReWZRgcqht4GAByPmj/4Ew5rq6Kd/wCvmKzCiiikM4W+F3plvBr+lWE19c293f2skEClmdJJ5CvA9JFjyewLHpmsu9Pi/wAOazo+kaQv+gJDEXmEMjx3M7OTOZfLtpdvXIJeLls5bnHd6B/yDZf+v27/APSiStOhaA9TzfU9V8XaLoltqIu7i8utQvJbFLKeCKNbd5HKQSABAxCkKTknIYnsK6jVE1j+1NItrS9uo4Fjke8lggjYysgQqpLKQu47umD1wR1GzNZWtxcwXFxbQyz2xJgleMM0RIwSpPIyOOKno6B1PLtO1vxpftqCKNVghmktDbzXNgBLBvnCzoFMCABEPfzBj5t5HTQ0DUPGX/Cfy2GrF20+NpFzNE+14lBEciulqsfmN8pYecRycIvQeg0U07A9UFFFFIAooooAK5bxHz428NYDsdt5xGcMf3Q6H1rqa5jXiF8eeF2Y4AF4Sf8AtkKT1Q1ucbpFve6LDqB8G6C/2tbBg09zpc1jKZgV/wBcxyl1IfnO9FONvU7+b+h3fjXVLS2S6vry3XdcP5y2ZErhVQoknn2kIGWLjKxrlehyM10c/jvTiALBJp5VnEMsU8Mtsygo7K4EiAsp8sgMODzg8VPp/jPSb57SB5HiuriGOQp5MjRxsyBxGZtuzfg525DEc4pvVP8ArzF8LX3/AKHN2+t+KNYjWK1/tSw/d6fFLNLpflssjO4uWUSR4OAF5wVHBHB50fCM3iY6lCNdury5hmt7jetxaJEsTxTBIyCqKcuhLEEkHqoA4q4PiJ4aa3inW7ujDKnmLINOuNuw9HJ8vhDnAY8E5AJINTDxto8Wxb25Eckk8kX7mKWVE2ytEGkbYBGCy4y2FzkAt1N31vbf/K3/AASXF99rf18zlr6/8Tyax4jsmS91C18pzar9gIgi5Xau17YeYcZ5WWQHBO1eKg1qbxNqVnq9o39pT3O84sX0zFrFtuE8oxzhQXyg3MAZO/3MYPca14s0bw9cRw6tdPC8kZlG23kkCoCAXYopCqCwyzYAzSW3i7RbqNXS6kjDNImLi2lhZWjXcwZXUFTt+YA4yORkVH2fQr7T8zkrq88Z3GkpPBdalaXdpp1xPPClhGy3F0kgCxDdGSYz823bhmXBznmi11fxxL4x1G2uQLW0VZ/KDW00saIFPlOm22Cs5O0lTOxIyAoNdRa+OPD95eR20F6+6VcpJJaypETt37PMZQm8LyUzuAByOKanjrQZLSa4inu5FhZQ0cenXDSkMCVdYxHvZCASHAKnB54pvb7/AMf60A4X+3fGo8OWk3naw08d2yyf6CwlvF2ggLnT/wB0oOR88S5P/LTAyfTIdUjubW8Nskr3Fn8k0Ow7hJ5YfaM4DHDLyDjnrWdP458PW7Ya9kkBgjuA0FpNKpST/V8ohGW6Kv3mPABrLk+JNhFpz3z2sxhVpwsccUzTsIpkiz5YjyOZBkHBXpg8kGrugXR/13MHR9U8aatdS2rXGr2dpPc27RXk2nqs0UbLL5q7ZLZFXaUQcq+Mg72BFP1jX/GVrp+mR2cOqyX8YLSsth+7ugsrKd+2B8NsUNtBi3bvlbtXYW/jLS5dTXTi8z3jyOixW1rPNsVXK7pCI8R8gj5sDIOCcVt3E8drbyTzkrHGpZiFJOB7Dk/QUXW/T/gCau2vkeU3Go+I9e03W7aG41K9DPewPC+mhYYVSZlhMUgQGVuMEbm6chT11NY1rxV4Z027n8641X7NqQsoPtMMUTXKzRIImyqKDtmfGVH3d2ckVup458L2NiskLXECSTSg28elXAlVxh5C0Ij3qfnDEsoyG3e9S3viTwxNqllBdFLm5R0ktZTZSSpFJIvyYlCFUdlbpkHBz0o06j+05ev9fI5DVJ/E+iQ6pDp66pJf3N8GS8t7MFJ3W1gX5iIJQqswbkIFypG5KsvqHinU3lguJ9XsZ7i0wltb6WDBsa2yZDM6fJKJSRtLEjAHlnO4dPY+OtEu2soXusXF1HE2YoZngRpFDIhmKBVYgjCttY5HHNSr420B4bmX7a6x2y72Z7aVRIu4LmLK/vRuIGU3ZJA6kUS1TT9PuQ9mvI4qG98RW1vHsk1m1tHhi330OjCS7klEEYVXjMOSpbeGYqMbQNyjmuy1U6zcTaFDZXNzZrM5a+kht0JAEZYKdwdUBYAd+uAc4NVrX4haPLBLNc/aYFW5eCNRaTPIVRVLSPGE3RKN+CXAC9yM1Nc+P/DlreS2r3dxJLExUiCwnlDMFDFVKIQzBSGwuTt56Amh6699SLaJdtDjtN8Q+ORb6q+tQXiFIwClraSyyW8jOBmHNoqOiruJw054GM9Kks9b8ZyaXZ/2o2rWcqtKqPa6WLl7mQSYjWUGFAqFMHdiEZ6smMV3M3ivR4Lixie5kIvwhgmS2leI7/ubpQpRC2QAGIznirup6naaPp0t/qMvk20ON77C2MkAcAEnkij4dWU/e26nmiN4n06W6+yjU7iaOe/33M2mq8kEbXUBHkt5Y3/ui7qoLBiMYO0KLK3fjO9SQWepaxFaQwXc1tdTaXHHPdlBCYlkR4htJZpRgIjMFyAOtdjF4y0Ka3877Y8SCOWRhcW0sTIIgDIGV1BVgGB2kAkcgEVCfHmgAOVnvJCj+Xti025cs3OVULGSxAGWAztGCcAii+lvL+n/AF+JXNrfzNXTtQjvVeLLC5twguEMbLsZkDY5HPB7Z9OtXayR4o0d54IYr5HluUSSBFVj5qsCQy4HK4UkkcDHOKr6f4w0u9k06BpXW4v4UliKW8xgYsu4KJmjVc4BIU4bH8Io3ZC0Rb1X/kJaL/1+t/6TzVp1mar/AMhLRf8Ar9b/ANJ5q06QzmfBf/Mwf9hu5/8AZa6auZ8F/wDMwf8AYbuf/Za6agAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMzQP+QbL/1+3f8A6USVp1maB/yDZf8Ar9u//SiStOgAooooAKKKKACiiigAooooAK5XxHCLjxr4ahZnUSJeqWRtrDMQGQex966quQ8XK0nijQERSzNDfAKBkk+T0qZaRY47oj0z4YaRpk0s63l7NPMY2llcQI0pRZFUt5cagnEpBJ5OFyeuVtPhfoFl4hh1iBP9IiRFPmWttIXZUCB/MaIyqcKPuuoyOnJzgJqPifwf4ZN3cT3l/aabY2Vy0E1tFGXDB0lt0IQcrhGAJLZwCSDipU1fxZF4ig0+a/vZ76KGzd7aDT0a1kaRm8/zJhH+7CqPl+ZTwPvHIrWStJr5EXulft/X9f8ABLWt+ANUdrGz8PXyQactjDYXTSzbZJI42JUsPKYPwTgKYiCTksDgbieB7S3u/tFjqWo2ckju1wbeRFNwrTPLsYlCQoaRsFSrYOCTXJ6TrHj+6i1NL8SW86iMBVtpHMDmZQfK3WqIyBN5P7yU9DuxVmXUfGen+INXs7Ga/wBa8myc2jXFsIIRKEBXefsqK7E90lIyfuADieZ7vzZb3d/Jf5HYa34Yste8/wC2Szp59m9m3lMBhGYMSMg85Uf4Vj+KfAia7YtYwlfJvNTjvbyWaUho1VVVljCrzvRdhBI4djk/drE0W88a6tp9lBc397aCbUTHJdpZnz0hEEjHcJrOFQPMCAMIyOcZJqS11fxb/wAJBosd4dQnhntUF1bR2JiRXwwZ5Ga2ZD2O0TRkdlbOCaxt/Xn+ZNlq/wCux0b+B7CXUWmlu717JpHm/swun2cSupVnGF38hj8u7bznGaqXfw6tr+xS0vtc1e6gQhRFO0EkZiClfKMbRFCuD94rv6fNxXMaVZ+IyLeIPqFvczw2TIsmmR+RZH7M6syDytqEPgFc5GcYANWNTm8V6/4dluZLS9sZ547qOG3W0TzrYrasuQxUkF5Q2CDypXHWk1ZNdv0K+0l3/X+rnUQeBNOttI+wW13exbIbaKKdXTzITb/6t1yuN3rkEH0xTG8AWL2rRy6jqEkrRzqblmj8wtNIkjP9zbkNGuOMdeDWZYavrv8Awl2l6HFPcTWdxax6g91dQLHKkKpseJ02KVZpCjcqDy44wBV3V9Q8SWfiaa0tIbuex8s3yzRW6MAiRlWtgcY3tJsYZ5IZsHjipXTbfn/wf68vQmNrWX9dvz/H1H3Xw7029vrS5uby6ka1uXulDRW5ZpGfeT5hi8xOf7jLxwc1s3GjzX+g3Wm3+pXDNcGT/SoAsUkas5KgYBHyjC5IOccg5NeeR6740l8O6o4uNUhMdzC9pPLpkhnliYNvQKtkShBA6wPgfxHIatW21bxTcahALj+1rORok8m0/s9JopUMQLvNNsURyCTIxuXgD92c8S9FYa1d/wCtzX0X4eaToRka0nuWaVpnfKxRgtKiI7bY41UE+WDwAMk+tZT+BNVi8TWwsr1I9Bjkt5pIzN87vCioCyeUcsQi/MJFXH8BIzVdNT1vXxbCex1Lyrc6a7i4054f34kk88jcoJAwmT93oRwcnM0mHxFb3tgXF9HK9vbybJdIDW9kRYyqSgWIbCJNoKAg87cANg1a12+n6K6Eve08vz3/AOCdfafDzTrI20cOoaj9ihMDyWRkjMU8kKqscj/JuyBGnCsqnaMiqunfCnw9pS3i6ept/tAURvDa20clsVcOpSRYg7EMqn94z9BnNS+C9R1278J3r6uL6S9iLiKe6h2NN8uQVQ28DAZ4w0f4sOa57UtR8f6e2ipbzz3AuLaOWWaa2bBuGPzRSJDaSFI1GMZMZ5OXOODVyt/Wv/DDvpf+tP8Ahza1D4U6LqqxvqdzcXl2kzytd3dtaTu5cKGBWSFowDsX7qgjsQDitmPwdp0VxDLG86eTcSXCIpRVDPD5JGAvChegHf24rkZta8bRXfiOKyju794xutHe2aGCFfMUFVDWoZ2CFiCrzglegyFNZdT8fXGgefHc3iSwWV5cR+XYM0lw8fleVHIJbWI5YmQYSNdw6cjNKKurLt+H9IOW8l6/j/TOln+GmlXN3ps017fOumrbfZ4n8lgjQEbXDNGWUkDDBWAIJ471p61oV9qnha40xtRMlxNOHW5KiMonnBwBtBGVUBQcckAnqa5HVxr6vbDULvWZEsdX3pf22mrLPHE1kxJVEiKsA7lAdh9Dk1Xn/wCEn/tmDUjp9w121hFumNiHIdYb0qcFSEfJiyB0L7ejYLls7+pUY7W7f8A3tZ+Hy6lZ2Nk07Xa/2kt9f3t3IBPNtUKV2xoEIdQEI+UBexq3rfw60XX7AW16GJS7lu45HggnMbyHLAJLG6Ec45Ukeueaw73UvEejW4ttS1jUnhnntgb9LCJ7lA8cjOkMSxESEMi8bHZVZic4yOr8Gajc6r4Rs729na4mlMmZXjCFgJGCkqAAOAKTX9fd/kjNPbz/AOD/AJsji8GafBeWV1DLPFJYwrb2wiEcaRRYwyBFQKFbgkY6quMYFZll8MdJsdW06/W9vppNM2fZVm8lvK2xiM4by94DKOVDbc8gA12dFF2V0sYs8M9vJ4fhvLo3c6XbB52QIZD9nm52jgfhW1WZqv8AyEtF/wCv1v8A0nmrTpAcz4L/AOZg/wCw3c/+y101cz4L/wCZg/7Ddz/7LXTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBmaB/yDZf+v27/wDSiStOszQP+QbL/wBft3/6USVp0AFFFFABRRRQAUUUUAFFFFABXLeIpPJ8beGZMZ2LeNjPXEQrqa5fxDGJfHHhiNsgOt4px7xClK9tBq19TOtviD4T8Rx6Uslzo96ZIDfzxC7jnbT2jQPuZeSCCcZwCCK1D4z8NwQ/2hm4jkuZltig0y4FzI4RnVTF5fmH5QxGVxjp1qa78GaVfaLZ6VeCWa0tLRrNUdh+8jaMId3HXA7Y5qpoXw90jw+lqLJm3W10bpWS1trfexjaPDCGJAwCueoznv2qna7sTHZX3/4H+ZaHjjw809rEl8zfaljZJFtpTGvmfcDyBdsZboA5Uk8VV1L4haNZRTG3eS4khnijdPJlQOrzLEzxsUxKFLc7N3OBwTRH8P7CFoVh1HUo7VTEZ7RZI/LumjIKF/k3DGB9xlBwMg1JH4HtYx5R1PUmtEmjmt7MyIIrcpKsuFAQEgso++WIGQpGaFa6v/X9f1YZq2Wt2mp6M+paaJriJQ/7swtHLuTIKFHAZWyMYIFYmi+Nhe215cavDY2cNqiu5tb/AO0vHuxiOWPYrpIcj5QrZzwSa0U8IaKtw9zJZRy3hkmkjvHRfPg80ksI5AAyD5j0OapN4EtbkyPquq6lqU3liO3nuWiD2yh1kGzZGoJDohy4Y/L15OUvMCKb4j6HBeQLI84tZYJJGmNrNuhZHVWWSPZujA3ZLPtA4z1q+fGvh9b6e1e/2NBv3yvBIsJKDLqspXYzKAcqrEjByODUT+C7a4tLiK/1PUb2S6s5bOW4nkTeySEFiAECqRgYAAUelVrj4daTetPFfXV9c6fK0zrp0jp5ETzBhI64UOSd78MxA3HAFPS3nr/wA/r+v6/yJB4t8LWqtqqpLFcXcq2z7dKnF1K4QuqtH5fmn5QxGRjHSnjxzpYuZdzO1p9lt7iCaGOSV5/OMgCLEqlyQIicAE8ngYqLQvh7pHh9LUWTNutro3SslrbW+9jG0eGEMSBgFc9RnPftUF/8MNB1KwFrdmaUJFDHG0qQy+X5Rk2tskjZCf3zg7lI6cAjNDt0Grdf61/yLsvjrRYGZ5LgtAUiMfkQTSzO0jSAL5Sxk5zEwwMtkEEDAzel8UaRD4dj1yS6YafIUVZPJcsSzhAuzbuB3EDGMg9az9N8BaVpc1pJatKhtREEWOOGJCY/NIOyNFUZMzk7QB06c5XV/CjXHhOPRdLu5INt7FcCdmAdALgTMQdpGeuMjHTNDtf5/gLqu1vxLkHi3Rbi3E0d04UwTTlZLeRHVIiBJuVlDKVLD5SAeelV5/HWgW7TK9zcsYZFhYxWE8gMjLuCKVQ7nIwdoyeRxyKqXfw+tLu1VDq+qRTsk8dzdxvEJbpZtvmB8xlRnYv3ApG0YwKdqPgxpLOC30rULizI1Fb2S4Vk8xMR7PkyhUnheGBHX6Uv6/H/ACB7aef/AADRg8WaLcW7TQ3u5Ejikb904KiR2jTIIyDvVgR1BHIFQSeN9DjhuJfNvJI7eZoJHh064kAdSQ2CsZ3BSp3EZA7kZFUn+HenmSNodS1KBcJ9pSOSPF2yTNMGkJQnO92J2lQdxGMYwuq/DzTNX01LC4u7xbUTXEskX7p0m86QyMrK8bLgE/KQAy9m60S8hq3X+tP8zqIriKe1S4hkV4ZEEiuvIZSMgj8KwbTx54dvtPlvba9lMEUaSZa0mRpFc4QxqUBkyeBsByeOvFaGnaVLptqbRL2Se1jt44II5UUGPYu0ksAMluD04xxXL2Hwws5fCMOk+JLufUpRaQ2+6URSJb+WQwWMGMBl3qD+8VicAHI4pu13bb/hxR+FX3NibxxoqW6NDPK80sMsqRNaTgoI/veaBGWiAOAdwGMjjJAqaXxho1tdC2u7iWKXyTNuNrN5RAQuwWXZtZgoJ2g7sDpVPTPAOk6Vp7Wdszqj2ktoxigggDLIQWbbFGiBuByF+oNVLj4Y6Tdax/aNxfX8kqq6xBvJPlK8RiZVfy9+0hs7SxAIGAOlL+vz/wCAC8/62/4I298ZeFNca60vV9PuLuyW3juCt7pEzxz7nZVVI3jy7ZXKgA7uq5wcaB8X+H7HT7eOwfarW8klvBHaTKsaRcMHCxkxBSNp3AbTxjPFRa98PdJ8RH/T5Zyn2aO38opDIh8ti0blZI2BYbm4PynccqeMS2HgXS9O04WduzpH9ilsj5UMMIKyNuZtkcaoGyOoUD2pu1nb+t7B1Xy/S5BB8QtLkuLxbjzLaKxaRZpJYZhu2Ijkxjy/nH7wDqD0wDkV0WnahDqlil3apcJFJnaLm2kt3/FJFVh+IrCPgWy+13U6X96puEZRGVhdIy0aRswDRnJIjXhtwz2rQ8M+G7Pwpow03Tmd4hI0hLpGnJ64SNVRR7KoHfqTRp/X4i1t/XyJNV/5CWi/9frf+k81adZmq/8AIS0X/r9b/wBJ5q06QzmfBf8AzMH/AGG7n/2WumrjfC0WpPNrxsLu1hj/ALZuMrNatISfl5yJF46cYrf8jXf+gjp3/gvf/wCPUAadFZnka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1AGnRWZ5Gu/9BHTv/Be//wAeo8jXf+gjp3/gvf8A+PUAadFZnka7/wBBHTv/AAXv/wDHqPI13/oI6d/4L3/+PUAadFZnka7/ANBHTv8AwXv/APHqPI13/oI6d/4L3/8Aj1AGnRWZ5Gu/9BHTv/Be/wD8eo8jXf8AoI6d/wCC9/8A49QBp0VmeRrv/QR07/wXv/8AHqPI13/oI6d/4L3/APj1AGnRWZ5Gu/8AQR07/wAF7/8Ax6jyNd/6COnf+C9//j1AGnRWZ5Gu/wDQR07/AMF7/wDx6jyNd/6COnf+C9//AI9QAaB/yDZf+v27/wDSiStOuc0SHWTp8vlX9iq/bLnIaxdjnz3yf9aOM5OOw4561oeRrv8A0EdO/wDBe/8A8eoA06KzPI13/oI6d/4L3/8Aj1Hka7/0EdO/8F7/APx6gDTorM8jXf8AoI6d/wCC9/8A49R5Gu/9BHTv/Be//wAeoA06KzPI13/oI6d/4L3/APj1Hka7/wBBHTv/AAXv/wDHqANOiszyNd/6COnf+C9//j1Hka7/ANBHTv8AwXv/APHqANOuT8UtKni7w61vnzVivSmBk7vJGOO/NbPka7/0EdO/8F7/APx6ue1mLVh428NiW9s2mP2rynWzcKv7sZyvmktkdMEY96TV1Yadncx/tnjKxtYY77UdXmt5orSe6vodLjkuLXesvmpFGkRDYdIgQUdlDknsRU1m78VahoSW2of2sizWp8iO20vebxvOcf6RhD5J8oRtgFPmZvTbXonka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1W5Xd7E2923kcS+q+LWutQSO61OKcLc+bHLpBNvaBSfJaB1iLTMwxkAy9T8oxtqle+I/GS+DbM2Vvrn9qkzMsrWoYXBXG1X/ANDBQNk43QxZ243jIJ9D8jXf+gjp3/gvf/49R5Gu/wDQR07/AMF7/wDx6pH1FttSF7Y3CQuyXlvEomVoH/dyNGHHBHzdRwM+nWuBtPE/ifTPBd7rOpf2hePpd0skguIBD9thI2siI9tAykEhgNp5AG9ua73yNd/6COnf+C9//j1QXWlalfLGt7caRcLFIssYm0xnCOvRhmbgjsaOtw6WOQiuvGS+I7fT9Rvb64S4sQJvsdp5cVvKYyWYu1sUfDdMTA/dyh5JzvDmqeOItT0OxkF39hWC3jY3trMplUIPOMm20O1w24LuljBwCQ2cn0fyNd/6COnf+C9//j1Hka7/ANBHTv8AwXv/APHqd9f68/8AMT1/r0/yOJgl8bqiTy6lqTn7LFdmE6fCFMhlKtB/qs7dnzEZ3Z5yBxUj3viO21uWIDULG1N5I1qLHSlmW6YzNlZvk+Rdm0h9yZyTuOMV2Xka7/0EdO/8F7//AB6jyNd/6COnf+C9/wD49SWjQ3qn5nP+LJNUsPEMOpaZb3Uiw2iCZre2Mx8v7VEZFCgElvLDnABbjjmuf1DxR4kmv0jtZ9ZtGlS7ltLePSA7TFZlWFZQ0ZMcZU8sdvB5ZTXoHka7/wBBHTv/AAXv/wDHqj+waubkXBvNL88IUEv9mvuCk5Iz52cZAOKcdLeV/wAQfW3l+FjmrrXfEg1ZtOjivYZheykz/wBmvLbpb/ZWZDvC4bEoHAO7Iweozb8Fajr934UvH1OO7n1CJmEEl9H5XnnbkYU28DKueOY/+BMOa3vI13/oI6d/4L3/APj1Hka7/wBBHTv/AAXv/wDHqT1VvK3/AAQ2scD4f1Dx3qcIg1G6urPzbuKOSZLRjNbgrIZAvm2kcewEIFOJMHq7AijU73xRqa+IdIF7fImiKA11ZwRPNdl5Fkj2qEblIgQQFBJbp0rvvI13/oI6d/4L3/8Aj1QWulalYrItlPpFsJZGlkEOlsm92OWY4m5JPU9TTvr/AF5AcbpieLNJ025m0pry6a4/tOWCyu7VY0jkE7NC2dgcF9xOGOD2AqPSb7xzqemQxzX17bZnlzcLZEz7VhZgrCa0hUAyAAER8g4yTzXe+Rrv/QR07/wXv/8AHqPI13/oI6d/4L3/APj1J63B6u/nc41NW8VWfh+5k1F9WmmntrOZZIdPUyWskobzUVViYlUKrwUkZd3OayrW/wDGnkw6heNq8d81i8DxR2AkRQl3hpQPJXMvk/MoIUOeifw16P5Gu/8AQR07/wAF7/8Ax6jyNd/6COnf+C9//j1NvW/9bWFFWSTPP7zW/GENraTWdxrN1bLeukStpZhur2HahBk/0V0j+beuGWHIwdy9TtNruvyao+nRxX8Esc92Xnk0x2hWLy2MBDhcPzt4Uk5GDyeem8jXf+gjp3/gvf8A+PUeRrv/AEEdO/8ABe//AMepPa39dBmH4D1fVbnRwniJdRkuWuDHHcXNsy+YNm7OPs0BjXgj50HPAZsiuvrM8jXf+gjp3/gvf/49R5Gu/wDQR07/AMF7/wDx6m9RINV/5CWi/wDX63/pPNWnWBdRakmsaMb+7tZo/tjYWG1aMg/Z5ucmRuOvGK36QzxzUtN1C51ganpdtczS6Pr1/eAQRlt20R5j47um9QO5NTzL4r0Ww1S/0m0u4Z9U1KO6vJBG7SxI0AOEUQTk7SEjOI2xg9OSOg0nxJp/h2311795DJJrN20UUUMkrNtCkkhFYqoyMsRgZGTWnaePtMkhhN55iT3DIsdtaQT3UmTDHKdypHkACQZYZXBGSCcAim72/r+rIfVX/q3/AA5y/wDaHiaye9vb+XWGubzTrMKLDT3kihbe4d1DW5YMPlJUozDcTsIAxUF94se307Ub1dYtdWWyuYAbbTPOE8q3AESS5hAVXVQS+2PjnKV38/jTQbbUJrKe8dJYQ+9zbS+VuVSzIJNuwuFBOwHdgHiqV98Q9GtreFrb7TPNM0eyNrOeMBXlEYZmaPCAnJUtjfj5c9aaet1/V7om2ln/AFaxzl3feKryfUbO4XUpHlS8juLH+zgLWKHy38l4pwgMjsdmRvY/M3yrior+98UaUkB02K+jT7cQ9paaeVkuV8uLGZPs0qgZ3DL7M/8APQBa7Q+NtAX7YXvXRLNGkkke2lVGVThmjYriQKSAShbBPNS6Z4s0rV9RaxsDetOihpPM064jWPIB2s7IFVsEHaSG56UR0d/L9Qlr8mctdt4ymv5mg1TUreGV7zZHHYwkQrFgw4LREnfyMknI+7g81reKdU1e28J2UljHfxX11sDyWVtvaFihb5h5UpVSw2k+W2M9utdZRU20t6D639f6+R5xa33ja8gtb24mvrOSCysZJbJbFCk8zzOs6sWj3cKFPylccHoan8OtrF54/gudWOpO0NldxzLPYeTBbOZYdqRSBAJFKrnJZicHkcgegUVd/ev6/iH/AADz7UZ/GcDX91Y3d9M0j30VvZmyi2QhEYwOp2biSwABZipz0zzUd5qesazqNnfW/wDblpYW+rw7FGmtGzxm2YHcjRl9nmnBJAxknIABHotFT0SHfV+d/wAf8jyueDxPJp2n3moXmrG4aHT7m6lg06PzUPn/AL2IBYSxVR8xQ5I5zwSKmGo+KbWWGGFNStWBJtLW20lTb3TGeTeJ38s+UAu0g7o85Jyx4r06inf87kyV5X8rHG+GpPEq65C2sXl5c2t3DdO8U1pHGlqyTqsSqVQH5kYn5ic4yMc12VFFHRIYUUUUgOFvhd6Zbwa/pVhNfXNvd39rJBApZnSSeQrwPSRY8nsCx6ZrLvT4v8Oazo+kaQv+gJDEXmEMjx3M7OTOZfLtpdvXIJeLls5bnHW6RFqzWs5tL2zih+23W1JbN3Yf6RJnLCVQefYVe8jXf+gjp3/gvf8A+PULQHqcVqeq+LtF0S21EXdxeXWoXktillPBFGtu8jlIJAAgYhSFJyTkMT2Fbniy61mxi0+O0u9QhgMbi4vNPsBdTGYBfLUx7GARjuycDGB8y5zWlNpWpXFzBcXFxpEs9sSYJX0xmaIkYJUmbIyOOKn8jXf+gjp3/gvf/wCPUdP6/r+vIOpx6at4rOv7GbVPN3yB7M6Wq2iQCIlZVm2nMhfaNnmN1I28bqZp0vjSK5t3vNR1K5RPsDyRvYRKsnnHbOh2xggRgbhggrn5iRxXZ+Rrv/QR07/wXv8A/HqPI13/AKCOnf8Agvf/AOPU07fh+H+ZLTfXv/XyOJgl8bqiTy6lqTn7LFdmE6fCFMhlKtB/qs7dnzEZ3Z5yBxUk2reLRrF8kDam0ytdhrRtNAtYYlRzBJFNs/eOxEeV3t95vlXFdl5Gu/8AQR07/wAF7/8Ax6jyNd/6COnf+C9//j1T0t6l31v6Gf4WGtQXN7ba1e3V+ixwSxXFzbxxHc6neg2IoIUgdiRnkmujrM8jXf8AoI6d/wCC9/8A49R5Gu/9BHTv/Be//wAeqm7smKsrGnXKeJwW8Y+HFUEkx3oAHf8AcitjyNd/6COnf+C9/wD49XPazFqw8beGxLe2bTH7V5TrZuFX92M5XzSWyOmCMe9TJXVik7O5laNo3i1LTw2l5fW6CPTJI4jb6W8UlnIYFC+YzyOpIPGCi5I/Cs+Pxd4k1SCxvZ7rUNLgvpLiOODTbBLuVTCqJnHlv8rS7/mxjaV5XqPRJbPWZ4XinvtMkjkUq6PpzlWB4IIM3IqGHSNRt1t1t5tHiFshjgCaWy+UvA2rib5RwOB6Cqk+Zt9yYrlSRyB1nx9/wl1hBc2y21u8cG+NY5XhfMYMxLJbOFcNuC5mQcDIPU1FXxdb6t4b1W4OoXby6cDqkv2NRLbh5YS0aIseMggkhgW2h8cgY9C8jXf+gjp3/gvf/wCPUeRrv/QR07/wXv8A/Hqadnf+uv8AmDV1b0/A891fUvFGqarrFilnqkmly286CKezKiORHUIExCNwZctu82TPTCkYq1Lr/jR/EmrLpVlfS262tyIIb628uOO4QjygrCEZVhk7vNkB6YU8V3Hka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1T0sPrc4LSb7xzqemQxzX17bZnlzcLZEz7VhZgrCa0hUAyAAER8g4yTzVu3uvFP9nxPqUV5qEjHT7zZLYR5hdyxmjQBBgJtXlvmXPLdK7LyNd/6COnf+C9//AI9R5Gu/9BHTv/Be/wD8ep3/AE/D/Mnlffv+P+Ry3gjXtduL7Uv7fj1NrE+Q1lJdWDpIGkZldCogjwFIXqGwDuLkHI7yszyNd/6COnf+C9//AI9R5Gu/9BHTv/Be/wD8eobuUadFZnka7/0EdO/8F7//AB6jyNd/6COnf+C9/wD49SA06KzPI13/AKCOnf8Agvf/AOPUeRrv/QR07/wXv/8AHqANOiszyNd/6COnf+C9/wD49R5Gu/8AQR07/wAF7/8Ax6gDTorM8jXf+gjp3/gvf/49R5Gu/wDQR07/AMF7/wDx6gDTorM8jXf+gjp3/gvf/wCPUeRrv/QR07/wXv8A/HqANOiszyNd/wCgjp3/AIL3/wDj1Hka7/0EdO/8F7//AB6gDTorM8jXf+gjp3/gvf8A+PUeRrv/AEEdO/8ABe//AMeoANV/5CWi/wDX63/pPNWnWBdRakmsaMb+7tZo/tjYWG1aMg/Z5ucmRuOvGK36AOB0fw5Frkmsy/brywnh1i8i860KBmjfZvjO9WGDtXoARgYIq5ffDPSb/TPsEt1dCAzJMwaK3lJKQpEMGSJinyxg7l2sCSQRxi54L/5mD/sN3P8A7LXTULQDlp/ANjcTSB9R1L7G5kkFj5qeUkroUaQEpvLYY8FiuTnbmptQ8GWt/dJKNQv7ZNkKTQwNHsuBE26MvuQnIP8AdK5B5zxXR0UAcXZ/Czw/YXGoyWieUL9GRhHa2yPEGbc22VYhIcn++7fyrTfwbYyeNI/E0k8rXkSFEQQwIANpGC6xiVhyflZyuecZAx0NFC0t5B38wooooAKKKKACiiigAooooAKKKKACiiigDhb4XemW8Gv6VYTX1zb3d/ayQQKWZ0knkK8D0kWPJ7Asemay70+L/Dms6PpGkL/oCQxF5hDI8dzOzkzmXy7aXb1yCXi5bOW5x3egf8g2X/r9u/8A0okrToWgPU831PVfF2i6JbaiLu4vLrULyWxSyngijW3eRykEgAQMQpCk5JyGJ7Cuo1RNY/tTSLa0vbqOBY5HvJYII2MrIEKqSykLuO7pg9cEdRszWVrcXMFxcW0Ms9sSYJXjDNESMEqTyMjjip6OgdTy7Ttb8aX7agijVYIZpLQ281zYASwb5ws6BTAgARD38wY+beR00NA1Dxl/wn8thqxdtPjaRczRPteJQRHIrparH5jfKWHnEcnCL0HoNFNOwPVBRRRSAKKKKACuU8Tgt4x8OKoJJjvQAO/7kV1dcv4hkSHxx4YllYIiLeMzMcAARDJqZK6aY1o7nPaNo3i1LTw2l5fW6CPTJI4jb6W8UlnIYFC+YzyOpIPGCi5I/Cs+Pxd4k1SCxvZ7rUNLgvpLiOODTbBLuVTCqJnHlv8AK0u/5sY2leV6jq08faHfzX9vLHM9lHBCQXs5me5MpkGxYDHvcYjyCoYMDkcDNWf+Ek8K2Cab5bRRp5ey1MNm5W2Qtsw21MQruXb820ZXHUVcrttvqSlypLsc7JrHjFNVhFwt7Fd5tttjFYhrGSIopneS42HYysZMDzF+6vytnNZ2k6zqviG6tIHv9Q1EK9heSrNYrEIHaZt5jKoN8QC8PlgQM7m612v/AAnnh826Ti5umikZgjLp9wdwUDc/Cf6sZAMn3QeCQabY6h4T0LVJbDTba306a6zPJJb6e0UM7bS5PnBBG77QWxuLYBOKL63+f3f1cJRvFx7qxy0Ov+LbsXqSzXUNppl2um3d1ZWqT3DlQ7NcRxiNtxIMK7QpwS/y8CnXuv8Ai1NU0WKxi1eXa1uLsS6b5UU8TvteRtsT7WAOSvmxkddpAxXTWHijw1Z6BHdadDcWtg8uyGGLSbiNpmbLExwiMM4PLblUjqc9aTUfHukWhtI7N2vZbqW3RRHFJsVZpFQFpApVTySFYgnBFCvdL0/r5jet2cppOsfEC6i1NL8SW86iMBVtZHMEhmUHyt1rGjoE3E/vJT0O7FX1PiyKG9S6u7/UYil9bLFcWEW1wi5ikIWMZZs4/uN2Wuw1bxDpuiSQpqUk0fnHAdLaSRE5xl2RSEGT1Yge9UpvHXh63uLyGe9kjNkspndrWYIPLBMih9u1mABO1STjnGKm11byHf3r+a/4Y5rStf8AEQ8aRR3NvqUWjxxSJdJPYlI4SiZVkKwDIbb1ErdduxTitrxNbXOuv4Zm0e6ubeNr0zfbLeEM0UbW0uGw6lRncB8ynkjjNXB420I2DXaz3LKswh8kWM5nZyNwCw7PMbK/NkKRjnpzVb/hPNMl1KW0tRLIsa2z+e0MojkWYkAIQh3N8v3fXjIwcU2SvdTfTX/IwW1zxXFe6Bp0kjibVrdZJZXgRGtTAd05KEf8tFKKOOCTjHFUNF8Q+K7/AMJrfR3erXSzW1tJc3LaSqyW7Mw8z7MgjAmAQlgcSDPTd90dNpvjHwxqH2DVmt3t73UrVB5kunyeZHEWIVZZNmI1LZ27yFY9M10V1daf4e0V7ify7PT7KLJ8uP5YkUdlUdAOwFG2/cp22ODN14yvbVPsmoarBDFbXs0Vw+mRpNdFDF5AlRovkLZkG0KhIHQHos2s+KrzxlFZ28eqwWMqSW90Gs9scJMDMksbGAg5cAZMpAPBQZzXT2njrw9eXBgjvJo3AcsbizmgVCg3MrM6AKwUbtpIO35sY5qOTx3pAjtWgW9mNxeR2mz7DOroXztcoyBgh2nDY2nsaVr6fL79Lhe2vr/n+Byui3fiW08Hy3Nzd+IH+zWtvbRQ/wBmr5wZkQSS7TCXco27orcZO1+KpXOv/ENdA0thBcRS+dcJPObeRnYq48neqWTkoykkkRRdOqHg9rqXj3SrGKcwrcTS288Mckb200WUkmWIvGWT96AW/gzk8Z5qaXx14fgtILiS6uNs+/CLYztIgQ4cyRhN0YUkZLgAZ5p3u+YSVkkc7KfGlzqgB1S/tIZ7qWFktrGIpAi24dXVpIiTmQFctkEHGM81Bfat4ki0951tNQtry8trIGez0/LJKY3Zwx8mVgN2FOY32bug610kXjewN5cpctDDbwmXEokZ2lVPJwyqqYOTMBjOc4wGycatlr2n6hpL6layyG3jLCTfA8ciFeqtGwDhh/dIz7UP4fkv6+ZMVre/V/18il4S1i51HRbOHWEkh1lLOKa9geFk2F9w7gDqjdPToMit6udPjvw+tj9ra5uVXzGjaI2FwJkKgFt0WzeoAZSWKgAEHOCKg1Lx/pOmWN3PLKJ3h80xR2ySy+YERXLMVj+RfmXLHKjI+bnFEnqyl0R1NFc6vjrQRP5FxeNBIsZZ3eCTyVYJvZPO27C4XJKg7sA8USeNdKXTbXUTJJBZTyOhkvbWe2bCxNIWVHjBbhO+ARnBJwCWBanRUVT0vVLfWLFbyzW5WJyQBc2stu599kiq2PfHNXKQGZqv/IS0X/r9b/0nmrTrM1X/AJCWi/8AX63/AKTzVp0Acz4L/wCZg/7Ddz/7LXTVzPgv/mYP+w3c/wDstdNQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGZoH/ACDZf+v27/8ASiStOszQP+QbL/1+3f8A6USVp0AFFFFABRRRQAUUUUAFFFFABXK+JbeK78Z+G7a4XfFMl7G6nuphAIrqq5PxS0qeLvDrW+TKsV6UwMnd5Ixx35pSsk7jje+hWvPhdpOp2ssWrX19qLsIVilvEt5TCIvM2bVaLY2BKw+dWzwTzzV218BWFgloumXt3p3kQrBN9hSCAXUaszhXCRgL8zMcxhD8xrlZtR8f2Wq6LCJ7i4hnt4JZJJ7ZgrSuf3sciw2j7FUYC5eI88s2DjRF/wCK7D7Tf3U+qXkUhvwLOOwjP2dY5sQsgVAzEpz8xbcBkA97ldXv/VhL3l934/8ADGjq/wAMtC1qx0y3uwzNpiNFDLLbW9wxRiCVKzROnJA5Cg+h5NPT4daWniWHWvtd2Z7Zma2QpBtgDRmMop8vdsIOdhYqCBgAcVjeFrjxFqWo6bJr0N7ILTUZxFcXFuUZoGtsqzfuYgPmYr/q1wRjkjJlS/1jQvEmpvKdau7KTVWLIuntMqxtbDy/LKR5K+YMEgnGBuIySV8P3X++2n4ivf77f8Elf4Q+HpdKls7h5JmkuhdCZ7S0+WTaVyIhB5JJDHJMZJ4OcgEaKfD7TofsyWl7eWltC0DvaWyQRQzvC4ZGZVjG05UAhNoI7cDHMWF14mXWLK7f+1or+8tNO86H+zB5E7YPniaTy8RFQScBk54w33asyapr2t2C2NxZakWggj+1+bp7xK9wt1H91ioDAIGOVyuOexw9VK3n+X9feHS/9as6LxR4D0/xZeRz6ld3apGgXyEETR7lJZXG9GKOCfvIVJ6HI4rLv/h7cX2m60k2pSyzXbXb2Vs7gW9u8ysofhN+7a5B5YDJwM1k/wBveM7nXdQjs49Vis5IyIzcafzbSrPGuEBgUFTGzNnfKDjIK4NdF4yu9Z0rw/Z2ukXGqT3sh8v7ZBbK7lguR5m2CRUDHqwi2j/Z61OyUv61/wCG/wAi9eb0/T/hxmo/DPStZ0z7PrN1c6hc+cswvbqK3mdSqlVGx4jEQFYjlD1z15q3beA9NtJrdre4uIooI7dRbxRwxxMYXZ0bakY2nLNkLheenesO01jxRdXGktqP9p2cs1tbMbSDSvMgmZl/f+c7LmIqc4G9f91/u1k6ZJ4lnn0CG+h1GKW1eB0sF0oR2iILU/OZFjGx/MJUpuAAwNg61TTV/UiycfkdD/wqfQGvNPuZnkuJrBFiR7m0tJy8aMWRCXhJULkgFNrEYySRmuluNHbUNCudM1W9luRcNJmZUWNlQuSqjAx8owucc4yeTXBw6v4uk0O/eK91YTrao8kl5oxRre53jfFAqQMXTbkB9kwHBy3SoJtT8WNpE19CmoWF0bW0BmfTjJcT4knDDdHaMRkbG+aD5Q3KIWJo1sP4rt/1/VztLrwRpV61z9rM80d1cy3MsTMNrGSDyGXpnbt98579qo6V8NdJ0Wxa202eS2Y3UdyJ7e0tIHBj+6p8uFQwwSPmBbk4IPNbuhX815pdsL2C6gvPs0ckyXMZBBYHgsFVC3ByAARxkDIrTpNWdv602ErNf11OIh+FelQTz3C6nqRuphGDcnyBLiOVZY8sIgXKlANz7jgkEnjF2TwHbtGhi1nVYLsiRbm8jeLzLtZCC6uDGVGdq4KKpGOCK6qil0t/X9Pr3H5nKv8ADzRmJ2vdIAG8sK6/uiTCVZcr1U28ZGc985rSbw95nh240q51bUp2uA2+9eVBOCe4woRcegXb7cmtiihttWYLTY4yw+Gem6VGzaXqWoWV08zytdWy28bnzFRZFCiLYA3lqThQQeQRVm88A2Vz5xh1PU7R7jzFnkhlRmljkVVZGLo3HyKc/eznnk11VFAHMJ4GtI71ZU1LURbo7TR2RaMwpMylTLym4nBPylimTnbVfTvhvpWmWCW1tdXIKXL3IdYbeMF2iaI/u0iWLG1yeE5PJzznr6KA2Od8OeEIfCtrDa6ReyrbCZ5p42ghQTFlwAFjREjAIB+RRk5zkkmuioopt3AzNV/5CWi/9frf+k81adZmq/8AIS0X/r9b/wBJ5q06QHG+FotSebXjYXdrDH/bNxlZrVpCT8vORIvHTjFb/ka7/wBBHTv/AAXv/wDHq87l8OTeJNSlt47XTbiOPXr95Dqmmm9t0+RQMpvTB9DmtG5t9d8Kal4f0vSbm8urBeJraysiiEtISfnMEqJGobCoZIiFX7zcULXQHtc7PyNd/wCgjp3/AIL3/wDj1Hka7/0EdO/8F7//AB6uGGveLLi51a2824jt9GuFsrm6tLZJ5pQ7b/OjjCNlliMY2hTy7fKcCi3i8TNqsur293qgZbSyT97pqRNer9pmBEiFSVIjYMQuwjIJC/dDSurg9Lrt/wAMdz5Gu/8AQR07/wAF7/8Ax6jyNd/6COnf+C9//j1cDqus+KtO0+wg0ey1GK5R5Jmjg0/EMy+e+VbbA+CEAbGYi27IYnilhh8TbdRsI73V2iVtUnkE+nxuJWEiGCIF4trIyOxwuc8gEbcBdL+v4Dir/h+J3vka7/0EdO/8F7//AB6jyNd/6COnf+C9/wD49XO6Lfa43iqO3vpNRijGVNmNMH2QQiMFZPP2rhy3BUM2OmwD5hm+IH1u78XLC/8AaTxW97vgtU03famH7O+JDNsOX3kgqW9Pl53EloKOp2nka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1cFb6r4ytNS+z2kF3dL/AGSGgtFsjBBbzCAEBy1uqt84xhJxjcBsABNWNOvfFV/fW1rbalrf9ny3May6heaTHb3CfuZmkTa0QUIHWIBynViNzVXLrb+uwk7xv/W1ztfI13/oI6d/4L3/APj1Hka7/wBBHTv/AAXv/wDHq84urrxedWlv7KPUbrU7exuY2jubAwwWzNPB8sMgiPmfu1Zh/rCSvT+GtbRbvxhqdjp4vL+6tAWuHedLJjIyoE8tZRLaxEEtvHyxrlenPNT9m5VtTsfI13/oI6d/4L3/APj1Hka7/wBBHTv/AAXv/wDHqw/h7qGt32m3a+IDfTSxTAR3N3AYRKMc7Ua3gZQPQq3Xh27dfTasSZnka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1adFIZmeRrv/AEEdO/8ABe//AMeo8jXf+gjp3/gvf/49WnRQBzmiQ6ydPl8q/sVX7Zc5DWLsc+e+T/rRxnJx2HHPWtDyNd/6COnf+C9//j1cxfC70y3g1/SrCa+ube7v7WSCBSzOkk8hXgekix5PYFj0zWXenxf4c1nR9I0hf9ASGIvMIZHjuZ2cmcy+XbS7euQS8XLZy3OBag9NTu/I13/oI6d/4L3/APj1Hka7/wBBHTv/AAXv/wDHq4rU9V8XaLoltqIu7i8utQvJbFLKeCKNbd5HKQSABAxCkKTknIYnsK6jVE1j+1NItrS9uo4Fjke8lggjYysgQqpLKQu47umD1wR1B0uHkXfI13/oI6d/4L3/APj1Hka7/wBBHTv/AAXv/wDHq4HTtb8aX7agijVYIZpLQ281zYASwb5ws6BTAgARD38wY+beR00NA1Dxl/wn8thqxdtPjaRczRPteJQRHIrparH5jfKWHnEcnCL0DSuD0VzrvI13/oI6d/4L3/8Aj1Hka7/0EdO/8F7/APx6tOikBmeRrv8A0EdO/wDBe/8A8eo8jXf+gjp3/gvf/wCPVp0UAZnka7/0EdO/8F7/APx6ue1mLVh428NiW9s2mP2rynWzcKv7sZyvmktkdMEY967SuU8Tgt4x8OKoJJjvQAO/7kUpOyuNK7sbHka7/wBBHTv/AAXv/wDHqPI13/oI6d/4L3/+PV5poli1hounz+AvDMunaxaaY4v/ADtLksEuZPJwqNvRfNbzMHI3YweeeZYfEniuPRbD+1r/AFC2W41MwGe2015rvy/s8jkeXJZxZw6rgrE3HUnmras2kTHVX/ra56N5Gu/9BHTv/Be//wAeo8jXf+gjp3/gvf8A+PVxst546Ok315C9x9qt7ODyLRrdEWVnYiSQny3beqANsXIDHG1uBWa2u+N00XS7l5b6VzdOrW9tYzCe4jG3aJHksAqHO4cxwqQQd4wTSSu7Be6ueieRrv8A0EdO/wDBe/8A8eo8jXf+gjp3/gvf/wCPVw95qHieXVvEVm8d7f23ks1shsMQRcrtTa9sPMOCeVlkBwTtXim3OreMjJqK2cuq/bAtwHgfSlFvagHELQSbP3pIwSNz9TkLjFJapA3ZvyO68jXf+gjp3/gvf/49R5Gu/wDQR07/AMF7/wDx6s7Qr690+5udN1+9urt21A29hc3FsqNcL5CynJjRUwD5gzgD5ccmsye21u18ZX2oWE94lrJqFrG9qtsjRzxmNVdyxUt8vqrAAg5zR1S7/qN6JvsdJ5Gu/wDQR07/AMF7/wDx6jyNd/6COnf+C9//AI9Xn0ep+J9auNSt7qz1R9Pk8mWFLqyKNDItzHuQAQpwFOc75QQCQ3BFWbPU/EGi25sI7LUh5xjNoItPaRVY3kvnFm2kL+7KH5iOOV70LVJi6tdv+B/mdx5Gu/8AQR07/wAF7/8Ax6jyNd/6COnf+C9//j1cV9t8R3czx3I1G4lF5bme0n0hfs9ti6j5hlKDePLyxb95jG7chGCqah4t07S2uL+51i8N3ZCRhFp0Zeyl81V+RUiJOEYsQyyH5cgHpR0TGdp5Gu/9BHTv/Be//wAeo8jXf+gjp3/gvf8A+PV5pNP4tvdO0261RNUa4WG/t2txYCaOc70MRlUwL1QEhiiDIxgEkHR1PWPGUd1qYsG1RrxBeAWp0sG2hjVHNvJFLs/eSMRHld7/AHmG1cU7bAtWd15Gu/8AQR07/wAF7/8Ax6jyNd/6COnf+C9//j1UNAm1OyvLyx1q7vdQH2hVtbqa0C7gYg7AmNFQKDuAJA7Aknr0VIS1MzyNd/6COnf+C9//AI9R5Gu/9BHTv/Be/wD8erTooGZnka7/ANBHTv8AwXv/APHqPI13/oI6d/4L3/8Aj1adFAGZ5Gu/9BHTv/Be/wD8eo8jXf8AoI6d/wCC9/8A49WnRQBmeRrv/QR07/wXv/8AHqPI13/oI6d/4L3/APj1adFAGBdRakmsaMb+7tZo/tjYWG1aMg/Z5ucmRuOvGK36zNV/5CWi/wDX63/pPNWnQBxvhaLUnm142F3awx/2zcZWa1aQk/LzkSLx04xW/wCRrv8A0EdO/wDBe/8A8ergYdIvdU1p5NNklgns9ev5o51BKI+xQFkx1VuVIPrxyBVOfU/G1jolm+l6bc6aLi/vpbhWhkkdJDcExqwS2nJjILHcFXIAw65GRajtpc9DtNK1LT4WisJ9ItY2dpGSHS2QFmOWbAm6kkknuan8jXf+gjp3/gvf/wCPVy8t54ss7W+1qWS9u/sd4o/si2tE2zQbF3GPKCRjuYsDnnZjGc5qQX/jGDW7W2vrjUJbrzbdRBFpqmzmhZVM8jzBPkZSZABvX7i/K2cl2v8AgTfS52fka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1cRceIfFN1pMkdt/adld21iRcTSaRJhrgTKMR4hfdlN2GVHXnOGwa2xqGuT/AAvN2rXllq/kHEk9sZpshsbvLSAHLAZH7nIyMpwVpfZ5h/a5Tc8jXf8AoI6d/wCC9/8A49R5Gu/9BHTv/Be//wAerhW8Q+LItO0GJRdLc6zI1huu0QSQSBt/2jBhiJHlLJ8rRryEyoyTVW7u/FV7a63bXF1rbpb3cEsV1a2JTbGtwu5I42tVZvkyflaYEL15wXbW39f1/W4f1/X9fgeieRrv/QR07/wXv/8AHqPI13/oI6d/4L3/APj1efDWviBJqWuRlJYdkc32eP7LJIEw2Imi/wBFVGJXBYGZ+vRcEDd0dvFNv4kSO/1DUL2yXUJbQieziRXhEHmLMWSNTnf8gIIUjjBbmhK/3XJckjpPI13/AKCOnf8Agvf/AOPUeRrv/QR07/wXv/8AHq5Hxg2sXXiKGzU6l9lW8sZILe2sPNglQTo0jyShCUZcdNyjAzhucU7HUfFVprOi28cV41u9ooksYbEwRRPhvmdjbFMZx8omjIx91s8rpcux3Xka7/0EdO/8F7//AB6jyNd/6COnf+C9/wD49XC2Go+ML2OOCO91lTM0C3k9zpKQtZyNIBIkOYwHQLn5yJAMA7mziotQn8VnXWkthqN7qNi159nt57AJaKBE4gdZljAZnGCw3H5jjC9C+l/60Jv+n4nf+Rrv/QR07/wXv/8AHqPI13/oI6d/4L3/APj1cT4bvfGeqJYxahe3lvC14wluBZt53lrEW2v51pCoBcAArH0OM55rW8Cahr11fapBr73tysUn7q5mtjbxHk/KiPbxMOMfxSjp85otrYL6XOg8jXf+gjp3/gvf/wCPUeRrv/QR07/wXv8A/Hq06KQznNEh1k6fL5V/Yqv2y5yGsXY5898n/WjjOTjsOOetaHka7/0EdO/8F7//AB6uQ1O0t5ms5de0yfVdBS51BZ7WK0a7UTG5Plu8CKzOAA4HynaTn3EGo3us6dp1rFoNvrek2Yt5GsbeGw+1tLN5h2RTblcwxlcYBKbQcblxihajOvm0rUri5guLi40iWe2JMEr6YzNESMEqTNkZHHFT+Rrv/QR07/wXv/8AHq42dvGs107jU9Rtlla8xFDYwlYfKwYtpaMk7zkZJOR93B5qe5k8XXmpRPFf6hYwST28DRQ2MRVEeDdJJl42OVfgEnaDkEHoFf8AT8Rf8H8Dq/I13/oI6d/4L3/+PUeRrv8A0EdO/wDBe/8A8erh77V/GEVva/PqkdyLMG3S30tZEvbkSMCtwdh8pdoQ5BjHzMQeMVs+H5PE39uxy6td3k1rcy3qtbS2kaR26xzYhKsqBvmTuzEMOR61VtLhsb/ka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1adFIDM8jXf+gjp3/gvf/wCPUeRrv/QR07/wXv8A/Hq06KAMzyNd/wCgjp3/AIL3/wDj1c9rMWrDxt4bEt7ZtMftXlOtm4Vf3YzlfNJbI6YIx712lcp4nBbxj4cVQSTHegAd/wByKUnZXGld2NjyNd/6COnf+C9//j1RyWGrzSRSTXmlyPC2+Jm01yY2wRkHzuDgkZHYmuFtrHxtp2h6FOn2O9uLTSZRbWsenSW7Qy+QoVZXaVwTkYxtXJ/Kktde8YHwfK12dSN1JdiKC4gspTPGNhJ8wPYrhSwChlgcAHk8ZqpaNrsTF3Sff/I7/wAjXf8AoI6d/wCC9/8A49R5Gu/9BHTv/Be//wAerzua88U6vb6OmtR6pDO0unytZwaaWhcrMhmaWTy8oykdNyjHOCOk3/CQ+NJdc1IWdtqn2FoXI+02OGtnWaNW8oeQoY+UzsvzyhyOMYIJb9fwH/wPxO+8jXf+gjp3/gvf/wCPUeRrv/QR07/wXv8A/Hq4K5XxLOW1TTL/AFlprPTLlreefSUimuyJEZIpI2TjOCMBI2OOAve/bax4wHxIlgvI2j0hGY+X5Ezo0ATIZWW1I8zd2M/TI2ZwaEtF8/wFff8Arodd5Gu/9BHTv/Be/wD8eo8jXf8AoI6d/wCC9/8A49WjFIJoUkQMFdQwDoVIB9QeQfY806kMzPI13/oI6d/4L3/+PUeRrv8A0EdO/wDBe/8A8erTooAzPI13/oI6d/4L3/8Aj1Hka7/0EdO/8F7/APx6tOigDM8jXf8AoI6d/wCC9/8A49R5Gu/9BHTv/Be//wAerTooAzPI13/oI6d/4L3/APj1Hka7/wBBHTv/AAXv/wDHq06KAMzyNd/6COnf+C9//j1Hka7/ANBHTv8AwXv/APHq06KAMzyNd/6COnf+C9//AI9R5Gu/9BHTv/Be/wD8erTooAzPI13/AKCOnf8Agvf/AOPUeRrv/QR07/wXv/8AHq06KAMzyNd/6COnf+C9/wD49R5Gu/8AQR07/wAF7/8Ax6tOigDAuotSTWNGN/d2s0f2xsLDatGQfs83OTI3HXjFb9Zmq/8AIS0X/r9b/wBJ5q06AOZ8F/8AMwf9hu5/9lrpq5nwX/zMH/Ybuf8A2WumoAKKKKACiiigCB7G0kvo72S1ha7iRo47howZEVsblDdQDgZHfAqeiigAooooAKKKKACiiigAooooAKKKKAOe0iLVmtZzaXtnFD9tutqS2buw/wBIkzlhKoPPsKveRrv/AEEdO/8ABe//AMermL4XemW8Gv6VYTX1zb3d/ayQQKWZ0knkK8D0kWPJ7Asemay70+L/AA5rOj6RpC/6AkMReYQyPHczs5M5l8u2l29cgl4uWzlucC1B6and+Rrv/QR07/wXv/8AHqPI13/oI6d/4L3/APj1cVqeq+LtF0S21EXdxeXWoXktillPBFGtu8jlIJAAgYhSFJyTkMT2FdRqiax/amkW1pe3UcCxyPeSwQRsZWQIVUllIXcd3TB64I6g6XDyLvka7/0EdO/8F7//AB6jyNd/6COnf+C9/wD49XA6drfjS/bUEUarBDNJaG3mubACWDfOFnQKYEACIe/mDHzbyOmhoGoeMv8AhP5bDVi7afG0i5mifa8SgiORXS1WPzG+UsPOI5OEXoGlcHornXeRrv8A0EdO/wDBe/8A8eo8jXf+gjp3/gvf/wCPVp0UgMzyNd/6COnf+C9//j1Hka7/ANBHTv8AwXv/APHq06KAMzyNd/6COnf+C9//AI9XPazFqw8beGxLe2bTH7V5TrZuFX92M5XzSWyOmCMe9dpXJ+KLj7J4w8OXBjkl8mO9fy4kLu2IQcBRySfQUPQa1djZ8jXf+gjp3/gvf/49R5Gu/wDQR07/AMF7/wDx6uB0m38X6FDq0l7arZzaxbPeC5tHlvjDdA5O6MQAqSjKqqA4/dd+9O48QfEA6XpZtIb2PcZA9xcwSM00gYbfMSOw3rFg944Tx97oS7a2F5npXka7/wBBHTv/AAXv/wDHqPI13/oI6d/4L3/+PVwtxqniXVNa1iws77U8pLNbmGGwQW8MX2cEOk5j5kEhAClicHlP4g2C816201Csus2tq4hE1/Bo4kvCRbrjMRhJbL5ViU4xj5RyF0v6fiHW3r+B3nka7/0EdO/8F7//AB6jyNd/6COnf+C9/wD49WVq76/c6boMVjdXVjPcyYvp4bSMvGv2eRuVYSKnzhR/EM8ZOa5VtV8fw+GWnH2ye6uLKzuZPMtBG1o7lxMkYSBySoVTtKSMN3Q8Cm1a47Nq53/ka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1cO1545udBhuVvbqC4t9NuLnZbWO77VKsg8qOQTW6MGK9VVIyTkjFPvn8Wr/AGhJpct5YLbR3t1HDb6dERdSrKPLRt0ZJDLn7uGbrmny6pev4C6X87fedr5Gu/8AQR07/wAF7/8Ax6jyNd/6COnf+C9//j1cDP4k1i81i7slvbueSU38J0/7Aj2wWON/LEcnl/vGJC7l3NgnaQvQsK+IbO51DyJdQEwupJYpp9K81LZDZrt8rbCT98FcLuOQAQckNPf0uJ6NLzseg+Rrv/QR07/wXv8A/HqPI13/AKCOnf8Agvf/AOPVznhvTJvEmmaRqviVdQXUNLuJHha4whlJGNxXyITjBIAaND3weGrW1zVbm48IjUfDrTsJjG3mw25eaOEsA7pEyks4XJClTyOh6FtWGtdi75Gu/wDQR07/AMF7/wDx6jyNd/6COnf+C9//AI9XCXes+LEii+zXOuPi3Laex0RVN9L5jjbdDYfJXaI+f3OdzHjG0aNr/wAJnNLMx1K7V7v7ekUU1lEIrUxy4tyDsBO5f7xIYcj1oasrjtqdV5Gu/wDQR07/AMF7/wDx6jyNd/6COnf+C9//AI9XJp4k8RR20Gq3tjqkVvem4VLCPTjLLbMEVYgwRSwyyu25vl+YZIGKxLi68Wafay3lr/aMNxdX0UtxDBYv5lyfscAOG+zTKg3hgcqozxvXBoSu3/W4v+D+B6P5Gu/9BHTv/Be//wAeo8jXf+gjp3/gvf8A+PVxOp6h4jtby68pdU023kuJnifTtJS4eaXZF5aSYjb5D8+XwOmN64q5Z3HjH+1Irq9urpY5rt7eSy+xI0ECC1LiQMqbz+9G3O4g5xjODSWqv5XFfW3r+B1Xka7/ANBHTv8AwXv/APHqPI13/oI6d/4L3/8Aj1c34G17UntTb+J5L+S4muvJtbi6tWiE52FyFU20LIAEY/MpHYO1dvTasBmeRrv/AEEdO/8ABe//AMeo8jXf+gjp3/gvf/49WnRSGZnka7/0EdO/8F7/APx6jyNd/wCgjp3/AIL3/wDj1adFAGBdRakmsaMb+7tZo/tjYWG1aMg/Z5ucmRuOvGK36zNV/wCQlov/AF+t/wCk81adAHM+C/8AmYP+w3c/+y101cz4L/5mD/sN3P8A7LXTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBmaB/wAg2X/r9u//AEokrTrM0D/kGy/9ft3/AOlEladAEE1la3FzBcXFtDLPbEmCV4wzREjBKk8jI44qeiigAooooAKKKKACiiigArl/EMqQ+OPDMsp2oi3jMcZwBECa6iuT8UwtceLvDsCEBpIr1AT0yYQKUrpOw1a+pZt/Hvh26sXuoLud0XZtQWM/mShwShjj2b5AQrYKAg7T6Gi+8c6Na26NDcNNJJD56D7POVVclSZGWNvLwVIO4DB461jp8LNOvfDtvY+Iby41K6iihRJ7hIJhb+WpAVEeLYyje/30YnPJOBjWt/AmlW2lPYQtJHC9mLNvJjhhG0Oz7gkaKgYljnCge1W0lLy/r9SNXG63t+JBc+OdAsbHWZtMHm3FlHcXEsf2eSBZ5IciQCQptZgVwcZIGD0xVtfHOhNZm4E10SsvkmBdPuDNv27uIgm8jad24LjHOcVmWXw9V7K/h1rUrqdbqS98qCN08u2W4kclk+QNvKtg7iwBzjrzY8Q/DnRfEjSSahvMrzLMrtDBMIyIxHwk0bpyoHVSc9MVL2Ldr6d3/wAA0B4x0R3mWC5muPJgWd2t7SaVdjAFcMqEFiGBCg7jzgHBosfFVpqmrWVrp6vJDdW88xlkVonjaJ40KNG6hgcyc5wRt6c1XbwRYDR7nTrS5urKO4MJ3WqxR+X5SqqhU2bMEKMqVKnkYxxS+HvA+l+GWtjprzBbZLhI0IjVAJnR3+VFUD5kGAMAZPHTDVr6i6EkHjfw/cXV1bpeujWolMry20scf7ptsm2RlCttPUKTip7HxVpGotEtvPMskrsixT2ssMgIXeco6hl+UZBIAI6ZqpP4H0m7sWs7vzp7dxdh43YYYXL75AeOxPHp3zWfYfDLS9KsY4NMvbmyljnMwubO1s7dzlChUiOBUYbSRkruHYil0G99O/4C/wDCQeEbXVl1HS7S1bU9QS2eS7TT5FZ4pmVYy8qxHBOflViMkY4wSJrP4h6Tcacl/OLi2geNWWN7Wc3DMZGjAEQj3NkrxjJ68Y5qxbeB9NtbCK0jnuzHGtmoLOpJ+ysGjz8vcj5vXtiq8vw+sZdNuLNtQvGjni8kmWK2mCx+Y0mwLJEyEZcj5lJxjnPNOVl8P9IFqtdzp7W4S7tYriJZFSVQyiWJo3APqrAMp9iAa5/VPHmj6Zb6kzfbJZtOhaZ4VspgZVUgExkpiQAkAlSQM84q/oehf2DbwWVpeSvYW9usMVvIi/KwYkvuAHUEDaAFAAwBWCnww0lby/u5L6/mnvrWa0eV/J3rFIwbbvEYZtpHylyxGSORRpfy1/4Altr5G03izSY9QSykkukneMyIGsZwrYXeUDbNpcKCdgO7g8UkfizS7mS3NldxTwSu6mVd+Dtj8w7SFIY468jHI68Vln4dWTeII9al1bUpb+Es0Mzi3LRFojG21vK3YOd20naCBgAcVOPAOmR6etlb3d/BbxmVolimAMRkjKOVbGcksW5J+Yk9OKOgtdDY0fXbDXYZZNOeY+S+yRJ7aSCRDgEZSRVYZBBBxyDTZ/EGmW11JbT3OyaOWKFk8ts7pPuY45BweRwMHJGDWX4f8FQ+GJGbSNQmVbi6+03qvBAPtLeWU6RogUk7WJUDJX3NXb7wvp+oeJLXWrjzTcW8LRCMN+7kBBALLjkqHcA543tSfkMrDx34eNrJcC7n8uNkUf6FPul3nahjXZmVWPAZAwJ6Gqtp8Q9JuZrjzFntIbYzBzdWs8cjGNo1+SMx/NkygYzuzgAHJxDofwv0Hw+x/s4GMCaKVNlrbRMgjbcqF44ld1zjO9mPvnmk1zwCLsX15pt7N9vlLSWyXDqsULs8TkqVTcDuhUgtvAJPysPlpq19fP8AS36jWrt/XX/gGi3jzw+lok5uLo7pGj8ldPuDMCgBfMQTeoUMuSVAGRkituO8gnsFvbeQTW7xiVHiG/epGQRjrkelcdpXgS++wCfV9au7bWGmmkkurCWN2KSBA0ZLwhWz5anIjQgjjbXUaTpX9kWxs4bhnso0jjtYGUfuEVAu3d1bJGcnnmk9vMlb/wBd9PwMGx+I+j3WnQX84uLeG4gglji+yzvcFpTIAvlLHk58o4K5z6AYLWx4+8ONPbQrezM1ykciEWcxVFdyimRtmI8spX5yMEYNR6Z4D0/TJrWRL2+na0ESxea0fCxebsX5UGQBMw9SFXJzkmSHwRpsMdwiz3RFwsSvl148ud5hj5f70hB9sfWqdr/1sU99P6ZFB490xtY/s65EkbksBNHBM8Jb7SbdV3mMAMXxkdB6kcm9ceLtHtrqG2aa4lnmmkhSK3s5pm3IwVyQiHaoJALHC89azrr4f2FwD5eo6jbHdJJmJosh2uPtAb5kPKydB0xwwaob74badqWmQWN9qF7OkV1JdNJLHbPJJI7bmO9oSYzknBj2EdiOKStpf+tf8gla7sb2q/8AIS0X/r9b/wBJ5q06xLiCe3vdIS5umuidSlZGZApRDBMVTjrgcZPJxzW3SEcz4L/5mD/sN3P/ALLXTVwOg/8ACSfa9d/sL+yvs/8Aa9xu+2eZv35GcbeMYx+tbH/Fdf8AUvf+R6AOmormf+K6/wCpe/8AI9H/ABXX/Uvf+R6AOmormf8Aiuv+pe/8j0f8V1/1L3/kegDpqK5n/iuv+pe/8j0f8V1/1L3/AJHoA6aiuZ/4rr/qXv8AyPR/xXX/AFL3/kegDpqK5n/iuv8AqXv/ACPR/wAV1/1L3/kegDpqK5n/AIrr/qXv/I9H/Fdf9S9/5HoA6aiuZ/4rr/qXv/I9H/Fdf9S9/wCR6AOmormf+K6/6l7/AMj0f8V1/wBS9/5HoA09A/5Bsv8A1+3f/pRJWnXF6R/wmf2GT7L/AGFs+1XGfM87O/zn3dO27OPbFXv+K6/6l7/yPQB01Fcz/wAV1/1L3/kej/iuv+pe/wDI9AHTUVzP/Fdf9S9/5Ho/4rr/AKl7/wAj0AdNRXM/8V1/1L3/AJHo/wCK6/6l7/yPQB01Fcz/AMV1/wBS9/5Ho/4rr/qXv/I9AHTVyXilrhPF3h5rJFe5WK9MSt0Z/JGAfxqf/iuv+pe/8j1h6r/wlf8Awl2gfaf7G+1/6T9m8vzfL/1Y37889OmO/Wk1dWGtGZVg+sPrcuo3A1q7BS1Etxc6MEliKrdFxEnlAHaWUAgE/MBubPMK694hbw1JINZ8Yi+uLpRDu8N/NZxlT/rf9C/eDjJ2L12qGxlj2/8AxXX/AFL3/kej/iuv+pe/8j1Td7iObth4mup547DUNTtIXeSU339kxQzXO21g2F1khwCz7xyoPBUY2jANb8dP4u0+KSD7NZyxQEq1vMY3BjUyl9ls+1w24ANNGOBkHqek/wCK6/6l7/yPR/xXX/Uvf+R6L6/cDOOj1rxmfDGo77vVBdwXcey7/s2QechzuSKP7DvToCWMUygHG8nJHomhX815pdsL2C6gvPs0ckyXMZBBYHgsFVC3ByAARxkDIrM/4rr/AKl7/wAj0f8AFdf9S9/5HouB01Fcz/xXX/Uvf+R6P+K6/wCpe/8AI9IDpqK5n/iuv+pe/wDI9H/Fdf8AUvf+R6AOmormf+K6/wCpe/8AI9H/ABXX/Uvf+R6AOmormf8Aiuv+pe/8j0f8V1/1L3/kegDpqK5n/iuv+pe/8j0f8V1/1L3/AJHoA6aiuZ/4rr/qXv8AyPR/xXX/AFL3/kegDpqK5n/iuv8AqXv/ACPR/wAV1/1L3/kegDpqK5n/AIrr/qXv/I9H/Fdf9S9/5HoA6aiuZ/4rr/qXv/I9H/Fdf9S9/wCR6ANPVf8AkJaL/wBfrf8ApPNWnXKD/hJP7d0f+3f7K+z/AGp9v2PzN+/yJcZ3cYxn9K6ugDxzWbBb2aVp7GC7t4vEF8ZPtOgzatGhKKATDEQwPo2cCts6lqul/wDCPaX4cijgtdWXyEWLSzYJZtG5eVxbyDegaPeAGzhgp/izVrQf+Ek+167/AGF/ZX2f+17jd9s8zfvyM428Yxj9a0TZeLzfrfG28MG7WMxLcGObzAhOSu7rjPOKFoD1M/wHqni++1q9j8UR+VEkZLRPFKBFJu4WNjbRoyYznEkpzjnFYviJvEN9qd5vj1K6ntlvxHZtpQe1jTyXWEo5jxKXGMqWbk4wvQ9j/wAV1/1L3/kej/iuv+pe/wDI9NO1h9b+dznJNX8Xw65rsFv9vu40jLWpSyKRW4yvCq9unmOFLY2zSAkfdXgVPp914pvzbw22oat9jN5IEvrzTY7e4liWHcA6NEAg835d3lqSOnZq3P8Aiuv+pe/8j0f8V1/1L3/kel0sI4c33jBI73UrH+1bi+Nnbx3El3pxtzbnzXMqwhYH8wLkbSI5eDnL1t2dz4yvtNtXudRnsnTT7iZpIdPaQSyBwIhIsluj7tpyVWNCSMgAcVu/8V1/1L3/AJHo/wCK6/6l7/yPR0/rz/4cHv8Ad+AeAb/Vr/w4X11L37SkzIJbxNjSrgHcFMEDAckfNGp4PUYJ6auZ/wCK6/6l7/yPR/xXX/Uvf+R6bd2JHTUVzP8AxXX/AFL3/kej/iuv+pe/8j0hnTUVzP8AxXX/AFL3/kej/iuv+pe/8j0AdNRXM/8AFdf9S9/5Ho/4rr/qXv8AyPQB01Fcz/xXX/Uvf+R6P+K6/wCpe/8AI9AGXfC70y3g1/SrCa+ube7v7WSCBSzOkk8hXgekix5PYFj0zWXenxf4c1nR9I0hf9ASGIvMIZHjuZ2cmcy+XbS7euQS8XLZy3ONrSP+Ez+wyfZf7C2farjPmednf5z7unbdnHtir3/Fdf8AUvf+R6FoD1Od1PVfF2i6JbaiLu4vLrULyWxSyngijW3eRykEgAQMQpCk5JyGJ7Cuo1RNY/tTSLa0vbqOBY5HvJYII2MrIEKqSykLuO7pg9cEdRSmsvF9xcwXFxbeGJZ7YkwSvHMzREjBKk8jI44qf/iuv+pe/wDI9HQOpymna340v21BFGqwQzSWht5rmwAlg3zhZ0CmBAAiHv5gx828jpoaBqHjL/hP5bDVi7afG0i5mifa8SgiORXS1WPzG+UsPOI5OEXoNv8A4rr/AKl7/wAj0f8AFdf9S9/5Hpp2B6o6aiuZ/wCK6/6l7/yPR/xXX/Uvf+R6QHTUVzP/ABXX/Uvf+R6P+K6/6l7/AMj0AdNXK+JEMvjTw3Gv3mS9UZ94RUn/ABXX/Uvf+R6w9V/4Sv8A4S7QPtP9jfa/9J+zeX5vl/6sb9+eenTHfrSaurDTs7kWn/2pf6foun6Xa3+n6lo+myRTTXNk6RxTeUqKFaRQsoLA8oWGOcjiq2s6/wCOX0i11KxtLyyhvLiRnga3bz7RVCrGhVLadiGYOxOzoQNy8V1X/Fdf9S9/5Ho/4rr/AKl7/wAj1TbbbfUSSSsjktdj8RyTR3Usd0kgkAlj0/T/ADIrh2sSPnDRFnTzPly2MZwcYGNXSNW1638aXEOof2hcaWlrvCRWLxxW+EU4A+zAyNkEfJM5ycbBjjY/4rr/AKl7/wAj0f8AFdf9S9/5HpdbitokdKrB0DDOCMjIIP5Glrmf+K6/6l7/AMj0f8V1/wBS9/5HoGdNRXM/8V1/1L3/AJHo/wCK6/6l7/yPQB01Fcz/AMV1/wBS9/5Ho/4rr/qXv/I9AHTUVzP/ABXX/Uvf+R6P+K6/6l7/AMj0AdNRXM/8V1/1L3/kej/iuv8AqXv/ACPQB01Fcz/xXX/Uvf8Akej/AIrr/qXv/I9AHTUVzP8AxXX/AFL3/kej/iuv+pe/8j0AdNRXM/8AFdf9S9/5Ho/4rr/qXv8AyPQB01Fcz/xXX/Uvf+R6P+K6/wCpe/8AI9AHTUVzP/Fdf9S9/wCR6P8Aiuv+pe/8j0Aaeq/8hLRf+v1v/SeatOuUH/CSf27o/wDbv9lfZ/tT7fsfmb9/kS4zu4xjP6V1dAHk9x4dn8R380ENpptykWu37t/aunG9t1OxQNyblwSehz68GopZfF3h3wzo9loNrPaKslx9rEdpIFin8zKxJGlvcEW/LbcAfKFG9Twei0bxLpfh1daOrTyR+drV2UEVvJMSF2FjhFJAAOSTwBk9Aa3U8aaHJYy3aXM7RxSiEoLKbzXYjK7I9m9wRyCoIIyRkUloM4zVfEPi3TrzX5Hmu3jg0uWaForRkt7WVYtwwZbZfM+YHkTN15QYOHXGo+KX06S5sBqN8YVuHtLq90lY5xJ9mc4EflqQokwFOBuzjLDk9HrXjjQEsEhx/aX2wRqbc28hTZJJ5WJTsKx87htfBJUjrmrieMtKj8lLuRozLcSW6NDbzSRKVlMQ3yeWFjJYY+bAzwC3U3028hdE+z/y/wAjmta1LxTp3iLTLDTZtYvEjlgF1K9knlTRSSYd9yW5XKA9N8ZAGSHwc5dtfeLNO0uC1hutfeaGF/swbSRILu585wY528r5IwuzDjYCGJDnFdpfePNItNP1G7hS/u00+QRzGHT5yrNv2EI+za5B67ScY5po8f6HEUS9uHjkeR1AhtZ5VRVlaLc7eWBGNy4JbAB7kYJS6eobJ/1/X9dTA1zV/FWhWc+ti5uboNqD2MWlSwxRx4dzHBIrbA5O8pk7iCpPBIrsIpXudJutOF9LLqNrAIbi4WIK3mmMHeuV2knIPAI7Y7Vl+IvE+hWbXLXNp9s1DSYZbu2We0dVLpGSwjmZCm/aSDtJIBPFaeueJtP8P2kct+8nmTIzRQxQySs20ZJIRSVUZGWIwMjJqXb2ev8AX9a/0ilfmTX9f1ocBoFt4ltYLXUba51bzFg0yCeC6sQpufnKTeZujDDYGJyu3GMksDVmy1bxlPbzKs2qm5aBDdC40pY1srgzRqUgPlgSpsMhzmQYUHcM10lp4+0ySGE3nmJPcMix21pBPdSZMMcp3KkeQAJBlhlcEZIJwLzeMNETVn01ruQXCFlLG2l8ouq7igl27C4AJ2Bt2AeK0k3zO/mZwS5EkcnJq/i228bRWNiNUvrSISW8xvbRUidhCzRyh0t1U7nABYS4GceWMgiGO/8AFE8NtLaJqGp3UUzOBqmkLbiGb7LPlFfYp2B9ihwP4seY+446C6+JGhpaQy2LXN085i8tTZzxqVkkCK5cx4VTklScB8fKTV+XxroEMl4s166CzV2lka2lEZCHD7H27ZCp4IQkjvip1S1LTV7opeH9R1L+w9TuJ5dX1JoVLwi901bWZn2ZaNFwm8BuASo6/ebrXO6NqXjLVY5bWS61W0ikv4RFfS2CrMsDJIX+WS2jVcMoHKHGR8zAjPaaZ4s0rV9RaxsDetOihpPM064jWPIB2s7IFVsEHaSG56Vs0db+hPS3qeV6lceKL23tbPUpNWJzBsSDSwyXZW6Id5nEf7shFRhgoDkkbhwPVKKKQIKKKKBnC3wu9Mt4Nf0qwmvrm3u7+1kggUszpJPIV4HpIseT2BY9M1l3p8X+HNZ0fSNIX/QEhiLzCGR47mdnJnMvl20u3rkEvFy2ctzju9A/5Bsv/X7d/wDpRJWnQtAep5vqeq+LtF0S21EXdxeXWoXktillPBFGtu8jlIJAAgYhSFJyTkMT2FdRqiax/amkW1pe3UcCxyPeSwQRsZWQIVUllIXcd3TB64I6jZmsrW4uYLi4toZZ7YkwSvGGaIkYJUnkZHHFT0dA6nl2na340v21BFGqwQzSWht5rmwAlg3zhZ0CmBAAiHv5gx828jpoaBqHjL/hP5bDVi7afG0i5mifa8SgiORXS1WPzG+UsPOI5OEXoPQaKadgeqCiiikAUUUUAFcn4nWZ/GHhxbVgk7R3ojY9m8kYP511lczrn/I/eFv+3v8A9FCk1dWGnZ3OX06GPT9NMvh3wvqEHieGxcXl1NaOnmShOskrYW6JYfLhmHuKt2Ova9aeRcSPrmoaSl8qST3OjlLqSNoZNwMKRK20S+Xhgg75JAJr0OiqbuTax5V/wlniBbjTlvr7ULO6aSwRrQWCGNxLKok85th8p8EgLuXjkBuo1fDcmq+HJI5NXubw6TJDeTSxS2YC2jC5HlhSqb/mV2OGLZxkYANdnPoul3Oqwanc6bZzahbjbDdyQK0sQ9FcjI6noau0J2X3/wBfqD1dzkfHdxqsUdtDYS6hb2k0Uwlk06x+1SNLgeXGy7H2o2Wy2BjA+ZetYdvqPiezvtN8O2kjQK+lx33nyW4c2yJD5bQmMDcSZdjepBcA8AV6VUEdlaw3k13FbQpczhRLMsYDyBfuhm6nHbPSktL+f/B/z/TuN6tPt+tv8jy2HxJ4lXR9Ni1O+121ee9lilu4dME08qCEsCkLWkbABgAcxHvyR8w2rK48ZyXVve3txdx7JrSKTT1tI/KkV4181y20vwxJ+V8KQQciu7eCGWWOWSJHkhJMbsoJQkYOD244qSmK2jR5S2ueOxpdw9iupXN39nDXsd3p3kLZS+agZbZhCxlAQyEELN91eudpdqHiDxtH4Nsmt49QfVX854nt7OQiUKRsjm32YKMQT/yyiU7eGXNeqUUv6/r+vvK63MhdQTVNEvo4g7XMMRinjMTKVkMQfaARzw46Z6465rktF1fX7P7Bo8lnqSss1uFb+z28pLb7Iu4GTbtB80MCCdwPtXolFHfzt+H9fcT2+f42PMF1TxZpmjWj6xqupH7bbWkk8/8AZ0XnWkjlhIkMaxfO3C/IVdhknB6VsadqOpax8OPtRaTULo37Rq0tou940vCoJj24BCL6cYzwRXX3+n2eqWUlnqdpBeWsoxJBcRCRHHupBBp9ra29jax2tlBFb28ShI4YUCIijoABwBTvo/Ub1dzzTVbfxdfeH9Ttrq+1SddR0++PlLZRKbdkmVYkTEefnjZuG3EgZXFZ99oOq6e11Dp0OoWdvYlEin0/TkV3iWe2JISOLax2q5wq87SAMDFewUURfK0+wmrpJnnGpaj4qt9AkmS51lry8v7iO3WGwTFuiSOIgcW8jKrqFy7Iw6crnNU7GfxTLcJezwX82oXMdncfZbmwHkQP9mkDhWMY2HzMA/NkZ7A16nRSZV9fv/E81sL3xbqEkdrb6lraQSzQLPe3WkRwS27lZDKkatEFKDCYcqwyfvtW/pGjNejS/EGvtdPq2mxTwZMQQyJvI3NGq8khVbgDnoADg9XRTv2J6jYpBNCkiBgrqGAdCpAPqDyD7HmnUUUhhRRRQBmar/yEtF/6/W/9J5q06zNV/wCQlov/AF+t/wCk81adAHnWmQaHc3OurrGqRWcv9o38Ko1wkZKShFZsN/u8Hp161Y1bQPBGtae9pfazZSKTCyNJPbS+W0SFFYJIrITtJzuUjnoKqWJtRcatGuh2Oq6lc6zdiEXhVERECli0hRiqjI6KTlunU1e07VPCF14eOqXGk6RKqTGBxpEK6mpcAE7TChYjBzyqkDqBSsnceun9epBH4e8IW8FvBZ+KIrO3jSJZoLSa0hjufLfepdFjAU7ifuBM55zUN54U8F315HPceJ1ZY7g3Kwtd2zqsvnNMHUshZCGcj5SMjg5rWW/8ETTyQ2el2948dsLlmttIeWMIU3rmRYyoYrghSdxyOORVOy8QeA7vTY7t9Jih3W8c7xvo0hKeYFKJxHy53DaoyW7A1V3f+v66E9Lf1/WoyTw/4Ql1LVb9vE0K3Opx+W8kUtnEYxuDAgpGN5BUYMu/H4nNiLS/CUdnd27eJIpPtkTxyu17DuO6Z5SRgAA7pD2xjFEmseBo4xcPp+nra7MtnTXEyv5ixhDD5W4Hc4GDhskcY5DW1zwOLqzj/seAQ3UNxL576SyLD5JUOsgaMFGy2MMAc4HUjIr2X9d/+CN63RTvPC3gy/1a71C78ULJNcpPGCbu2zEkysror7N5X5sgMzBSBjA4ra1s+HdZa3kHiiKwngR4hNaXkG54nxvjO8MMHavIAIxwRUDan4FWziuP7LiJlmMC266HK1wHC7iDAIvMX5SDkqBgg9CKq3Gt+DrS+voLrRLO1i0+48q4muNOZAR9nM5KYiIYhVORkcDPdQytdW7f1+o1e91/X9WK994Y8GX+mfYJfEkAgMyTMGls5SSkKRDBkjYp8sYO5drAkkEcYuf2X4V+3eb/AMJVm1EjTLYG/hMKyspUyZxvJwx4LFcnOM1ZivvBM2mzX0WkxvHBKIpI10SUzBiAR+58rzCCCDkLjHPSpdNHhnVdUngtNF017aOygvEufs6YdZTIMbSvGPL/AF6DFN63bEttP66FC40rwtMbcReK/s0UUMEMsMV7b7bkQkGMvlScg/3Suc89sUo/CHgGDUtRvINX0+Jr8Sbwhsg0ZdtzFZfL83k54ZyOcYxjFiLW/CF5fSQ2Gi6e8KLbkXE9i0Kv503lDaDFlgeqsMq3qBki2mq+BJLBr2PTImt/NEMbDRJT9oc5wIR5WZvuk5j3DAz0ou/iFyq3L0B7LwpJ40j8TSeIbRryJCiIJbVABtIwXVBKw5Pys5XPOMgY6H/hJdC/6DWnf+BSf41zz6r4BSOJzZ2TJLCZwyaUzBEBIJfEfyfMpXDYO7jqQKr2mteDbiG9mm0GGKOC8FrEg0l3nmPlJIT5Ai8xcb+QV4AycUa7dv8AP/MfmdT/AMJLoX/Qa07/AMCk/wAaP+El0L/oNad/4FJ/jXPXereALM/vLKzkHkxz7rfSWmUpIcR8pGRljwq9T2Brbs9F8PX1nFcwaHaLHKu5RPpwhcD3R1DKfYgGizAm/wCEl0L/AKDWnf8AgUn+NH/CS6F/0GtO/wDApP8AGj/hGtC/6Aunf+Aif4Uf8I1oX/QF07/wET/CkBn6J4g0aLT5Vl1exRjeXLANcoDgzuQevQgg/Q1of8JLoX/Qa07/AMCk/wAa5VYbGARafpnhnTNR1K4uL2RFuQsMUcUdwyktII3IxuUABT+AGasz3nhTS7W3PiHQbTTrqRWeS3TT/tHkqrbTIzRoQsffe20YPOOQADof+El0L/oNad/4FJ/jR/wkuhf9BrTv/ApP8a5q41z4f21xNBJYW7PCWDeVoskgJU4faViIbbkE4zgcnA5qW81TwHY3v2SfT7VpsLgQaQ8oJZd6qGSMgsy8hQcnnAOKAOg/4SXQv+g1p3/gUn+NH/CS6F/0GtO/8Ck/xrn59U8A28ds8lnZbLmITKyaWzCOMnAeUiM+UuQRl9oyD6GptNufBOrarJp1hp1m9xGZFO7S2RGMbbHCuyBXKtwQpOKLMDa/4SXQv+g1p3/gUn+NH/CS6F/0GtO/8Ck/xo/4RrQv+gLp3/gIn+FH/CNaF/0BdO/8BE/woAP+El0L/oNad/4FJ/jR/wAJLoX/AEGtO/8AApP8aP8AhGtC/wCgLp3/AICJ/hR/wjWhf9AXTv8AwET/AAoAP+El0L/oNad/4FJ/jXPazrmky+NvDc8Wp2bww/avNkW4QrHmMAZOcDJ6Zrof+Ea0L/oC6d/4CJ/hXN6/o+k2vi7w+kWlWawut20sSwIFk2xAjIxg4PTPSk3ZXY0rux0n/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NcloOseGtbsNLuG8M2NpJdxu1zC8EbNassYkwcL8wKsCDxkEH2rUsJ/BWomJbfTLRZJpzbLFPpTQyeZ5ZkwUeMMvyKWBIAI6dRVNNOxKd1dGz/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWJa3Xgm91CGys9Mtp5ZYhMGj0h2jRDnBeQR7Uzg8MQaS1vPBF5a3M9tptq6WyB2/4lDhpEJwGjUx5lUngMgYHtmkM3P+El0L/oNad/4FJ/jR/wAJLoX/AEGtO/8AApP8ap6Xp/hfWbBbzT9JsXhZmU+ZYCN1YHBVkdQykEYIIBrD1fV/COm6pHp8OiWE83mSRzO1iUiiKQvKf3giKsRsAKqSw3Zx2INK+x1H/CS6F/0GtO/8Ck/xo/4SXQv+g1p3/gUn+NYvn+DF1COxm0uzjuJI/MUnS28psJvKrKYwjMFBO3O7Azisu78S+BYtMuLqx0aC6eG2+1BG0iSJTEc4cu0WFU7Wwx4bHGadmTfS513/AAkuhf8AQa07/wACk/xo/wCEl0L/AKDWnf8AgUn+Nc42s+AVthMdOgJMjRGAaLKZ1KgFi0Ii3qoDKSxUDDA55FWoLnwPc6lFZW9lp8skqqUkTTswksu5V84J5e4qQQu7djnFIZs/8JLoX/Qa07/wKT/Gj/hJdC/6DWnf+BSf41maZH4R1i7uLax0m1862wXSbSzCSCSAy70G9SQfmXI461p/8I1oX/QF07/wET/CgA/4SXQv+g1p3/gUn+NH/CS6F/0GtO/8Ck/xo/4RrQv+gLp3/gIn+FH/AAjWhf8AQF07/wABE/woAP8AhJdC/wCg1p3/AIFJ/jR/wkuhf9BrTv8AwKT/ABo/4RrQv+gLp3/gIn+FH/CNaF/0BdO/8BE/woAP+El0L/oNad/4FJ/jR/wkuhf9BrTv/ApP8aP+Ea0L/oC6d/4CJ/hR/wAI1oX/AEBdO/8AARP8KAD/AISXQv8AoNad/wCBSf40f8JLoX/Qa07/AMCk/wAaP+Ea0L/oC6d/4CJ/hR/wjWhf9AXTv/ARP8KAD/hJdC/6DWnf+BSf40f8JLoX/Qa07/wKT/Gj/hGtC/6Aunf+Aif4Uf8ACNaF/wBAXTv/AAET/CgA/wCEl0L/AKDWnf8AgUn+NH/CS6F/0GtO/wDApP8AGj/hGtC/6Aunf+Aif4Uf8I1oX/QF07/wET/CgCndavpt/rGjRWGoWtzILxmKQzq5A+zzc4B6cit+sC60jTbDWNGlsNPtbaQ3jKXhgVCR9nm4yB04Fb9AHEaFoyasutMt3c2N1b65dNBd2pUSRkhQeGVlII7MpHTjgVavPh3p19p5trnUL+QzXBuLyWTyZPtjFAhEiNGY8bVUfKq4xxip/Bf/ADMH/Ybuf/Za6agDkLT4b6Vaajpl2Lm5kOmWq2turRW4OxU2DMixCU8H7u/bn+Gp7XwHZWuiPpyajqDEtC8d0XjEsLQhRGVwgXgKOqkHvmuoop3YWRy8fgLT1dJZr2+uLgSLLJPK6bpnE0cu5gEAHMSjCgDHAA60an8P9K1ZDHdzXJidrkyxZjKyichmVgyHgMqkYwfl5JGQeoopdLAtDif+FWaN/wAIz/YaTGO2afz5Gj02wUynGOVFvs47MFDcdas3vw60y+E6S3uoLDMBmISIQrfZmtywYoWJMbDOSRlQfXPW0U02gWmxzes+CLHWhOJry7hFxMksqp5TpJtj8vYySIyspXqCDzyCKn0Lwhp3h+HybNpni+xRWISVlIEUZcr0A5/eEfQD8d2il0a7gcrbeAbOAAS6pqV0E+zrCJnj/cpBL5kaDCDIBGCWyxHfPNVofhnptveXF7bajfW9/NcC4S7t4raJonAYZCpCEckOwJkVyQevArs6Kd2BzcPgbTIbKa38+7fzoPKklaQby3mtKZc44fe5b06YArP1D4X6Tq1i8Wq3l1fXD3X2o3d3BazOHMaxn5HhMWCqD+Djtiu0opf1+oHOP4J046Vd6fDI8EN3bRWzqlvblFSMEACNozHzuORtI9AK0fD+h23hzQ7fSrFpGgtwQpk2gnJJPCgKoyeFUBQOAAOK0qKd3qK1lYKKKKQziGTRruINN4iGjanZ3t4qTwXMKyor3DllKyqykHCnBU9ARio7rSPDFxAsaeMJYC0TQXUkeows95GzFmWQuDjJY8ptIzgEDirVhBpMurw2V3otnczXs2ozNcyxIzDyrnaAcrk5D+vG2qn9ueCba2ifVtHtLSSV58JHprThUimMTSMyRkIuQCS2AM9e9CW39f11HqiyLHwipTZr1uoQ3O0C9iwPPGH/ACxx+uaclr4TSWKQeILfMVxDcLm9i5aKPy1H0x19/Slmv/Advd3FvPaafG9urM7tpxEZ2/eVZNm12GRlVJYelQvrPgGOyW5fToFDStD5J0WTz1dV3kGHyvMX5fm5Ucc9KPP0/DYXl6/juV7jQ/Cc0Qij8Vm3heD7NdRRX0GLuLezBHypIGXflCpwxGa07AeFdOuLaaDXrUtbSXMiBryIgmeTe+foent1zVRdY8APaPcJYWrosiRgLo7l5C4JQooj3OrBThlBBxwTToNW8AXNpcXMVnZCGCNZWd9LZN6sdq7N0Y8zLfLhMnd8vXinqtA3/r5f8A6H/hJdC/6DWnf+BSf40f8ACS6F/wBBrTv/AAKT/GuZl174fQQxvLYW4L+ZmL+xJTJH5e3eZI/K3Rhd6k7gOCD05rpU8O6BJGrpo+nMrDIItU5H5UgF/wCEl0L/AKDWnf8AgUn+NH/CS6F/0GtO/wDApP8AGj/hGtC/6Aunf+Aif4Uf8I1oX/QF07/wET/CgA/4SXQv+g1p3/gUn+Nc5rusaRdeMPDzpqlm0Ea3azSJcIVj3RADJzgZ7Zro/wDhGtC/6Aunf+Aif4VzPiLR9PtfFegJZaNYv5iXbG2ESIk7LECobjHXuQcUna2o1e+g2bRPBkv2Nk8QxwTWmnNpyzQajGjvGVCgtjgsvODjjJ7HFVbLwz4R063YWHixba5a8F8buG4s0fzvLMbNtEYj+ZSQfk754PNX1vvCxhsbiTQtOitZ7Br64lkt0/0ZcqApAUksWYjHH3T9Ka+ufD+K1E8thbplnVom0WUSxlQGbfF5W9AFYNlgBtOenNU73bf9a/5kray/rT/Iqp4b8GLe6VcS+I4JhpcQigSSa0LMBnlpdnm855AcKe461X0/wd4G0nT7y00vxDa2S3WwCW2NjFJEqNuC7liBkXgZEu/PfPNarah4Nkszc2ek2UqJP5Tq+mvG5/ds4KIYsvkLlSBtYdCehp2niLwRNpsF9c6LbwpciPyYE0mSWclohLgxrDkYXJ4yMDOaXf8Arce7X9bF/wAOQ+HPCsENnpPiWyXTo/OZrRpbcBpJHDbgUC7QMN8oGPn9hVe90nwtfX0k8vivZA8ksws0vbfykkkieN3GV3ZIcnG7Gecdc2ZNQ8CRz2sX2Kxc3axNE8WmF48SkCPc6oVUsSMBiCfwre/4RrQv+gLp3/gIn+FN36+gJ22OQPhzwc3iCPV5fE6SzwlvJWS6tj5QaIxsofZv2kHO0sQCBgDpWgbPwk1pcW58QW+y4sILBj9tiyI4t20j/aO857dOBW//AMI1oX/QF07/AMBE/wAKP+Ea0L/oC6d/4CJ/hRdisjmr7TvDN1qU+o2vi3+zr2eVnee1vbfO1o40aPDqw2kQoem4EcEVRs/CXw/0/wAQQ6tY6npsUkKIoQtaOcqgRWEroZlIUD7rgZGccnPZ/wDCNaF/0BdO/wDARP8ACj/hGtC/6Aunf+Aif4UhvXc5XQdF8K+Hby5vLDxWhu7qOOKa4kuLTe6o2VDEINxwSpZssQeuQCOq/wCEl0L/AKDWnf8AgUn+NH/CNaF/0BdO/wDARP8ACj/hGtC/6Aunf+Aif4UXAP8AhJdC/wCg1p3/AIFJ/jR/wkuhf9BrTv8AwKT/ABo/4RrQv+gLp3/gIn+FH/CNaF/0BdO/8BE/woAP+El0L/oNad/4FJ/jR/wkuhf9BrTv/ApP8aP+Ea0L/oC6d/4CJ/hR/wAI1oX/AEBdO/8AARP8KAD/AISXQv8AoNad/wCBSf40f8JLoX/Qa07/AMCk/wAaP+Ea0L/oC6d/4CJ/hR/wjWhf9AXTv/ARP8KAD/hJdC/6DWnf+BSf40f8JLoX/Qa07/wKT/Gj/hGtC/6Aunf+Aif4Uf8ACNaF/wBAXTv/AAET/CgA/wCEl0L/AKDWnf8AgUn+NH/CS6F/0GtO/wDApP8AGj/hGtC/6Aunf+Aif4Uf8I1oX/QF07/wET/CgA/4SXQv+g1p3/gUn+NH/CS6F/0GtO/8Ck/xo/4RrQv+gLp3/gIn+FH/AAjWhf8AQF07/wABE/woAp3Wr6bf6xo0VhqFrcyC8ZikM6uQPs83OAenIrfrAutI02w1jRpbDT7W2kN4yl4YFQkfZ5uMgdOBW/QBzPgv/mYP+w3c/wDstdNXM+C/+Zg/7Ddz/wCy101ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcSy6RdwjzvEa6NqVne3gSeC4gWVFed9ylZVZcEBTyvYEUNpvg9tOks/7fhCS2M1k7fboizLK293yf4y2Tnpz0p9nFpI1KODUtFspRez37/bZY0Y747hvkORn7mSDnohqOz1LwhJb2Jv8ARbK1mvkEyRrYGVY43YiNpHEe2PcMY3kc5AJxTXdf1uv8w/r9Rr6X4Wf7VEPFZjsrhnkFlHqEKRRSs29pFwNxbd82GZlB6AU+1sPDEMnn3XisX12ZHkkubi9g3yFovK5CKqgBegVR0yc81JFqPgOYzbbGzRIUmdpZdKaOMiL/AFm12jCtt7hSeh9DVy7j8I2T2KT6Ta79Q/49kj0syM44ySFQlQNwJLYAGScYNLdW7gUbSw8I2c1nJF4ggJs47eOPdexciBHVM/USNn6DGKiOk+D/AOzo7RfEUaiKBYYpVvog8ZWXzVcHGNwcA8jHHINTtqXgRIrqSTTraIWrosgk0d0Zt77EKKY8yAtwGUEE96nsZvBepagLK10y189gdol0polZgMlAzxhS4HVM7lwcgYp6t83UVlFWKMGleFInuJZ/FC3d1dQTw3FzNewb5fOEasxCqFBCxIBtAAx0NdHBr+gW9vHCmt6eVjQICbuPOAMetP8A+Ea0L/oC6d/4CJ/hR/wjWhf9AXTv/ARP8KLjD/hJdC/6DWnf+BSf40f8JLoX/Qa07/wKT/Gj/hGtC/6Aunf+Aif4Uf8ACNaF/wBAXTv/AAET/CkAf8JLoX/Qa07/AMCk/wAa57Wdc0mXxt4bni1OzeGH7V5si3CFY8xgDJzgZPTNdD/wjWhf9AXTv/ARP8K5vXtI0e08YeHl/s2zjtnW7adFt1CuFiBGRjnHUUm7K7DcWLTPB0UOrRrrtvjU5A7N9uj3QYYuFjI6AOzOAc8se2BUcWleFh58l54s+3XVxHNHNdT3tuHkEiKh4RVUYVABhQO5yTVSDV9G+3W0d/4a8O2qX9ubmyhN5D9rkTYWDNAUGAcEfIzkdx1xf0/VPBN7JaQSaZYw3VxFGzL/AGcWijd0DiMzbPL34OduQ2OcU2r3T/r+rBzWenqTC28J+aj/ANv25KPE4H22LkxxtGv6Mc+/pVfSNL8KaQ1s6eJ0uXtsbGnvIMkCHyQDtUDhMfiOc05dX8CPpqXyaUrQSyiGEroMxadiCf3aeVukGATuUEYHWm3uo+FrHV4bCTw/aO88vlIyacx8s+R5uZf3XycfX17EAfW/USS0t0MK40W2h1fT7fSfFGmR6JB9jM6yajH5khtypUsmw7mIRRlXjA7q2BXfW/iDRYYAkniGyuGBOZJLqIMef9nA46dO1ZOlTeENXvFsrXSLSW5EKSymLS3aGPcgYL5xiCZwwOCQ2COBVnWYPCegwRS6lpFoPPk8qKO30wzySNgnCpGjMeATwOAKp3WjBNS1Ro/8JLoX/Qa07/wKT/Gj/hJdC/6DWnf+BSf41zM2seCrbUryzu9CWKS1aJVA0WR2mMiFwEVYyzEAEkAHGDnGKfPrXw9t3hV7Wxbzo45VaPSmkULIzKmSsZCkspUA4O7jqQKkZ0f/AAkuhf8AQa07/wACk/xo/wCEl0L/AKDWnf8AgUn+NYUt94Hi0mHU30y3NrKzpuXRpGaMoSH8xBHujCkHJcADvisrUPEvhCxg1GY+HIHTT53hcf2Y26YrEJMxAREMMHrkADnOMZAeh2X/AAkuhf8AQa07/wACk/xo/wCEl0L/AKDWnf8AgUn+Nc8NQ8HJdLbTaPameWdooobbSZJpMBUJLqsOUxvXJPAyOc5A3LrRPDllZzXVzpGnJDBG0kjfY0O1QMk4C56Ch6K7Ba6Il/4SXQv+g1p3/gUn+NH/AAkuhf8AQa07/wACk/xrmxrXgA2guF06Fg0qxJEuiStNIWUspWIRb2UhSQwBBAJzV2STwXDqSWEum2azuF66WdiFhlVd9m1HIIwrEMc9KNhXRr/8JLoX/Qa07/wKT/Gj/hJdC/6DWnf+BSf41iyXXgeKwW8axsDC9tHdJt07czxyHam1Qm4ljwFA3Z7Vn2+veCGsRc3ej20AeeaKONNLeV9kTbWkdFj3RqOMlgApOCaOthnVf8JLoX/Qa07/AMCk/wAaP+El0L/oNad/4FJ/jXNT658Pre6kt2sbaWSMkH7Po0kwYhQxVSkZDttYNhcnbz0BNW3ufA6Xlrb/AGGwZrpI3jkTTt0QEn3N8gQom7+EMQT2zQK6Nr/hJdC/6DWnf+BSf40f8JLoX/Qa07/wKT/GuZi174ezSqkdjbksygMdFkC4Y7Q+4xY2bvl352g8E54pItY8FLNfxajpFnZNYvOHZ9OJjZIs7iJPL2lto3FASwHajcZ0/wDwkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jWGbvwUstnHJpMMRvGCxNLosiKCW2qHYxgRljwu4jdkYzkVXh1v4fTwTyx2VqEhUN8+juplBbYPKBjzL83y4Tdzx1oA6T/hJdC/6DWnf+BSf40f8ACS6F/wBBrTv/AAKT/GsW3ufA9zB5sVhYgeTNOyyaaUdFiKiTcjIGUruX5SAeelS2H/CH6nqk1hYaRbzTQDMjjSWEKnAO3zTHs3YYfLuz7UAWbrV9Nv8AWNGisNQtbmQXjMUhnVyB9nm5wD05Fb9YF1pGm2GsaNLYafa20hvGUvDAqEj7PNxkDpwK36AOZ8F/8zB/2G7n/wBlrpq5nwX/AMzB/wBhu5/9lrpqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5d/Dtp4m8NyWV9JNEq6jdOskDBXX9/KrAEg8MrMp9mOMHmm6z8OtC1rxDa6zcQRrc26JHg2ltMrohJVf3sTlMZPKFT78DGvoH/INl/6/bv8A9KJK06Ngeqszj9e8Cx6rpek6TFtNla3/ANrnlmlIk27mZo1Crhg+4oQSBtPeujudLhutRtrx3kWS2jkjQI2Bh9ue2c/KMYNXaKOlg2dzjdN+GWkabNNOt5fTzzNbtLNIIQ8nkSiSPcUjXcQRgs2WI6nODVnT/h7oml+LpvENnCiXUzvIVNpbHDv95xL5XnZOTx5mOSMYrqaKd2G+gUUUUgCiiigArmNfVX8deF0cBlYXgIPceUK6euT8UNOnjDw61miyXCx3piRjgM/kjAP40ntqNbk0fge1EkCz6pqVzZ2mTZ2Uskfl2p2FMqQgdsKxA3swGaba+BLKzuoWh1HUfssLxyixZ4zC0yIEWU/JuzhQcBguRnbXNrrHiT7Ahk1DxEts06C8ul0FftFsxRiyQp5R8xN4QbvKfAP326rVe38TX03nXFpdRXV1GivcLZrvTFtdBXG5WEb5MecdC23viqd4pv8AruSrSaT8zePwq0htP1C1N5OV1CZZpybKxKsVyR+7+z+XnLH5yhc8fNwK0f8AhA9PRYBb3l9CYXRlIkRiQsHkbSWU5BQ8nrnkEVxc9/4psdOtptMfVcFoBIBpTJc3eLdM7n+ySBcMGB3ovYb1Ar0g6qlxpuoNbM6XFkpSVXQgxyeWHxyMNwy8jIpS0T7L9BxvJrz/AFMQfD2yh1eHVLTULmK9tbP7Lay+Rb5ixHsDFhEHfGc7WcpnnbwManiPwzB4o0NdM1G4YR5VnYW1vLvI/wBmaN1HPPAyOxrhLDxJ4nl8LNdCfXrtbiG3IujpIjkgmZWMgRFgYtFwnziOTG7qwzttwXvji80eC7lnv7O6tbASyWqWSMLqcTOpRi0WeUUH5AhOQRgcVUk72ff/ADZKklFNdv8AJf18zffwBaLNFNYavqljLBHEkMkMkTGMohTd+8jbcShwd2R3AB5qQeAtKW38pZrsAi13EyKSxgmaZWJK9Wdju9umKwZNT8Vvc6gkVxqsd15hQ2/9lKbe3Xz1VGimKjzCYySRmTvnZjBa2p+NbHx4bFzcXWmwgBGkgZhdRCPJcmO18sSl8jBmReMbOQSlJ3v8yrW2NjWfhtpOuWZtLy7vfszyXEksA8p0k8597ZDxsAQ33WXDD+9Ulz8PtOuluUmv7/y7jcSgaMBGaAQsy/JnJUA85GR0xkVyFlqXivVLkPfy69FYQahZ3EMh08iVkYyLJGyfZkIVSFyMMQDneQcixpsOuw6nC00d9+9i09hbPpq/Z4NsriQqBHhGA2nGQRuz2GDVad9Py/r5Cm92+mp0eqfDjTdYtlhvr67kX7T9qkZobZneQqqkhmhJjOF6x7CCTgjjG1faZd3OharYm7Ez3ccqQGRQohDJtCkgZIByc9ea57wLrGtypfReJP7RuWW4WOG6ls3jRy2RhYzbROqjAJLb1GR+8PNdtSkrq3T/AIYa0focbL8OLW+0N7HVNTvLuWZYlmuLiC1nJSPOyMLJCU2gsxB27uck5oT4XeHotetNWjizPbJGp822t5mlMaBUYySRtKpAUco68jNdlRTu27iWiscjbfDuytbVoRq+quViihtZHeLdaLE5ePy8RgHaT1cNkcHNPbwDb+Soh1vVobgmYTXUbxeZcLK250bMZUAkdVCkdiK6uil/X9evXuP+v69OnY56DwXpltLbtA9wi287zxoHGAWh8kjpnAXp3z37VnN8L/D51fTtR2bp7CGGEGW1tpjKIhhCWkiZlIx1jKV2VFO7/ryJUUtjnF8EaatuIRPdbRZpZ53rnYsnmA/d65/TtUF38P7C+e8F3qOoyW9yZ3FsXj8uGSZWV5E+Tdu2uwG4kDPTPNdVRSWmxd+py2seAdO1zXrfVL28vC1tJDLFCBEyRyRMGVlLRl0JxghWAIJyM80+bwLp8tpawpd3sL2cAht543QPGRIsiuMqQWDKOoIIyCDXTUUbCsmrHJXPw9tLm1CHWNVjuHWdLm7SSLzbpZgokD5j2jOxMbFXG0YxVmz8EWFn4rHiAXE0l0sPkophgQKu0DBdI1kccdHdgDyB0x0lFPYNzM1X/kJaL/1+t/6TzVp1mar/AMhLRf8Ar9b/ANJ5q06QHA6D/wAJJ9r13+wv7K+z/wBr3G77Z5m/fkZxt4xjH61sf8V1/wBS9/5HrmrGz1i516R9CmgtpYtc1DfPc2b3EaAogwVWRME9ju/A1n3lz450TSbWGwRlMl/fvc3EFnKA8huCY/3awXLCJgSe3GP3g4yLUdtLna/8V1/1L3/kej/iuv8AqXv/ACPXP6dr/iOfxVdRma/ufs1y8c1lHp4FqsQtw25ZygJk8wgBS+cHlR94ZdpqXizU5997JrsVlBf2dxC508rKysZFkjZPsyEKpCZADEA7t5ByHbb5fiTfRv1O0/4rr/qXv/I9H/Fdf9S9/wCR64m7vPFWpaaI7s61MVe2mvUfSQn2KdbqI7bfEY85AvmHP7wfKDu5xV66/t7U7ez8+2vbyLbKI7m408R3DoLq2KFwEUxkqHJXC5C5KjHDSuU1Y6j/AIrr/qXv/I9H/Fdf9S9/5HrlLvWfFdjJplvpllqMTJPunij08LBLE1ywYkrA3zKmGxviJ3bst0qzqeq+LtF0S21EXdxeXWoXktillPBFGtu8jlIJAAgYhSFJyTkMT2FStfyJuuvqdF/xXX/Uvf8Akej/AIrr/qXv/I9VPGk2sW9pZW1tc6glvJBKk9xp9gLmWSbaojRlCNtRsvlgBjA+Zetc3eT+JtK0CP8AsxbyzdPsiFLfTmMswFqgK7xbTYw2QSydtu5aO4+3mm/uOv8A+K6/6l7/AMj0f8V1/wBS9/5HrBi1jxVJrwBGrRys777CTTlNtFB5RKyCcJhpd+0FQ56kbAOaz9e/4SiTQ4LO/vdZuTdafHLsg0tJBNOxzJFKUi/dKo27eVPJyzEYppX/AK/rsJuy/r+v6udd/wAV1/1L3/kej/iuv+pe/wDI9coNb8ff2l4iV4nTybe6a1hFtLIFK58gxH7KqMSMEgzSE54C4IrVtrnxLY/EK1sLi/1LVNOeIbybQRJGSpJZ3FqEbngbZlI4GxuSRa28xvS/9dv8zW/4rr/qXv8AyPR/xXX/AFL3/keumopAcz/xXX/Uvf8Akej/AIrr/qXv/I9dNRQBxekf8Jn9hk+y/wBhbPtVxnzPOzv8593Ttuzj2xV7/iuv+pe/8j1l3wu9Mt4Nf0qwmvrm3u7+1kggUszpJPIV4HpIseT2BY9M1l3p8X+HNZ0fSNIX/QEhiLzCGR47mdnJnMvl20u3rkEvFy2ctzgWoPTU6j/iuv8AqXv/ACPR/wAV1/1L3/keud1PVfF2i6JbaiLu4vLrULyWxSyngijW3eRykEgAQMQpCk5JyGJ7Cuo1RNY/tTSLa0vbqOBY5HvJYII2MrIEKqSykLuO7pg9cEdQdLh5EP8AxXX/AFL3/kej/iuv+pe/8j1ymna340v21BFGqwQzSWht5rmwAlg3zhZ0CmBAAiHv5gx828jpoaBqHjL/AIT+Ww1Yu2nxtIuZon2vEoIjkV0tVj8xvlLDziOThF6BpXB6K5t/8V1/1L3/AJHo/wCK6/6l7/yPXTUUgOZ/4rr/AKl7/wAj0f8AFdf9S9/5HrpqKAOZ/wCK6/6l7/yPWHqv/CV/8JdoH2n+xvtf+k/ZvL83y/8AVjfvzz06Y79a9CrlvEcEV1428NQXMSTQyreJJHIoZXUxAEEHggjtQA//AIrr/qXv/I9H/Fdf9S9/5Hrn7XwvH4ftdYn8K6Jb6RfzavFBHc2emxiRbVnhD7fkxsA3noVBBPaodT1rxdbeKXtdLGr3FrDFNBK09iNhZbdmjmUrbhWLOoGRJgE48sZFHS/l+l/1+8Em/vOm/wCK6/6l7/yPSOvjiRGR18OsrDBUicgj0rntTuPGGm6Hexpq2oTzI1tLHcnTQ0jB1bzIk8m2kAAIHJicgHBPIIbfeIvFf9q6GtlZ6xF/x6m9gltA0bxuwWRmdbcgsoOSA8RHXaQMU7a2+Qk9LnRRReNoIUihTw3HHGoVEQTAKBwAB2FO/wCK6/6l7/yPXOQS+N1RJ5dS1Jz9liuzCdPhCmQylWg/1Wduz5iM7s85A4pd3i1EvJLGW8sY7Qzzx2sGnRBbt/tkuFbMZJBjCn5SGOQ2eckWtvMb91Pyt+J0X/Fdf9S9/wCR6P8Aiuv+pe/8j1zt5rviuTxheQWC6lb2IjuIi1xpzPHBIqExyIFgy4YjORK/XBRTisybxB48Hhexkgh1EN58q3F3NA5lfAUx4jWwLhCSwObdT8v3sEMVug62O1/4rr/qXv8AyPR/xXX/AFL3/kesjSdU8Unx7Bbao1zcWc1spkS2tXitrd/LBYlpLYb/AJgcYmz8wBj4JqbU4vEFx4onttMubrS7aa6G+7tbKJmZFtsj5njYH5wBkg/3RQ9NQWpo/wDFdf8AUvf+R6P+K6/6l7/yPXP2Ws+LJ5rRtQOp21y9tEy2kOlh4JQYAZGkcqPLcSFgF3jgD5GzVObUfH9lquiwie4uIZ7eCWSSe2YK0rn97HIsNo+xVGAuXiPPLNg4q2thN2Os/wCK6/6l7/yPR/xXX/Uvf+R65m417xdL4j1WO0/tO2sfs1wEe405nFtKhAQxqtvlwy5IIeXPTaCMGjd+IPHo0DSntIb6Ms8wnuZ4HaSRwV8vciWBcRkFs5hiPy/eHBaVqU9DtP8Aiuv+pe/8j0f8V1/1L3/keufE2u3njjSW1b+0D9lvnke3i09vscUX2WULIs3lgklmwQW4JA2jgnZ8XXB1Xwlp9/pL3jRSXdrcpNZ2rSzJHuDbxGVJyBzgqfp2p22fp+JP+RP/AMV1/wBS9/5Ho/4rr/qXv/I9cqLrxMp/tBxqqB7eOGS/TTQboW4nlxJ5GwjzduwldhI3Z2DoFudZ8XLpkDGbWoj5Ups5IdHV5L2QSERLcp5Z8kMm0niLqeUxikira2Op/wCK6/6l7/yPR/xXX/Uvf+R6wtOl12+8eWDav/aO63ubjzLf7BttLeMxsI2SfYN5YYzl25OML3WNtYtPH2qJZ/2kI7rUVY27WGbSWH7NEGkMxThgVwAH5II2nkgEuvkbn/Fdf9S9/wCR6P8Aiuv+pe/8j1xVsniWx0j7XZaZNFf/AGMOu3TR+7lXTwAFTZhf3g27VA5+X2rojqmv6dq40iR9Vv3e8tmju204GP7O2PN3SJGI1wcjB+YDB96bVnYT0Tf9aGn/AMV1/wBS9/5Ho/4rr/qXv/I9cdoz+IYtOtLGOHUrm3hktfPgvtKCLauLqPiImMbx5e9i2W2lQdyngdR4TfxGL6A67eXl1Fd2JndLi1jiW2lDgBFKIp5U5wxJ4yMdKErpDehIP+Ek/t3R/wC3f7K+z/an2/Y/M37/ACJcZ3cYxn9K6uszVf8AkJaL/wBfrf8ApPNWnSA5nwX/AMzB/wBhu5/9lrpq5nwX/wAzB/2G7n/2WumoAjighgMhhiSMyvvkKKBvbGMn1PA59qkoooAKKKKACoJrK1uLmC4uLaGWe2JMErxhmiJGCVJ5GRxxU9FABRRRQAUUUUAFFFFABRRRQAUUUUAZmgf8g2X/AK/bv/0okrTrM0D/AJBsv/X7d/8ApRJWnQBBNZWtxcwXFxbQyz2xJgleMM0RIwSpPIyOOKnoooAKKKKACiiigAooooAK5fxDIIvHHhmRuiLeMeQOkQ7nj866iuU8TQfafGXhyDdt82O9TdjOMwgZpSvbQatfU1rXxNot3eQ2Meq2Iv5YxILL7XG0wBUN91WOeCDkZGDnOKQeK/DptXuhr2lm3jmMDy/bI9iyAZKE5wGx261iW/w9hisTbSX24Ncxzs6Q7WIS1FvtB3cEgFs9s4x3p1h4JuIb3T7nUNRtbhtPlQxeRpywlo0hliRWbezFh5ud2cccKuTVu12Sr2Xp+Jvw6/o9x9s8jVrGX7Dxd7LlD9n/AN/B+X8cVAfFvhxbS1um1/Sxb3j+XbTG9j2TtnG1DnDH2Fcrpnwxn0eC7Sx1xhI0Ags5phczNAm8OVZZLhkYHaAfLWM+hFNX4Y3sVnGlv4g8q6F3JcNfLHc+eocLuVH+05IyucSGRfugg45StfX+v6/q435HajW9KOoT2A1OzN5bx+ZNbi4TzIk/vMucge5qHRvEemeIGujo91HeQ2zqhuIJFkjclQ3yspIPXB965OX4VwzarfzS6pLJa3fnyJFI9wzQyzAhmAM/kkfMePK6d63dG0LV9JuZ7mW/sLqe+ukku2js2gXy1i2YRd7fNlVOSTxn2pLbUOrNa81rTNPvILO91C1t7q5z9nt5Z1WSbHXYpOW/CqGleM/D+r6I2qW+q2aW8UKTXPmXMYNqGXcBLhiEOD3NVtX8KT6hrj31tfW8MNykKXcNxZC4LCJy6GMswCHLHJKt2I2kZqh/wr3y9Ls7e11GOOays7W3hka0DIXgcursm4ZUk8rkH0bNC21G7WNxfFeiu6smoW72jWjXgvlmQ24jVgpPmZx1P096kl8UaBBa2dzNrmmxwXx22kr3cYW4PohzhvwzXLXnwzbULWf7XrBF3cFpXltoXgQTGVJAyhJAyrmMDAfcck7geaR/hvcjS7GC01hLS8t5pJZb+IXhmYuQW2M10WGcAkSGRSQCV7U1ayuTrd/10/z/AK79DH428NOs7PrmnwrBeNYuZrpEHnjqgyeW9utPj8W6PPq1xptveQy3NrcCC4UTRjyWMRlBILAkbQegJ4PGASOd1v4e6lq631sniIW1jeSTM8SWsiyASBc/vEmUkgr3G0gkFT1qXUfh02pvOlzqoW1mkWUpHbEOH+yNbN82/GCCrAbeMEEnPBG1te34/wBXK0/P/gHT2+u6ZfaRLqemX1tqFpGrEzWtxG6HaORv3bQfqQB3xSJ4g0h9Q+wf2nZLfeT57WhuU81Y8Z3FQc49+nvWPcaNqlp4S1uOTyNV1K/idQtjaJaKxMYjXhnOcAAks5PHHGFrPHgC+uNetNRvtc3Q2rM0dqkLjaHgaJlJ8zY2N2Q3lhh0JOaXVhpZHUXfiLRbC3M99rFhbQhEkMk10iKFbO1sk4wdrYPfB9Kq6p4x0HSdNhvbjU7V0uY/MtUjuIy10v8A0yBYb+DnisXTPAV3bX1rc6nrEN4bQWqRrHY+UNkAlC5zI3zHzck+q8AZ4jufh1O9s8Fnq0EUdxCYLnzbHzCyCZ5U8v8AeDYQZCD97OBwCKrS5Otvl+J0q+JNJDQJdX9raS3M8lvbxT3UQaZ0cqQgDHccjoOR0IByKsWusaZfX1zZWWo2lzdWhAuIIZ1eSEnoHUHK/jXML4CngupJbXVINt07/akuLETBozcSTqEDPtRgZCNxDA4BwCBUWjeALnw5qV1qGm6hHcy7JFslvHun8kSOHcNmdo8EgfcjToOvdaXHLRux0eseJdK0C5tY9ZvIbGO5Dlbi4lSOJdu3gsxGCdwxU/8Abelf2oum/wBp2f29ovOW1+0L5pT+8Eznb74xVfVtCTVdQtrl5VX7PBPCFMe7PmqFznPGAD9c1y9l8MhYa9DqCam88MYjka3ke5GZkhEQdQtwIgMKOGjY8nnGMT3uHodTF4p8Pz2dzdwa7psltaAG4nS8jKQgjI3sDheOearT+NdBiuIYItStbmW4tGvIFiuY8SxKQCysWC4565xwfSuY0XwFrkXhaxjuNXt7LUYLKC3RY7L5YkTDMkmyUF2zkb0ZMdupzZg+G01tpMFhHrQZEgu4JXlt3kd1nmEoO5pM5UgDLFiw9DzV2Sf9ef8AwP61FK6T5TsLXWNNvr25s7HULW5urQgXEEM6u8JPQOoOV/Grlc7oHhifRb/fJfW9xawxyRWiCyCTIrvvbfMWJfkdgg9QxwR0VT0H1MzVf+Qlov8A1+t/6TzVp1mar/yEtF/6/W/9J5q06AOZ8F/8zB/2G7n/ANlrpq4HQf8AhJPteu/2F/ZX2f8Ate43fbPM378jONvGMY/Wtj/iuv8AqXv/ACPQB01Fcz/xXX/Uvf8Akej/AIrr/qXv/I9AHTUVzP8AxXX/AFL3/kej/iuv+pe/8j0AdNRXM/8AFdf9S9/5Ho/4rr/qXv8AyPQB01Fcz/xXX/Uvf+R6P+K6/wCpe/8AI9AHTUVzP/Fdf9S9/wCR6P8Aiuv+pe/8j0AdNRXM/wDFdf8AUvf+R6P+K6/6l7/yPQB01Fcz/wAV1/1L3/kej/iuv+pe/wDI9AHTUVzP/Fdf9S9/5Ho/4rr/AKl7/wAj0Aaegf8AINl/6/bv/wBKJK064vSP+Ez+wyfZf7C2farjPmednf5z7unbdnHtir3/ABXX/Uvf+R6AOmormf8Aiuv+pe/8j0f8V1/1L3/kegDpqK5n/iuv+pe/8j0f8V1/1L3/AJHoA6aiuZ/4rr/qXv8AyPR/xXX/AFL3/kegDpqK5n/iuv8AqXv/ACPR/wAV1/1L3/kegDpq5PxTM1v4u8OzoAWjivXAPTIhBqb/AIrr/qXv/I9Yeq/8JX/wl2gfaf7G+1/6T9m8vzfL/wBWN+/PPTpjv1pNNqyGtGZ958QfE2laMZb6DTp55ILO5Fxbw+XFaRzrKT5gmuFVgpixuMiA7x073Y/iBqc0elPO2k6YbqBJgLl/OGoFpGXy4GhkYBtqh+PNxvA7E1v/APFdf9S9/wCR6P8Aiuv+pe/8j1TabdielvL+mc3deOtcs9M0+6v9Q0LTxfQSXMUlzayhHK7Qtsp80ZlbJOfTgI2M1XvviFqbXWt2VyLOPytLkuYrW3bdNCwiD4mdLgSRnOR/qk7YfNdZ/wAV1/1L3/kej/iuv+pe/wDI9C03K63/AK/r/My9I8cTSeNNW0vWLvTYrSzjaRTA0beSi4+aaTzyUOD0eJB6M2M11t5bXM99p81tcMkUMrNPGGwJUMbAducMVPp+lY3/ABXX/Uvf+R6P+K6/6l7/AMj0dESdNRXM/wDFdf8AUvf+R6P+K6/6l7/yPSGdNRXM/wDFdf8AUvf+R6P+K6/6l7/yPQB01Fcz/wAV1/1L3/kej/iuv+pe/wDI9AHTUVzP/Fdf9S9/5Ho/4rr/AKl7/wAj0AdNRXM/8V1/1L3/AJHo/wCK6/6l7/yPQB01Fcz/AMV1/wBS9/5Ho/4rr/qXv/I9AHTUVzP/ABXX/Uvf+R6P+K6/6l7/AMj0AdNRXM/8V1/1L3/kej/iuv8AqXv/ACPQB01Fcz/xXX/Uvf8Akej/AIrr/qXv/I9AGnqv/IS0X/r9b/0nmrTrlB/wkn9u6P8A27/ZX2f7U+37H5m/f5EuM7uMYz+ldXQB5VeXFvb2mpm91hNNg/t68LLNfy6fFOQq7Va6j5j5IwP4ueDipLTxdf23iHRhG1z/AGddWkcU899L5qxZndFk4K795CqsmOjKxz0rc0HW9N0K01+51e+t7ONtcuVQzzLH5jYXCruIyx7CtiLxnof2GO7v9QtdNildEiN7dRR72eNZAo+c4bDj5Tg98YIJI737P/gBLa3l+qOUtvF2veY5tf7PWytPJedJo5pZZfNu5YSFcyfLgIDyG9MAYxe+I3jq48IJCLCS0a58prg21xGC1win5lQmWMAgcnG9gOdhrqX8QaNHqUmnvq9gt7FEZpLY3KCRIwMlyuchcd+lUrzxt4dtLeGVdYsrlrh9kEVvdRu8x3hG2Dd821jzjpg01ug0RgP4v8QQXNxcmCxu7NpLyG2tIIXWYtAjMpMhcg7tpGAg6g57VP4I1651rUNanm1iw1VI4rcxy2G5bdSQ5IALvgg8Mc9uQOg6VfEGjPNeRJq9g0lh/wAfaC5Qm3/66DPy/jioIvFvh66lMNlrenXdx5BuFgt7yN5GjAzuChuR79KXT5f0xWbfz/pHGaJ8TLiW0kn1y70tI7fUI7e7uYdn2aCNw/8Ay2WeRSdygZbYRkZQZFVYPHuoSa/9qi1CwC3Ntb+Tp0quWu/9IuExAN42uVVSThs45AAyPRNB1mHxDodtqlrDPBFcLuWO5QJIvOCGXJwQQRitGq2eobrT+tbnncnxAvobjUnludJC2jP5tgUk+0WMaTKnmTEMV2shLgkJgYxvGSIJviBK/iCO+h1ewXQ41vlTZE0gu/KjidCrB/mPzOflByqt9R6XRUr9CjzDRvHviLXwtpp82kC4N68IvWtjJDLEIPNDokdwwOTxnzPXIBG2j/hZusvreh20Wm2qx6ha20xjkmhRrjzQC/lNJOjfJ6LHIT0+XOa9Pop/1/XqT0PM7L4kajJbT3E02lTrHbC5uYreN1bSv3qK0VwS5ywVnOcJjy2O3FJq/wATriBorrTbvSX01tQktxKuyWSeNVQjykaePzCdzcpvP3cI2a9NooVr3/rf+kN6nG+ONYvtKutNe3v7e2tZYLvzIZlYNcOsJZFVw6lTwTxk8HGMVi23xB1X7frVk0+j+ZZWbTWy+YjJFgLgzy/aCynnOHjj9A5xmvTKKm24+x53YfErGg6dqGq3VjFFci5je4aNYo3mQAxpGVmlRt2T92RtxBAwQRUOk/EbWL/xpY6TNYWscNxHCTG0kMcjh4lczJuuBIUBJXaIW6H58givSqKpPW5Nnax57qd5b27WcWvapNpOgyXOoGe5ju2tFMwuT5aPOrKUBBcgBhuIx7GDUfG02i6dappmq232b7PJNb3GtRO0mpFZCFghIZSWIAw2HZgVO1sk1tWP/CV7Lr+yf7G+yfbbry/tPm+Z/r3znbx1z+GKs/8AFdf9S9/5HpIrqYE/i7xS90/2Y6TBFI14IkmtJXeP7PgncRKoYsDjgDBGefu1Pc+K/EU+pRJpzaXBbzT29qontpJXV5oPM3kiRQQp/hwM56rjnY/4rr/qXv8AyPR/xXX/AFL3/kel/wAD/g/f+Av+D/wPu/E5q++Imq2tvau0mlW0xsxOsE8UhbU5fMZGht8ONrfID/y0Pzrx3Oz4f8Sa3f67HHqP2D7FdS3scMcEDrLF9nm2As5chtw7BVwfWrn/ABXX/Uvf+R6P+K6/6l7/AMj1V9AOmormf+K6/wCpe/8AI9H/ABXX/Uvf+R6QHTUVzP8AxXX/AFL3/kej/iuv+pe/8j0AdNXKeJ2K+MfDjKSCI70gjt+5FS/8V1/1L3/kesPVf+Er/wCEu0D7T/Y32v8A0n7N5fm+X/qxv3556dMd+tKSurDTs7mF4Zv9S0FdP1HW5Z7OGTR2u/Mm1q71Jb9hGGPySqBE6/fIXOQSBkAkT/8ACz9YbwteXyz6KHtL9IPtbmFIpomTcHjVrsIxycD9+OAeMjbXZf8AFdf9S9/5Ho/4rr/qXv8AyPVN3d/63v8A8AmKsv67GJZeI9ZbXGvYZ4X0u4urKJ7e5t5FlXzoU5TL4iwTkqQ2cnkdT3tvcwXltHcWk0c8Ei7klicMrD1BHBFc7/xXX/Uvf+R6P+K6/wCpe/8AI9AHTUVzP/Fdf9S9/wCR6P8Aiuv+pe/8j0hnTUVzP/Fdf9S9/wCR6P8Aiuv+pe/8j0AdNRXM/wDFdf8AUvf+R6P+K6/6l7/yPQB01Fcz/wAV1/1L3/kej/iuv+pe/wDI9AHTUVzP/Fdf9S9/5Ho/4rr/AKl7/wAj0AdNRXM/8V1/1L3/AJHo/wCK6/6l7/yPQB01Fcz/AMV1/wBS9/5Ho/4rr/qXv/I9AHTUVzP/ABXX/Uvf+R6P+K6/6l7/AMj0AdNRXM/8V1/1L3/kej/iuv8AqXv/ACPQB01Fcz/xXX/Uvf8Akej/AIrr/qXv/I9AGnqv/IS0X/r9b/0nmrTrlB/wkn9u6P8A27/ZX2f7U+37H5m/f5EuM7uMYz+ldXQB5zp/hu41q41e5sb2C0ni1W+t2Nxa/aEaKURhwF3rhvlGGye+Qc1ZuPhrObNI7LWUt7hZUdbsQTJLGogihIRop0xnyg3zbl6Aqcc6/gv/AJmD/sN3P/stdNQtNh3OJu/h/cXcs0L6xH9geaW5VDZAzieSJoyzS78FfmJ2hQeg3Y4qfU/A815dIbTUbe3t3itY7iOSy8xm+zvvQo28bO+Rhu2MHr19FC0/rsJ6nn1t8K44G1FG1NpobmGWG3843MjQLI4dwQ9wYiCQPuxp0FbaeFLmLxw2uwaktvbOMy2dukq+e2zaDJmUxtjjkRBvlUbscHpqKadreQW38wooopAFFFFABRRRQAUUUUAFFFFABRRRQBwt9qr+GreDXZJJ2sku7+2uIEbKlmnkaNtv97eoQf8AXSsu98Ya/wCF9Z0fQZoIriSaGKSeS7uIVa6lkc+YkTy3CEbOwVJOCowvGe70D/kGy/8AX7d/+lEladNaA9Tzy78beINL0WLV7u3s7u3vbiaztbe2tnDxz7ykAdzIQVZlwTtXBYemT0eqalq1tqmkWNtJZxtcRyS3ckkDycRhCwRQ4wTuIBJOODg4wdS90qz1G4tJr2JpWs5fOhBkYKHxgMVBwxHbIODyMGrlLoHU8u074mapqbahHYtptxiS0FpciHEYWecRMrKszMWTPOfLOeCo4NaGgeOdavvH8vh/ULS0VYWkjkCtDFKoQHEwQ3LSlHIGF8oYDD52616DRTVkD1QUUUUgCiiigArlPE7FfGPhxlJBEd6QR2/ciurrlfEtzDZ+M/DdzdSLFDCl7JJI5wFUQgkk9hipl8LHHdHGadY+JbLwDJrb3Utt5mkK4J167vmuJGCFZCJVAhI54QnO7HYVq3/jnWtMuZtP1LUNDsJLe5lifVLq2kW3kKxRSJEE83IdvNIHzn7hIU5wOm8N+NtK8TafFeWri3inAMPnXMDNKDuPAjkbBwjHBwRg8ZBA0ote0efUIrCHVbGS8miE8dulyhkeM9HC5yV9+laS+J6Ewsl3/qx51F491mG4vG1HU9K0kXE9sR/aUDbNMje1WT94PMUkM4KAkoNwbr90Xl+IWpjW/D8FyLCGDU413QxKslxIxcruVGmSRYyArBhHJgEltoGa7HTvE2k6vq1xp+l3kN5JbRh5Xt5UkRDuK7CVJwwKnINQv4y0FNZfTf7TtWliikkuHW4j2W+xkUrId3yMTIuAR60rptW/qyHZ7HC6d8TPEWpi8jjsdPt7hZreJUmeJmtGkuEi2Sxx3LSMcMxyyxcrjFW7/wAf6zpdzpsF9PpIL3k1rc+VEplnKS7AYoXuEcAjrt80gn7prvrbW9KvYEms9Ts7iKRgiSRXCsrMV3gAg8kqQwHpzSadrelawZRpGp2d+YTiQWtwkuw5I52k45Uj8D6ULS3l/wAD+vmD1TsednxPqaapIsl9bpbOZlismaUSSOmomMur+bu4UjKgYGccLxWhL4v1W7ae1eCGKTTb22tbxgsqAzSXSquwq4O3ysOQSQfMUHIyD2KeItEkF2U1iwYWLBLrF0h+zsTgB+flPscU+DXNJurZbi11SymgZgqyx3CMpJXeACDjJU7vpz0oWln2/wAxvVtnAaV41123s9Is55bPVrzVJWtoLiGBlWKZJj5yy/vGxtiywGQcoR3Fdh4l8Qvpfg+71jRok1JogNgidWX74VmJLKMLyTlh905I6inc+IfBsmp2OrPrFhczrONPt5I74SJHLIM7dobaHIHXG7HHStG08QaFHJa2K31hZ3N0z/Z7I3MQklwxDFVVju5BPGffBzS1at1/r9BXtK5xll8RtVuNDsrto9Ndrid4XljkR0SJSubo+TNKqxoSVZS5OcfMozVZ/Ees6FqupTXmvaZbxXl9cCO81KOc28KwhQkCp54UO4YkFdudp+Vj09Esdf0fU7ye003VbG8ubb/Xw29ykjxc4+ZQcjn1qXUdW07R4Em1fULWwidxGsl1MsSsx6KCxGT7Uef9dP8AL8e2geX9df8AP8O+p57H4zu7bU7jUNRDWkbWf2loZ3lZbU/Z4WKlAQMBnOcjjk5Xk1Vs/HusarBYzzahp9tFFqk1nM6RhUvV+ymSMoUncLuJwMOxJweOVr0c6/o41MaadWsRfMQBa/aU805GR8mc9CD0rKufiF4Ztry4tTq1rLJaPElz5c6EQb2K5c7sAAg7vTj1odnfz2+8L2WvQ50eOtatbNbaDTY7u8h08akIkWRvNtvIBADMxzJ5x28k8Anqc1r+A/Ft/wCJ9DvLu8itZWt32xyWcsBWb5c7dsU8wUg8cvz1wOlbr+JdCjtrO4k1rT1gv2C2krXSBbgnoIznDH6Zpl34s8O2FxNBfa/pdtNbrumjmvI0aMZAywJyBkjr6inLVsUVZJHm5+IusRR3uqRXWn6gy2dvvitfli09nlcOJlkmVdyAAMS8ee4WtSLx34ju9An1KGPS4fsmky37ggTi4IaRU2tFOyIp2KxG58crk9R3ja5pKalBp76pZre3KeZBbG4QSSr/AHlXOSPcU298QaNpt4lrqOr2Npcuu5YZ7lEdhychSckfK35H0o0RS3v6fp+f/DHJWHivxAniH7HqjaZLbxaj9gl+z2siOxa1+0K6kyNjA+UjB3dcr0rAHxJ1TVftAtdT023tYLqylW/EAEfkyT7HjbE7EFeAxbYRyNgyDXp0Gt6Vc20dxbanZzQSxNPHLHcIyvGuNzgg4KjIyegyKyJvHuhQX01lJcqt0gmZIXljQzCJFdipZguMOMEkDhjwATTXxLTb9N/x/wAhPWNl10/r5HIW3irUx4jt4Zr62FtOIfJsneUOx+2Sxu4cy5YABcggr8yjAHB3vAvjaXXkvk1q70/z7e4WFTZ+X5JZsgIsizyh2yOh2N0ygyK0LX4heG57jUUm1O0s4dPuhaPc3N5Akck2MlF+cnI5HzAZwcZxV2/8SeGbaVoNU1nSYpIMStHc3UamPGGDYY8dQc0k0l/Xl+gnq7r+rafmbNFZtv4i0S7S5e01jT51tED3DRXSMIVIyC+D8oI5ye1WrDULPVLKO80y7gvLWQZSe3lEiP8ARgSDSGVNV/5CWi/9frf+k81adZmq/wDIS0X/AK/W/wDSeatOgDmfBf8AzMH/AGG7n/2WumrmfBf/ADMH/Ybuf/Za6agAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMzQP8AkGy/9ft3/wClEladZmgf8g2X/r9u/wD0okrToAKKKKACiiigAooooAKKKKACuW8RR+d428Mx5xvW8XOOmYhXU1y3iNtvjbw025lwt4dyruI/dDkDv9KUrWdxrfQpT/DlLrR/7MuNTzbSW9rBNttwGYQIwBBLELliCeDwCO+aYnw4J8U/2tc6p50cjrPPbg3MY84RCPeircCNRgdGjcjJG7pjlotdls9G1ldC8Qtf30WlyTyXy6jLexxyJtLNNBJg2rnLBUVscNlflArW0r4g6/q/ie60iyt9Odlil8gtJCCdqnZPtFyZXjc7cARjAYHe3WrerbfXX+vuJSSSS22Om8MeE7nQb0z3WoW92qWUVjAsNl5BWKNmK7jvbc3zckBR6AVmf8K6medFn1WB7S3ieG3iWxw4Rp45iHfed5zHjOB97J5znJ1X4napH4fi1fT7O3gsri6+zx3F0qKIdiDzPM82eFcmTcg+cY2n73StC18YeIri6huZYdMt7MTWkE1qQZJN00asSJ1kKYUt2VsjuOtLW9/61/4cNEv66F7VfBV7fard3EWqotlcXH2xrT7ORI0v2fycCbd8q4wfuEgjqRxUHgLStet72/u/EdotoWtbazhRUjQlYvM5xHJIMfOBnKk4PyrwKh8I+O9T1m2vvPsF1e6trhY3TRvs/lxKc8+a10yvjbyMo/IzGM03WfGyrq13deH72K6SwtPJukcsY7OVrhE3zIMEbV3tzglVPIBzQtPd7/5f0hybf9ef9MTS/hYmnR3ELam1xEUSK3MpuZHijWVZCrCS4aM5KD7iJ9O1aOp+Db+41e6vLbVIxaTXP202ZtcyNMLfycebvwFIAONuc98cVzf/AAl/iG+vhc6ZqOl3CWVnfP8AaooZGs79I/s7B0QS8H52TdvYAhuucVsjxZrza1KyjTBpqXqWawvG4ly1qs28y79oAY4xs6dxjlSV4/L9f8/x3KV737/0xNE8C6nb6Zp8t9qVqmo20dmiLHY7Y40hydjKJPnb52G8MB0IXqC+L4dzwSvHFq8P2K5uY7m7jexDSu0cpkQRyb8IOgOVbuRtJrFsPiXqN1oYludS0W0k+2+RNqkkIextl2Fh80dy6uSV2gmSMjIyoJAN+Pxr4iuWjuIo9OhtYba0muI5IJC83nTyREo28bBhAwyrdce9W7uV/O/3maSS06K33Oxt23hK40pra50q6tzdWsF1GgmgIRzPMspLbWyMbSPfOfajxl4NbxS9lPb6g9jc2gkRTvnCOj43AiGaJj90fxY65Bqr408X3nhvXNIt4ZrFLW7fEqOEkuJPmAxHGZ42PB6qJDnHy1m3vjjxANRvdMsrSzjutPuYre5muIJDETPcIkBQBxn90zMwz1wMioS5rL+v61LWjLWq+Cp9P8GavY6ArzXt3LBJZGIhDayRxxRxuWkcllUxBjkkkZGGPWzb/D8Ws1osN8n2SCOzDQyQF3d7eRn3by/8RY5ypOec9qw9f8a61aaDLb3N/pOn3IS9ia8eKREuJIjtWOEeZlJGB3DLORtOA3a1N4w1u0sXnlvNJsrJb1LEXl7BIy2w8kOZpm8xQQSQgHy8kEt2qlJvX0f6ImSVuV+a/wAyTVPhauoeVs1Rk+e5WeNvtCRywzTNKU2wzxcjdjLFgcfdrW/4QiIanHdrdKNl7NdlfJyTvt/J25LZ4HOe/T3rmh4/8STwrPbJpSwxi0Vi9vK32gz3UluJEO8bUIVZADuyDjPO4N1z4j67o+n2O62sGme5uoJ7t/LhgkeGXywi+dcxhGfr99yMH5W5wOLSt6r9WU4t+8/X52/ryNdPh5erqGku/iAvaaWbZo7cW7ruaJVU52yhGUgEjcjMpPDY4rT1zwYmtalc3jXaxGf7CMGDdtFtcGbGcj72ce2M89Km1S/uXuvDsJL2q305adUfJG2FpAm5evzKM44IBHINcl4Z8Q6fp2sSvNrs2qKtrJJezx6jNceWV5LT2jqTansAmMncCowKLtP53/r7iY2SuvJGzf8AgK7licabrMdpJL9ujlaSy80GK6k3sFG9cMpAwxyDz8vPDb34eS3Mc6Q6skQuIrqGTfaF/kmijTj5xggxKc85BIwOtY+pa1a32mz30viSOLTJdTmNtK+qS2dtcoI0CqLuL/VqHzgA4b5uDitnTNcMa+H7x7i6S0uIbmK4N7OGASMFhOW4BX5eHwNyuCaUW1r5fmrjcm5J9bv772J7vwTd/a/tmmarBBd+Zcc3Nj58flz7Ny7d6ncPLGGzjk5U0ul+AbfSoYIYrvzI4b2C6XzIQWIitlgCk56/LuzjjpjvS+MtavtJu9BudPu4FtpriRZYXTd9qPkOyRq24YLMoA4OSR6YODa/EXU2srmaCbSdckiELJHpsci75H3brXl3/eqF3E8cZyq9aS0VvT/gf1/nqf8AB/Hf+v8ALTVk+G0M2gjTH1F1VbNbcSQo0R3LN5wbKuCBnggEHrgitLwv4cvfDcCW/wBqt7mOaSWa9lJuC8khChCpmmlYcKQcse2Mc1z1741vLSQul/pdtHOlr5mq3Ikazg3xyMWKGVQASoUfMvLDJJwK7jR7yTUNFs7ufy/MnhV28oNsyR/DvAbHpkA00nG6/ruK/NZ/12IdV/5CWi/9frf+k81adZmq/wDIS0X/AK/W/wDSeatOkM5nwX/zMH/Ybuf/AGWumrjfC2r6bYTa9Ff6ha20h1m4YJNOqEj5ecE9ODW//wAJLoX/AEGtO/8AApP8aANOisz/AISXQv8AoNad/wCBSf40f8JLoX/Qa07/AMCk/wAaANOisz/hJdC/6DWnf+BSf40f8JLoX/Qa07/wKT/GgDTorM/4SXQv+g1p3/gUn+NH/CS6F/0GtO/8Ck/xoA06KzP+El0L/oNad/4FJ/jR/wAJLoX/AEGtO/8AApP8aANOisz/AISXQv8AoNad/wCBSf40f8JLoX/Qa07/AMCk/wAaANOisz/hJdC/6DWnf+BSf40f8JLoX/Qa07/wKT/GgDTorM/4SXQv+g1p3/gUn+NH/CS6F/0GtO/8Ck/xoA06KzP+El0L/oNad/4FJ/jR/wAJLoX/AEGtO/8AApP8aADQP+QbL/1+3f8A6USVp1zmieINGi0+VZdXsUY3lywDXKA4M7kHr0IIP0NaH/CS6F/0GtO/8Ck/xoA06KzP+El0L/oNad/4FJ/jR/wkuhf9BrTv/ApP8aANOisz/hJdC/6DWnf+BSf40f8ACS6F/wBBrTv/AAKT/GgDTorM/wCEl0L/AKDWnf8AgUn+NH/CS6F/0GtO/wDApP8AGgDTorM/4SXQv+g1p3/gUn+NH/CS6F/0GtO/8Ck/xoA065nXePHvhbP/AE9/+ihWn/wkuhf9BrTv/ApP8a5jxJqWj6l4o0JP7VtTbeXeRzyxXK4jDxBRlgflJ7Une2g1vqdIPFfh02U14Ne0w2sEhimn+2R7I3AyVZs4BwDweafJ4j0mGJribULSOzW3W5N49zGItjEgHO7px1xg9jXmkPhqz0eK1/s3xVpFzdpeQFLm5uJZhDDEsm0Ok1027BfpGY+vAHbX/sXRokhktfF2lrdwBZI3l2PH5omklLGMSD5MyEBQRjAw2RT/AM/0F/l+p1ll4w0K9trab+0ra3F3cS29qtxOiNcNG5Q+WN3zAlcjHYipJ/Fvhy1MwuvEGlwmB/Ll8y9jXy25+Vsng8Hg+hrz2bwZoczQu/jLTmZjIt2guZYYpo3nebaqQ3UeDmQj5t44HFb0en+Hkgtoz4k0xvs91eXOTJHybjzP9vqvmde+O2abtZtA99DqV8SaG9nd3aazp7W1kxS6mF0hSBh1DtnCn64pbLXbDUr4W+nzLcq1qt0lxC6vFIjMVG1geeVPtXFDSdNtdLFvpnjPS7aZbSzthI20qRBuBJCyqw3b/wCFlK46mrfhGx0PwqefFdjefunjy9wu47p5JclmkYk/vMZJJOMk802lf+u3+Yk3y3e51EHibQbmS7jttb06Z7JS10sd3GxgA6lwD8o4PXFI/ibQY9Lh1J9b05bC4YJDdG7jEUjHgBXzgn2Brib/AMNeG7/TYrRvFVjEI4rhN8M6xktJcJOGysgYYMeCAQTk8imWmg6XY2cTW3i/R/7QDTiee4eS6imWYIr5Sa5dt2I1AJcjr8pBIqen9f1/XUZ29z4r8PWYuDd69pkAtSouDLeRr5JJIAbJ+XJBAz3Bp9v4h0251N7GO4j8zbGYnLrtn3qzARnPzHajHjsM1yP9naTa2NsNK8WaPDe2l9LdwyzxxyRHzFKlWjWROitgFWXGBxjisrVdH0+y8LXVpofiO0m1Cf7OtvcR3MEX2WVHZjNy+Nvzn5QCccAGjp9wtb/eeg/8JRoTXgs4tZ0+W8aIypbJdxmR0GckLu6cHnpwaq6Le+G4NSmtdOvbVdU1AC+ntWvlluH3KMMRvY7QMAY+UDGOK5aPQtDtNWgm0vxXpthYxWq27W8E7Bp9sewGQ+f5b8Y5Me7gfNUuk6Zpek+IrXUIfGGmx20NukUttBMyfamWMIGkBnMZ6A5EYbgDdgEFq13/AF3/AOADv0/rb/gnU6n4jFibxbPS77VJLIKZ0szCCm4FussiDIABIzn5lrNj8cyzQae0PhXW5J9QjeaC2D2YcxKEPmEm42gHzFwN27rwKjtb3SYNS19W1rTvs+qMsyTfa4ztYxLEy43Z48tTn/a9qx9e0TQtYtdDi/t7wvcf2TbNb7NXs0vYpMqg3hPOTaw8vrk/eNJf5frf9CtLr5/8A6mPxfZjXItHvbW6sdQlsvtghnCHAywKbkZl3jYTgE8AkE4OLel+ILTVWt1hSWJrmzjvYhKAN8bfQnkZGfTcOtck+laBc2siXPiTR4JTYQ2kLacEt0tXiaQpJEpkbbjzMbckYBHIOKtaU+k2GraSX13T3g0jSfsSTfao189mMe47dxxgQjr/AHvaqVr6/wBb/wDAJe+n9bf8E3LHU9P8S3V7bfZbhW0m8CF5RsBkXnchByR1Ge/zA9xW3WRN4j0lmi8jXtKRQ+ZQ86MWXB4GHG05xyc9DxzkSf8ACS6F/wBBrTv/AAKT/Gp6DNOq02n2lxdfaJ4Flk8pocvyNjEFlweOcDPrgVV/4SXQv+g1p3/gUn+NH/CS6F/0GtO/8Ck/xoA0lUIoVQFUDAAHAFLWZ/wkuhf9BrTv/ApP8aP+El0L/oNad/4FJ/jQBp0Vmf8ACS6F/wBBrTv/AAKT/Gj/AISXQv8AoNad/wCBSf40AGq/8hLRf+v1v/SeatOsC61fTb/WNGisNQtbmQXjMUhnVyB9nm5wD05Fb9AHmVjqnh3T9cmtNe0yO5uNW8QXVrbzvbJIsZAUgMzcgEnAxnk10Gly+ENW1C/s4NIsYpLK8Nlma0iUTyBN5EfdsDdn/db0zWHbeEh4nbV2N59le21e+ETeVv2yN5ZR+o+6yA47+1a6+BLm0WGXTNXjivILmO5SWe08xWYQGF9yh1JLbmbIIwT37i8xl0L4HbULexC+HzeXSb7e3Ag8yZefmVerDg8j0NOtYfBV+7pYx6DctHN9ndYVhcrLgnYcdGwDx14rKs/h7dWl9psset+XHaW6w3Bt4pYpLvaCPnxN5RHPQxsR2YdnQeBdStrS3WDWbJbmwMK2Mx0ofLHEGAWXEgaQkOeQyDPIUc5P6/r5CfkW7ibwTaTzLeWujW8EMCzvdzRwpAAXZMbzxncpFTOPA0UtlFIPDySagM2aN5ANyPWMfx9e2ayx8PLqJrC6t9ai/tDT/milmsd8bPvlYlow4JGJmGAwIIBz2pU+HlxBcaZLZ6wttJauz3M8EMsck+6Uysg2TBAm5mAV0kwDxzzQvMH5dvxLlhN4LvtNmvTY6TaxwCRphcwwo0SJI0ZdvRSUbBPpSiXwSXRltNHa0e0a8F8IoTb+UrBSfM6dT16e9ZSfCxYtJ1Kwh1iVI9QnF221XTbcLMZFcFJFYDBVSqsudoIKmkf4WrNpH2WTVXSfYWM0TXPzS+ckocs9w0uMoAQJAecgrR1/rt/n/Wui1t/X9f19+qbrwF9ssbZU0J21CCS4tnRISksceNzBuhGDn6A+hp9u3gy+ew/syy0jUIb+SSOG4s4oZYsopZssPoRxnms5Ph7e22nWsen61FbXcSXKzXDW81wJTMUJYedO7g5jXOXbI3YwSCLXh7wLNot8t3c6sbyX7dJevmOTlngERUGSV2AGMjLHA47VWn9ev+QO9lYvtbeDF1VtMaHQhqCR+a1oUh81U/vFOoHvjFV4ZvANxp9zf28nhuWztTi4uEaBo4T6Mw4X8aq3vgS9v/Fa6tca5mCGaWSC2EDjaJIWjKtiXY2N2Q2wNwQSc05vATRJC9jqEUNxbW1nDAz2m+NXt/MwzIHG4HzPuggjGQc9JW2vl/wfuG99C/otn4Y17Tft2n6NYNAZZYlY2sRDbHZCwIyCCVJB9MVf/wCEa0L/AKAunf8AgIn+FN8N6M+g6KLGW4S5fz5pmkSHylJklaQgLk4A3Y69q1abtfQDM/4RrQv+gLp3/gIn+FH/AAjWhf8AQF07/wABE/wrTopAZn/CNaF/0BdO/wDARP8ACj/hGtC/6Aunf+Aif4Vp0UAcdpNnoAuk0+60W1aaeW9kjme0jKFY7hl2Z65AIwPQe1TWc3gq6isGks9HtJdR3GzguY4EluFBwGRerAjBGOcEZx0ptx4ffxD4dMVtfNp9zDqN20dyibioaaVHGMjqjMAc8HB5xiq2sfDiDUdetb61vWt7aOGG3ms2kuQjpExZAoinjUEZ/jVxwOBzlrzB+RowL4Hurma3th4fmnt1ZpooxAzRhcbiwHIAyM56ZFS3Nn4OsltmvLfQ7dbohbcypComJIAC5+9ksOnqPWsLxB4HnutE0nRrEykLfSPdXcRWJVt5HZpo2Bbcd6uV+XPOCcYrqrvRludWsL1JRF9iimjRBGD98KMg9sbfTnNLpcOplo3gSSG6mjPh14rN/LuXUwFYHzja5/hOeMGpLOHwVqF4bSwj0G6uREsxhhWF3EbDIfaOdpyMHoaxLL4bXUdxNPqevfbZZjabs27hcW84lGFaVgpbGDt2rnkKOQbumfD9dM8ZSa0L954DPNcxW8slyWillzuI/f8AlYwxGPKzjv3pq3X+v+HB7aG9/wAI1oX/AEBdO/8AARP8KP8AhGtC/wCgLp3/AICJ/hWnRSAzP+Ea0L/oC6d/4CJ/hR/wjWhf9AXTv/ARP8K06KAMz/hGtC/6Aunf+Aif4Vz2s6HpMXjbw3BFplmkM32rzY1t0CyYjBGRjBwema7SuT8URzTeMPDkdrMIJ3jvVjlZN4RjCMNtyM4POMihjW43Tbjwbqban5el6fBHpkpjmluLWJEIGRvU903Ky5OOUb0rPHij4aPMRA2gzQpci2luYxbmGFjE0oZnzgLhCM/3hjscS/8ACr7K2tHt9M1G8iSeyNndC7uJbtZlyGUhZJCEw244XA+c8Vpv4QeTxT/ar3sRtxfJfLbG2ywcWzQEb92MYKsPlyCD1zw9BLrcVl8DpIsbjw+rtCbhVIgBMWM+YB/dxznpVdbnwPLLAYLbRprWe2mulvoo4Gt1SJkViZBx1ce3B6Uy18DTWGkXltp+qpDcz21vAlwbQME8oseV3ZIO4jAII5wQeRi3Pw3v9P0eeazv21O+RpJo4mVv3kjywSfellYsAYOFd+QwUsuN1CtfXYa6HRwL4Mu1ilsrXRLq2lR3+0wi3aNQgBPOcnhgeAQO+MjNnTdP8JazZLeaRaaLf2rEhZ7WKKVCR1G5QRXO6V4R1y/0ya71O6TStTnluZABbI2wyiMAlFkZR/q8lQ7fe+9nmtjwv4Y1Hwy84Oow3yX1411dtIku5SYlUBC8jnG5M4ZjgHA6Cj17fiT0+Y69PgTTbp7bUT4dtLhEMjRT+QjqoGSxB5AAIOfSpltPBzwmVLfQ2jESTFwkJARyQj5/usQQD0OOKZd+EUutabUDcqGbUIL3aYcn91GUCZz7k57elYt14Hnk1rw5bxmU2Onh3vZwVSO4UP5kURTJYkSBWzjGARnnFJeY35GjcXHgiLzRb2mj3ssFzDazw2kcEjwvJII13qPu8tznnAPWn7/BMhuEs4NCvJrZxHNDB9nLxncFwwJGMFhwee3UgVk2/wANr3+0Teah4hN1J+5Axbuo2xzpMPlMrKrHYQSiqDkHbxzQ8PeEfEFzK9trcK6fa2dqlpayeXGzOqTrIOUkYvwn32EZO77g5y1ayv5/1/X/AA49E7eR11raeDr7ULmxsrfQ7i8tMC4t4UheSHPTeo5X8au/8I1oX/QF07/wET/Cuf0zwTqmn+JX1qTXo7mcQTW8SSWsmxUeRHBKedt3DbglAm7IyOK7Ol0QdWZn/CNaF/0BdO/8BE/wo/4RrQv+gLp3/gIn+FadFAGZ/wAI1oX/AEBdO/8AARP8KP8AhGtC/wCgLp3/AICJ/hWnRQBmf8I1oX/QF07/AMBE/wAKP+Ea0L/oC6d/4CJ/hWnRQBmf8I1oX/QF07/wET/Cj/hGtC/6Aunf+Aif4Vp0UAZn/CNaF/0BdO/8BE/wo/4RrQv+gLp3/gIn+FadFAGZ/wAI1oX/AEBdO/8AARP8KP8AhGtC/wCgLp3/AICJ/hWnRQBgXWkabYaxo0thp9rbSG8ZS8MCoSPs83GQOnArfrM1X/kJaL/1+t/6TzVp0AeYL4kutBbVI7e60/To59ZvWa+1NGaEMvl7YcKyne+44OT904VjxU1z8RNTh1GeNJNKMiCUf2V5Uv2qNUhZxcMSw/dEgDBjX7w+bPFa/haXUkm14WFpazR/2zcZaa6aMg/LxgRtx05zW/5+u/8AQO07/wAGD/8Axml/X9f1+Oo7rQ5VfEnincunvNpBv5ri2VLgWcvlRpNG7kGPzcsymPruAOegrJm+JmuwatpNk1hZZuFAkLSQwrdv5zxsITLcIVxs3YCyn5gOOCfQPP13/oHad/4MH/8AjNHn67/0DtO/8GD/APxmqvrciztv0/pnAan451ifT75rfWNGsZLeaJpofIkabTUFyiMLg79uChLZJj4BwGHzDQtfGOqQzW1pHDBI2p3s9vYuRK4Dx3TrJuYuePKG9QCB8rAcYA6/z9d/6B2nf+DB/wD4zR5+u/8AQO07/wAGD/8AxmhOySLeqaOV8HeOdV8Q+Lr/AEy+sreCGASExiWATWxVwqh0Wd3bcMnJjjxgdc5qi/inVrK+1VH1HTbm4tZ74xiZ2gS2RVjMaygy7SMNnLbeOhXJNdx5+u/9A7Tv/Bg//wAZo8/Xf+gdp3/gwf8A+M1PT5W/4IdfmefR/E/UTaaHcNc6aY7uZ4rjbDEZJiHA/cxi8IdcH70bTHP8PBFacnxHnU3VvawW97qVmmoPNp8GfNXyHxCCM/KXUg89c5HFdd5+u/8AQO07/wAGD/8Axmjz9d/6B2nf+DB//jNU9VYS0Oe8FeMdR8Q+GtRv7m3tbmS0LeU1nLAVnIXdt2xTzBSDxy+T1wOlc9YeMNQvdSurn+1dP1EY04KtnJLFBCzyzBkYeYcMMAMTwdoyoxivQvP13/oHad/4MH/+M0efrv8A0DtO/wDBg/8A8Zo639P6+Yvstep5/YfEvUbrQxLc6lotpJ9t8ibVJIQ9jbLsLD5o7l1ckrtBMkZGRlQSAbr+OfEEtnJdwx6dbw29jb3ExmgkYfvZZIzLneu2NVQSYIJK5GR1HZ+frv8A0DtO/wDBg/8A8Zo8/Xf+gdp3/gwf/wCM0DWm/wDWp5rP8RNX0jSXuYbqx1KO41KZTqYaMWgVUi2qnnXMaqH3Ej942MHAate98a+IotF1bVM6Np8dlJBCIbtlJRniikYmVp442x5jKBuUHg7ux7Pz9d/6B2nf+DB//jNHn67/ANA7Tv8AwYP/APGaXS3p+gLT8fzuHhvVDrXhux1FzlriIMx8rywT3IXe4A9MMwI5BI5rTrM8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/Gabd3cS0QaB/wAg2X/r9u//AEokrTrnNEm1kafL5VhYsv2y5yWvnU5898j/AFR4zkZ7jnjpWh5+u/8AQO07/wAGD/8AxmkM06KzPP13/oHad/4MH/8AjNHn67/0DtO/8GD/APxmgDTorM8/Xf8AoHad/wCDB/8A4zR5+u/9A7Tv/Bg//wAZoA06KzPP13/oHad/4MH/APjNHn67/wBA7Tv/AAYP/wDGaANOiszz9d/6B2nf+DB//jNHn67/ANA7Tv8AwYP/APGaANOuZ1z/AJH7wt/29/8AooVp+frv/QO07/wYP/8AGa57WZtWPjbw2ZbKzWYfavKRbxyrfuxnLeUCuB0wDn2oA7Siszz9d/6B2nf+DB//AIzR5+u/9A7Tv/Bg/wD8ZoA06KzPP13/AKB2nf8Agwf/AOM0efrv/QO07/wYP/8AGaANOiszz9d/6B2nf+DB/wD4zR5+u/8AQO07/wAGD/8AxmgDTorM8/Xf+gdp3/gwf/4zR5+u/wDQO07/AMGD/wDxmgDTorM8/Xf+gdp3/gwf/wCM0efrv/QO07/wYP8A/GaANOiszz9d/wCgdp3/AIMH/wDjNHn67/0DtO/8GD//ABmgDTorM8/Xf+gdp3/gwf8A+M0efrv/AEDtO/8ABg//AMZoA06KzPP13/oHad/4MH/+M0efrv8A0DtO/wDBg/8A8ZoA06KzPP13/oHad/4MH/8AjNHn67/0DtO/8GD/APxmgDTorM8/Xf8AoHad/wCDB/8A4zR5+u/9A7Tv/Bg//wAZoA06KzPP13/oHad/4MH/APjNHn67/wBA7Tv/AAYP/wDGaANOiszz9d/6B2nf+DB//jNHn67/ANA7Tv8AwYP/APGaADVf+Qlov/X63/pPNWnWBdS6k+saML+0tYY/tjYaG6aQk/Z5uMGNeOvOa36APJ7iDUby/mtNMjknaTXb9ngTWLjThIFRSMywgscHoCMVFL471nwz4Z0eOLyp5J5Ljzpb+4RhbukmBaGW4nhJcZ27yWYhM7Gzx2/gv/mYP+w3c/8AstdNQtBnCW/i/XBrSyXyWEemSXkln9nSF2njK2xn3GQOVbkFdqpzwQe1ZOhePb7xJrcFsbm3kgjv7d4rmxwiTxSJPlCFmk3bTHzkqc9UXHPqNFO6/L+vmLpb1OD8U+PZ9E8ZWGk2clpKrzQR3NtJGPOCSuEEgYyqQoJ6rHJzwSvWqsfjbxFb6W13ff2W4uLJbuBo7eRFtF85Y2aXMh3qqvvONnCke9ejUUkH/A/r5nCaJ4ivz4H8SaxFe22sXFrNPJbS24ZoJdsSldi7mIQnnAY9TgnrSweN7rXdbitPDV5pc1pJdiEXnltOpQW4lbbtcBjnK5zge5GD3VFP/gCtp83+J5vp/i7XitpLF/Z40+L7Ck0Ukcsk0huJTGSsjScbeDyGJ5HHWq3/AAs7UZ9d1Cy05tOuYljJt5PKx5LrPHE0cgExYtiTOCkRHGAwOR6jRRp+YzjrTxHraeNIfDF9FbTXKr9rmu4bZ4omtdmMqC7YfzvlxuPyjNZ2reKb9/HVvpQ1Cyto4dQWP7Au9bqaPyGbzSQ2DGWOMbcZX72eK7aDSbK21W61KKJvtl0qpLK8jN8q9FUEkKvJOFwMknqc1cpb2Dvb+v6f6HlFr8R9WtHsYDFZ3KyaOl1DZW7efcyyeRv+cmcyoNwxkxPnjL5OK0tP8bazqWLXTdQ0PUHkuYIU1O1tpGtlMiSM0ZTzSS6eWM/OPvDIWvRaKpu7v/W4Py/rQ8qPjrWP7Xnu1mtL+a00y8kbSLIMj28iywqFmDSEFgCWz8vBOODuN/w3428QeIlsUiOkoJZZt90PLmSaOMRk7VhuZFjbLsvMjYwGx/DXo1FT0t/W9w6nG/D/AMXXfiddRj1GWzluLOUKTYKjQqDn5RIk8oc8d9jAYygyK7KiimwOFvtVfw1bwa7JJO1kl3f21xAjZUs08jRtt/vb1CD/AK6Vl3vjDX/C+s6PoM0EVxJNDFJPJd3EKtdSyOfMSJ5bhCNnYKknBUYXjPd6B/yDZf8Ar9u//SiStOhaA9Tzy78beINL0WLV7u3s7u3vbiaztbe2tnDxz7ykAdzIQVZlwTtXBYemT0eqalq1tqmkWNtJZxtcRyS3ckkDycRhCwRQ4wTuIBJOODg4wdS90qz1G4tJr2JpWs5fOhBkYKHxgMVBwxHbIODyMGrlLoHU8u074mapqbahHYtptxiS0FpciHEYWecRMrKszMWTPOfLOeCo4NaGgeOdavvH8vh/ULS0VYWkjkCtDFKoQHEwQ3LSlHIGF8oYDD52616DRTVkD1QUUUUgCiiigArlPE7FfGPhxlJBEd6QR2/ciurrmNfdU8deF3dgqqLwlicADyhzSkrpoa0Zweg3+u6BaWWo3UF08kmivdwwtrl1qA1SQRhtoWYBYXH3iF6gkDIBxr6L478Ra/p9ktkdIS4utRNqLwrHPFtEEkp/dwXUmGBQDBk5BzgV20Xirw9PNbxQa9pkkl07R26JeRkzMv3lUA/MR3A6VJD4j0O5vLm1t9Z0+W5tVZriFLpGeEA4JdQcqAQQc1bd2/68yUrL+u1jg5videx3+gwKbAy3ZtlvbQR4cCZwnmIzSqQgJ7JJzwSvWthdWurf4f2t40jzzNqaRFpJXBKm92dVYE4B6Zxxggjiugt/E+k3z2H9mXkOoQ38kkcNxZypLFlFLNlgfYjjPNUI/H/h46hq9tcaja2kWkSpBc3VzdwpEJGGdnL7gR0+YAE5AJIOF5dd/wAv6+Y1a9/kcvp3jnxPMttNef2QY3ttOu5UitZVJS6lMWwMZTgqRu3EEHONo+9Viw+Id299qX2u50yaGza9EtvawyGezWCRlSSX5zkOF6BV56EjOOsu/FWm2V1FFcSBY5JvKFx5sZjX9y025juyq7VPJA7duact7oHh20kje/srGETsz+fdKoEkhMhyWPBO4tj06cU5WeyKdrfd93X8Tz2D4lapc6XdXhWyuZrB7kxTQkpDcKtqZUYLHPIpUnjlj06KwwNq48ReLYNV+x/adFI+2RWW/wCwS/eli8wPjzui9Nufm9Vrqn8S6T9mv5bS9gvm04E3cVpMkskOOTuUHggZODzxV+a8t4LB72WZEto4zK0pYBQgGd2fTHNS2t/T+vmSk9uuv9fI811T4l63Yvo0aafZlruAO7ySQxJcy+YyGKNpriMqflB4Ep+YDHc2Nb8U+J0s9Ue3n0+GFhf29oI7VzNC8EbMrlvM2tnaRgKOcHJ6V2uneJNH1XS4NQstRtpLedI3RvNX/locIDzwSeAO54qHSPFuia1ZNcWepW2YwvnQtOnmQFjhQ4BO0k9AeuaLPVPfX+vkCa0kttP6+ZQl1Oa4j8KpHfRTxahIHmurUlUn2wtINpBOFZlBxuOQCMkE1y9n8SNUms9SF1daPFNbXaQvdoiy2dkjFgXkkjuG3Y2gYbyTyCQBXb6jqekPfW9peyI5Rnn80SALbtCFY7myCpw449Cc8Hl0firRJ7eK7tdUsbixkSR/tkV3E0KhMbstu5xntnHfHFNu7uJKyscV/wAJ74hnsftVmdIkht41d5hbylLwNcNCHi/efKrABgTv9ASDmjX/AIg67oOmwiaGwedbye3nvykcNv8Au9u0bZrmMKX3cfvGI2nAboOxHjPw476csGtWM66lM8Fq8NyjrI6qSwBBxxjH1IHeph4p8Ptpr6guu6YbKNzG9yLyPy1cclS2cAjB4pa/16laX/rt/TPOr/xxrlhNqNzPNZtcRSrNBpzO2bZTpzy4Yxy4kQupGcbSVYjnG3csvFniJNfNnqH9m3EMOo/YJFtraSN5C1r9oVlLSMBj7hBBz1yvSt+78deF7O1uJ5Nf050tZY4bjyrqNzC7ttUOAfl59fQ+lIPGujHUGsBcxfbVUv8AZvtMO4oJvK3Z34+8Omc9sbvlq7p7L+v+G/zHdW1/r+mcJY/FLXr3QNTvXh0izktfLYm5ubZRbFmw0Tp9syXA6F2hycggYxXXy+J76XwDp+saf5Bu7yW2hDXEBWMGSZYy2xZG4+YkYcg8YYg5rUufFei25u0i1C3u7izeNLm2tpkeWEu4Vdy5yvLd6s6jr2j6RNBDq2q2NjLcHbClzcpG0pzjChiM8+lSrfkT1ucBD8RdeXxFqmmXVnZbrGC4YoWhjceUhIm8v7S0pRyBhfLGAw+dutJH8RtReyR21Xw+lvJLGG1swyfYrUsjsYnHmjLgqFyXUZcZAPynu7rU9DvHvtIutRsnlS3Y3dr9pUSRxEcswByox34qjL418M2Fnaumr2T2LTm0NzFdRtDbssbORI+7C8IR65IpLb7vzB76ef5HJan4w8TX+h3VxY3Wm6RHa6fb3k001rJIW3yyKWUmRNibYw2SDw340+H4k61J4m1Owj0y2uEtYp3jt0mgWZ1jUlJQPtDSMkhAwBCMBgdzd+2u/E+jWnkK2p2TzXCo8EIu4leZWOAyhmGR1OR1wcZqtZ+N/D99Zvew6paCxjWQyXb3MSxx+W+xs5bI5PXGMEc8jJ1+8Lq33f18zJ8Ea/caxqOs3FxrFjqsUUVuUl04MIFyHLBVLvhgRg4PJHQHgc2nxU1O4s9YltLjRmjtkhmt7uby4otjuVZCGuQGdcAYd4Tk8qOM+p2d7a6jZxXen3MN1bTLujmgkDo49Qw4Iqah7ijojmbDVDrWm+F9Rc5a4uCzHyvLBP2ebJC73AHphmBHIJHNdNWZqv8AyEtF/wCv1v8A0nmrTpt3dwWiOZ8F/wDMwf8AYbuf/Za6auf1jTtLhvrAnRtOle+vPLmeW1VmOUdyc465UcnPerv/AAjWhf8AQF07/wABE/wpDNOisz/hGtC/6Aunf+Aif4Uf8I1oX/QF07/wET/CgDTorz34fz2HitfEB1HQNGj/ALM1mewh8iyUbo48YLZzluecYHtXX/8ACNaF/wBAXTv/AAET/CgDTorM/wCEa0L/AKAunf8AgIn+FZXhjTtJ1rw5a391oelpLNu3LHaIFGHI4yD6UAdRRXLa9p2k6WdN+z6Hpbfa7+K2ffaIcK2ckYA54rW/4RrQv+gLp3/gIn+FAGnRWZ/wjWhf9AXTv/ARP8K5T4kSaf4P8HPq2maBo8s63EMQW4s1ZcO4U8DBzg+tAHfUVlJ4c0No1Y6Lp2SAf+PRP8K5jxSdP0TxR4W0200DR3h1i9kt7hpbNSyqsZcFcYAOR3Bo6h0ud5RWZ/wjWhf9AXTv/ARP8KP+Ea0L/oC6d/4CJ/hQBp0VwHxNlsPBfgC+1zS9A0eW5t3iVEubJWQ7pFU5C4PQnvXVReHNDeFGOi6dllBOLRP8KOlwHaB/yDZf+v27/wDSiStOvPfH09h4Vbw6NP0DRpP7U1mCwm8+yU7Y3zkrjGG44zke1df/AMI1oX/QF07/AMBE/wAKOlwNOisz/hGtC/6Aunf+Aif4Uf8ACNaF/wBAXTv/AAET/CgDTorM/wCEa0L/AKAunf8AgIn+FH/CNaF/0BdO/wDARP8ACgDTorM/4RrQv+gLp3/gIn+FZniTTNI0fwtqmpW2h6W81naSzxrJaIVLKhIBwAccetA0rux01FY9t4f0Sa0hlbRNNDOiscWiYyR9Kl/4RrQv+gLp3/gIn+FAtzTrlPE0H2nxl4cg3bfNjvU3YzjMIGa2P+Ea0L/oC6d/4CJ/hR/wjWhf9AXTv/ARP8KTSasxp2dzlbv4Yx3F/p08epMsVtaW9rcW5a5RJlhOVKrFPGoOST84cdOOub0vgaQWm2x1Nba4V711m+yhsNcS+ZyN3O3p159Vrc/4RrQv+gLp3/gIn+FH/CNaF/0BdO/8BE/wqm29xL3VZf1YwvD3gWbRb5bu51Y3kv26S9fMcnLPAIioMkrsAMZGWOBx2p2r+C7y/wDtf2LWvsi3l61xMPJfJRokjKh45EdWGzIYNjnBU1t/8I1oX/QF07/wET/Cj/hGtC/6Aunf+Aif4Unrv2t8v6QkrHKf8KvVtBh0yXV2KxxrGZFt8EgWbW2eWP8Ae3fhj3rRsvBt4NSh1DWNWhvLmO9W7bybIwocWzQBVBkYj727OTzx9Nr/AIRrQv8AoC6d/wCAif4Uf8I1oX/QF07/AMBE/wAKpybd2VfS3yOV0f4fTeGLfUJLK6bUpDZva2Mc01xujVjnDGSd48ZAJ2InTgdq6jR9NurHSDpl1LC8EMaQWrxht/liJVy+Ty24N04xjvmnf8I1oX/QF07/AMBE/wAKP+Ea0L/oC6d/4CJ/hU7q39f1qxdebr/X+RzEHgDUoo7OE69bmCJbITqNPIaX7LJuTafNOzIGDkNzyMdKWH4e3a2Bt59ahZoLb7PYvHY7PK/erLmQeYfM+ZF6beM9zmum/wCEa0L/AKAunf8AgIn+FH/CNaF/0BdO/wDARP8ACndt3/rUSSSsjnJvh/cX1vL/AGlrEctzNJNM8kVnsTe/lYwhdvlBiHBJyDjPemzfDye/F5NqmrQS3d8souGgsfLiO9I0GELseFiGcsck9hxXS/8ACNaF/wBAXTv/AAET/Cj/AIRrQv8AoC6d/wCAif4Uth9Lf1qYWr+Av7Tku9moiBLu9e4kVYDkI9qLdkUhhhsZYN2PY1DoXw7OktFJc6iLqaO7in8w/aXLJGjqiHzriXBG8nK7R/s10f8AwjWhf9AXTv8AwET/AAo/4RrQv+gLp3/gIn+FO/6fhsD13/q5zS/D++RdSWLW44Y7mWOa2t47eYwQOkwlDGN52Gcrg+X5YOTxnGJf+EDnDELqsYSRpGlBtCSS139oG07+MElTkHPB46V0H/CNaF/0BdO/8BE/wo/4RrQv+gLp3/gIn+FLZJdg3Vvmcqvw4vZdZfUL/wAQfaGKNEiC3cAIZ45RlTKUDfu9pKKgOQSOK3PEPhRNfkuna5WFrjTJtPBMO8p5hB39R029O/rV7/hGtC/6Aunf+Aif4Uf8I1oX/QF07/wET/Cmna1un9fqH9f19xyFx8NXt7zVL61vXuhNFdSW9rLLcbknmRgcZn8kD5iP9UDg9eM1e0rwNcR3mnajq1/BNd2jxMY4LPyo9kcMsaLt3t8w84kvnnaAABXQ/wDCNaF/0BdO/wDARP8ACj/hGtC/6Aunf+Aif4UloH/B/EwrbwCtvavCL8Eta2lsGFvjAgmeTP3v4t+MdsZ5qCb4fTTW1xE+pW0m8TiDzLSQCLzJxMCSkysWVgcMrIeh4xz0n/CNaF/0BdO/8BE/wo/4RrQv+gLp3/gIn+FHW4PXf+rC+H9MuNH0O3sby/l1GaIHdcSliWyScfMzNgZwNzMcAZJPNaVZn/CNaF/0BdO/8BE/wo/4RrQv+gLp3/gIn+FNu7uAar/yEtF/6/W/9J5q06o22h6TZ3Cz2mmWcEyZ2yRW6Ky5GDggZ6Gr1ID/2Q==" /></p><p>* see description of selected adverse reactions</p><p><sup>1</sup> Cholestatic jaundice and hepatic necrosis may be fatal.</p><p><u><strong>Description of selected adverse reactions</strong></u></p><p><u><strong>Aseptic meningitis</strong></u></p><p>Aseptic meningitis was rapidly reversible on withdrawal of the drug, but recurred in a number of cases on re -exposure to either co -trimoxazole or to trimethoprim alone.</p><p><u><strong>Pulmonary hypersensitivity reactions</strong></u><br />Cough, dyspnoea and lung infiltration may be early indicators of respiratory hypersensitivity which, while very rare, has been fatal.</p><p><u><strong>Severe cutaneous adverse reactions (SCARs)</strong></u><br />Stevens -Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (see section 4.4).</p><p><u><strong>Effects associated with Pneumocystis jirovecii Pneumonitis (PJP) management.</strong></u><br />Very rare: Severe hypersensitivity reactions, rash, pyrexia, neutropenia, thrombocytopenia, hepatic enzyme increased, hyperkalaemia, hyponatraemia, rhabdomyolysis.<br />At the high dosages used for PJP management severe hypersensitivity reactions have been reported, necessitating cessation of therapy. Severe hypersensitivity reactions have been reported in PJP patients on re -exposure to co -trimoxazole, sometimes after a dosage interval of a few days.</p><p>Rhabdomyolysis has been reported in HIV positive patients rec eiving trimethoprim -sulfamethoxazole for prophylaxis or treatment of PJP.</p><p><strong>To report any side effect(s):</strong></p><ul><li><strong>&nbsp;In Saudi Arabia:</strong></li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>- The National Pharmacovigilance and Drug Safety Center (NPC)<ul><li>&nbsp;Fax: +966-11-205-7662</li><li>&nbsp;SFDA call center 19999</li><li>&nbsp;Toll free phone: 8002490000</li><li>&nbsp;E-mail: npc.drug@sfda.gov.sa</li><li>&nbsp;Website: www.sfda.gov.sa/npc</li></ul></td></tr></tbody></table><ul><li><strong>Other GCC States</strong></li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Please contact the relevant competent authority.</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Symptoms</strong></u><br />Nausea, vomiting, dizziness and confusion are likely signs/symptoms of overdosage. Bone marrow depression has been reported in acute trimethoprim overdosage.</p><p><u><strong>Treatment</strong></u><br />If vomiting has not occurred, induction of vomiting may be de sirable. Gastric lavage may be useful, though absorption from the gastrointestinal tract is normally very rapid and complete within approximately two hours. This may not be the case in gross overdosage. Dependant on the status of renal function administrat ion of fluids is recommended if urine output is low.</p><p>Both trimethoprim and active sulfamethoxazole are moderately dialysable by haemodialysis. Peritoneal dialysis is not effective.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Combinations of sulfonamides and trimethoprim, incl. derivatives; ATC code: J01EE01<br /><u><strong>Mechanism of Action</strong></u><br />Sulfamethoxazole competitively inhibits the utilisation of para -aminobenzoic acid in the synthesis of dihydrofolate by the b acterial cell resulting in bacteriostasis. Trimethoprim reversibly inhibits bacterial dihydrofolate reductase (DHFR), an enzyme active in the folate metabolic pathway converting dihydrofolate to tetrahydrofolate. Depending on the conditions the effect may be bactericidal. Thus trimethoprim and sulfamethoxazole block two consecutive steps in the biosynthesis of purines and therefore nucleic acids essential to many bacteria. This action produces marked potentiation of activity in vitro between the two agents.</p><p>Trimethoprim binds to plasmodial DHFR but less tightly than to the bacterial enzyme. Its affinity for mammalian DHFR is some 50,000 times less than for the corresponding bacterial enzyme.</p><p><u><strong>Mechanism of resistance</strong></u><br />In vitro studies have shown that bacterial resistance can develop more slowly with both sulfamethoxazole and trimethoprim in combination that with either sulfamethoxazole or trimethoprim alone.</p><p>Resistance to sulfamethoxazole may occur by different mechanisms. Bacterial mutations cause an increase the concentration of PABA and thereby out - compete with sulfamethoxazole resulting in a reduction of the inhibitory effect on dihydropteroate synthetase enzyme. Another resistance mechanism is plasmid -mediated and results from production of an altered dihy dropteroate synthetase enzyme, with reduced affinity for sulfamethoxazole compared to the wild -type enzyme.</p><p>Resistance to trimethoprim occurs through a plasmid -mediated mutation which results in production of an altered dihydrofolate reductase enzyme havin g a reduced affinity for trimethoprim compared to the wild-type enzyme.</p><p>Trimethoprim binds to plasmodial DHFR but less tightly than to bacterial enzyme. Its affinity for mammalian DHFR is some 50,000 times less than for the corresponding bacterial enzyme.</p><p>Many common pathogenic bacteria are susceptible in vitro to trimethoprim and sulfamethoxazole at concentrations well below those reached in blood, tissue fluids and urine after the administration of recommended doses. In common with other antibiotics, howe ver, in vitro activity does not necessarily imply that clinical efficacy has been demonstrated and it must be noted that satisfactory susceptibility testing is achieved only with recommended media free from inhibitory substances, especially thymidine and t hymine.</p><p><u><strong>Susceptibility testing breakpoints </strong></u></p><p><u><strong>EUCAST</strong></u></p><p>Enterobacteriaceae : S&le; 2 R&gt; 4<br />S. maltophilia : S&le; 4 R&gt; 4<br />Acinetobacter : S&le; 2 R&gt; 4<br />Staphylococcus : S&le; 2 R&gt; 4<br />Enterococcus : S&le; 0.032 R&gt; 1<br />Streptococcus ABCG : S&le; 1 R&gt; 2<br />Streptococcus pneumoniae : S&le; 1 R&gt; 2<br />Hemophilus influenza : S&le; 0.5 R&gt; 1&nbsp;<br />Moraxella catarrhalis : S&le;0.5 R &gt;1<br />Psuedomonas aeruginosa and other non -enterobacteriaceae : S&le; 2* R&gt; 4*</p><p>S = susceptible, R = resistant. *These are CLSI breakpoints since no EUCAST breakpoints are currently available for the se organisms.</p><p>Trimethoprim: sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as trimethoprim concentration.</p><p><u><strong>Antibacterial Spectrum</strong></u><br />The prevalence of resistance may vary geographically and with time for selected species and local information o n resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. This i nformation gives only an approximate guidance on probabilities whether microorganisms will be susceptible to trimethoprim/sulfamethoxazole or not.</p><p>Trimethoprim/sulfamethoxazole susceptibility against a number of bacteria are shown in the table below:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><strong>Commonly susceptible species:</strong></td></tr><tr><td><p><strong>Gram-positive aerobes:&nbsp;</strong><br />Staphylococcus aureus<br />Staphylococcus saprophyticus<br />Streptococcus pyogenes</p></td></tr><tr><td><strong>Gram-negative aerobes:</strong><br />Enterobacter cloacae<br />Haemophilus influenzae<br />Klebsiella oxytoca&nbsp;<br />Moraxella catarrhalis&nbsp;<br />Salmonella spp.<br />Stenotrophomonas maltophilia&nbsp;<br />Yersinia spp.</td></tr><tr><td><strong>Species for which acquired resistance may be a problem:</strong></td></tr><tr><td><strong>Gram-positive aerobes:</strong>&nbsp;<br />Enterococcus faecalis&nbsp;<br />Enterococcus faecium&nbsp;<br />Nocardia spp.<br />Staphylococcus&nbsp;<br />epidermidis Streptococcus&nbsp;<br />pneumoniae</td></tr><tr><td><strong>Gram-negative aerobes:</strong><br />Citrobacter spp.&nbsp;<br />Enterobacter aerogenes&nbsp;<br />Escherichia coli&nbsp;<br />Klebsiella pneumoniae&nbsp;<br />Klebsiella pneumonia&nbsp;<br />Proteus mirabilis&nbsp;<br />Proteus vulgaris&nbsp;<br />Providencia spp.<br />Serratia marcesans</td></tr><tr><td><strong>Inherently resistant organisms:</strong></td></tr><tr><td><strong>Gram-negative aerobes:&nbsp;</strong><br />Pseudomonas&nbsp;<br />aeruginosa Shigella spp.<br />Vibrio cholera</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Absorption</strong></u></p><p>After oral administration trimethoprim and sulfamethoxazole are rapidly and nearly completely absorbed. The presence of food does not appear to delay absorption. Peak levels in the blood occur between one and four hours after ingestion and the level attained is dose related. Effective levels persist in the blood for up to 24 hours after a therapeutic dose. Steady state levels in adults a re reached after dosing for 2 -3 days. Neither component has an appreciable effect on the concentrations achieved in the blood by the other.</p><p><u><strong>Distribution</strong></u></p><p>Approximately 50% of trimethoprim in the plasma is protein bound.</p><p>Tissue levels of trimethoprim are g enerally higher than corresponding plasma levels, the lungs and kidneys showing especially high concentrations. Trimethoprim concentrations exceed those in<br />plasma in the case of bile, prostatic fluid and tissue, saliva, sputum and vaginal secretions. Level s in the aqueous humor, breast milk, cerebrospinal fluid, middle ear fluid, synovial fluid and tissue (intestinal) fluid are adequate for antibacterial activity. Trimethoprim passes into amniotic fluid and foetal tissues reaching concentrations approximati ng those of maternal serum.</p><p>Approximately 66% of sulfamethoxazole in the plasma is protein bound. The concentration of active sulfamethoxazole in amniotic fluid, aqueous humour, bile, cerebrospinal fluid, middle ear fluid, sputum, synovial fluid and tissue (interstitial) fluids is of the order of 20 to 50% of the plasma concentration.</p><p><u><strong>Biotransformation</strong></u><br />Renal excretion of intact sulfamethoxazole accounts for 15 -30% of the dose. This drug is more extensively metabolised than trimethoprim, via acetylation, oxidation or glucuronidation. Over a 72 hour period, approximately 85% of the dose can be accounted for in the urine as unchanged drug plus the major (N4 -acetylated) metabolite.</p><p><u><strong>Elimination</strong></u><br />The half-life of trimethopri m in man is in the range 8.6 to 17 hours in the presence of normal renal function. It is increased by a factor of 1.5 to 3.0 when the creatinine clearance is less than 10 ml/minute. There appears to be no significant difference in elderly patients compared with young patients.</p><p>The principal route of excretion of trimethoprim is renal and approximately 50% of the dose is excreted in the urine within 24 hours as unchanged drug. Several metabolites have been identified in the urine. Urinary concentrations of t rimethoprim vary widely.</p><p>The half-life of sulfamethoxazole in man is approximately 9 to 11 hours in the presence of normal renal function.</p><p>There is no change in the half -life of active sulfamethoxazole with a reduction in renal function but there is prolon gation of the half -life of the major, acetylated metabolite when the creatinine clearance is below 25 ml /minute.</p><p>The principal route of excretion of sulfamethoxazole is renal; between 15% and 30% of the dose recovered in the urine is in the active form.<br />Gram-negative aerobes: Pseudomonas aeruginosa Shigella spp.<br />Vibrio cholera<br />The pharmacokinetics in the paediatric population with normal renal function of both components of Co-Trimoxazole, TMP and SMZ are age dependent. Elimination of TMP -SMZ is reduced in neonates, during the first two months of life, thereafter both TMP and SM Z show a higher elimination with a higher body clearance and a shorter elimination half -life. The differences are most prominent in young infants (&gt; 1.7 months up to 24 months) and decrease with increasing age, as compared to young children (1 year up to 3 .6 years), children (7.5 years and &lt; 10 years) and adults (see section 4.2).</p><p>In elderly patients there is a reduced renal clearance of sulfamethoxazole.</p><p><u>Special patient population</u></p><p><strong>Renal impairment</strong></p><p>The elimination half -life of trimethoprim is increased by a factor of 1.5 -3.0 when the creatinine clearance is less than 10 mL/minute. When the creatinine clearance falls below 30 mL/min the dosage of Co -Trimoxazole should be reduced (see section 4.2).</p><p><strong>Hepatic impairment</strong><br />Caution should be exercised when treatin g patients with severe hepatic parenchymal damage as there may be changes in the absorption and biotransformation of trimethoprim and sulfamethoxazole.</p><p><strong>Elderly patients</strong><br />In elderly patients, a slight reduction in renal clearance of sulfamethoxazole but not trimethoprim has been observed.</p><p><strong>Paediatric population</strong><br />See special dosage regimen (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At doses in excess of recommended human therapeutic dose, trimethoprim and sulfamethoxazole have been reported to cause cleft palate and other foetal abnormalities in rats, findings typical of a folate antagonist. Effects with trimethoprim were preventable by administration of dietary folate. In rabbits, foetal loss was seen at doses of trimethoprim in excess of human therapeutic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablets<br />Sodium starch glycollate Povidone<br />*Dioctyl sodium sulphosuccinate<br />*Docusate sodium Magnesium stearate<br />*alternative ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See drug interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C. Keep container in the outer carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass bottles with low density polyethylene snap -fit closures and PVC/Aluminium blister packs.<br />Pack size: 50 and 100<br />Round enamelled tins with lever lids.&nbsp;<br />Pack size: 5000.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trimethoprim interferes with assays for serum methotrexate when dihydrofolate reductase from Lactobacillus casei is used in the assay. No interference occurs if methotrexate is measured by radioimmuno assay.</p><p>Trimethoprim may interfere with t he estimation of serum/plasma creatinine when the alkaline picrate reaction is used. This may result in overestimation of serum/plasma creatinine of the order of 10%.<br />Functional inhibition of the renal tubular secretion of creatinine may product a spurious fall in the estimated rate of creatinine clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited
 3016 Lake Drive
Citywest Business Campus
 Dublin 24, Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>